Document:

EX-10.13

 Exhibit 10.13 

LONZA SUBLICENSE AGREEMENT 

between 
 MEDIMMUNE, LLC

 and 
 VIELA
BIO, INC. 
 Dated as of February 23, 2018 
  

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 TABLE OF CONTENTS 

 

							
	 Article 1 DEFINITIONS
	  	 	2	 
		
	 Article 2 GRANT OF RIGHTS
	  	 	3	 
			
	 2.1.
	  	Grant	  	 	3	 
			
	 2.2.
	  	Application of Lonza License Agreement	  	 	3	 
			
	 2.3.
	  	Maintenance of the Lonza License Agreement	  	 	4	 
			
	 2.4.
	  	Restrictions on Use and Transfer of Cell Lines	  	 	4	 
			
	 2.5.
	  	No Other Rights Granted by MedImmune	  	 	5	 
		
	Article 3 ASSUMPTION OF LIABILITIES	  	 	5	 
			
	 3.1.
	  	General	  	 	5	 
			
	 3.2.
	  	Financial Obligations	  	 	5	 
			
	 3.3.
	  	Compliance with Applicable Law	  	 	6	 
		
	Article 4 CONFIDENTIALITY AND NON-DISCLOSURE	  	 	6	 
			
	 4.1.
	  	Lonza’s’ Confidential Information	  	 	6	 
			
	 4.2.
	  	Permitted Use and Disclosures	  	 	7	 
			
	 4.3.
	  	Public Disclosure	  	 	7	 
		
	Article 5 INDEMNITY, LIMITATIONS AND INSURANCE	  	 	7	 
			
	 5.2.
	  	Indemnification of MedImmune	  	 	7	 
			
	 5.3.
	  	Indemnification of Spinco	  	 	7	 
			
	 5.4.
	  	Procedure	  	 	8	 
			
	 5.5.
	  	Limitation of Liability	  	 	8	 
			
	 5.6.
	  	Disclaimer of Warranties	  	 	8	 
			
	 5.7.
	  	Insurance	  	 	8	 
		
	Article 6 TERM AND TERMINATION	  	 	9	 
			
	 6.1.
	  	Term and Expiration	  	 	9	 
			
	 6.2.
	  	Termination	  	 	9	 
			
	 6.3.
	  	Effect of Termination	  	 	10	 
			
	 6.4.
	  	Accrued Rights	  	 	10	 
		
	Article 7 MISCELLANEOUS	  	 	10	 
			
	 7.1.
	  	Independent Contractor	  	 	10	 
			
	 7.2.
	  	Governing Law, Jurisdiction, Venue and Service	  	 	10	 
			
	 7.3.
	  	Notices	  	 	11	 
			
	 7.4.
	  	No Benefit to Third Parties	  	 	12	 
			
	 7.5.
	  	Waiver and Non-Exclusion of Remedies	  	 	12	 
			
	 7.6.
	  	Assignment	  	 	12	 

  
 i 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II)
WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

							
	 7.7.
	 	Amendment	  	 	13	 
			
	 7.8.
	 	Severability	  	 	13	 
			
	 7.9.
	 	English Language	  	 	14	 
			
	 7.10.
	 	Counterparts	  	 	14	 
			
	 7.11.
	 	Entire Agreement	  	 	14	 
			
	 7.12.
	 	Construction	  	 	14	 

 SCHEDULES 
  

			
	Schedule 1	  	Lonza License Agreement

  
 ii 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II)
WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 LONZA SUBLICENSE AGREEMENT 

This Lonza Sublicense Agreement (this “Agreement”) is made and entered into as of February 23, 2018 (the
“Effective Date”) by and between MedImmune, LLC, a Delaware corporation, whose registered office is at One MedImmune Way, Gaithersburg, Maryland 20878 (and which is a member of the AstraZeneca group of companies)
(“MedImmune”) and Viela Bio, Inc., a Delaware corporation (“Spinco”). MedImmune and Spinco are sometimes referred to herein individually as a “Party” and collectively as the
“Parties.” 
 Recitals 

WHEREAS, Lonza Sales AG (“Lonza”) and MedImmune entered into a Letter Agreement, dated April 16, 2009,
incorporating the terms of the Licenses and Services Agreement between Lonza (as successor in title to Lonza Biologics Plc) and AstraZeneca AB, dated January 21, 2005 (as amended by Amendment No. 1, effective as of March 20, 2009)
(together, the “Lonza License Agreement” and attached hereto as Schedule 1); 
 WHEREAS, BioWa, Inc.
(“BioWa”) and MedImmune (then called MedImmune, Inc.) entered into a License Agreement dated November 16, 2005 (the “BioWa License Agreement”) pursuant to which BioWa granted MedImmune a non-exclusive, worldwide sublicense under BioWa’s technology to research antibodies made using PotelligentTM Technology; 

WHEREAS, under the Lonza License Agreement, MedImmune has developed a cell line for the expression of the antibody [***] binds to CD19
as its intended primary target [***] using PotelligentTM Cells (as defined in the BioWa License Agreement) and Lonza’s LB System Technology (as defined in the Lonza License Agreement)
(referred to as [***]) (the “551 Cell Line”) such that the 551 Cell Line is a Transfected PotelligentTM Cell (as defined in the BioWa License Agreement) and is a Cell Line (as
defined in the Lonza License Agreement); 
 WHEREAS, BioWa, Lonza and MedImmune entered into a
Non-Exclusive License Agreement, dated November 4, 2013 (the “BioWa/Lonza License Agreement”) pursuant to which BioWa and Lonza granted MedImmune a
non-exclusive, worldwide license under BioWa’s and Lonza technology to research antibodies made using Potelligent® [***] (as defined in the
BioWa/Lonza License Agreement); 
 WHEREAS, MedImmune has developed a cell line for the expression of the antibody known as MEDI-7734
that specifically binds to ILT7 as its intended primary target (“MEDI-7734”) using Potelligent® [***] cells and Lonza [***] (as defined in the BioWa/Lonza License Agreement)
(referred to as pCLD-2072) (the “7734 Cell Line”) such that the 7734 Cell Line is a Transfected Cell as defined in the BioWa/Lonza License Agreement and is also subject to the Lonza License Agreement (as referred to in the
BioWa/Lonza License Agreement). 
 WHEREAS, MedImmune, MedImmune Limited and AstraZeneca Collaboration Ventures, LLC have agreed to
sell, or to procure the sale, to Spinco, of certain assets relating to certain products and programs aimed at treating inflammation and autoimmune disorders, including specified Patents and Know-How relating
exclusively to such products or programs, on the terms and subject to the conditions set forth in that certain Asset Purchase Agreement dated February 23, 2018 (the “APA”); 

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 WHEREAS, MedImmune has by separate agreements granted sublicenses to Spinco under the
BioWa License Agreement and the BioWa/Lonza License Agreement and is willing to grant a sublicense to Spinco under the Lonza License Agreement with respect to the Product Cell Lines, and Spinco is willing to receive such sublicense, on the terms and
conditions of this Agreement. 
 NOW, THEREFORE, in consideration of the premises and the mutual promises and conditions set forth
herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound, do hereby agree as follows: 

ARTICLE 1 
 DEFINITIONS

 Definitions in this Agreement. Unless otherwise specifically provided herein, capitalized words and phrases used in this
Agreement shall have the meaning ascribed to them in the Lonza License Agreement. In addition, the following terms shall have the following meanings: 

1.1. “551 Cell Line” has the meaning set forth in the Recitals. 

1.2. “551-Product” means any product containing or comprising MEDI-551 expressed using the 551 Cell Line. 
 1.3. “7734 Cell Line” has the
meaning set forth in the Recitals. 
 1.4. “7734-Product” means any product containing or comprising MEDI-7734
expressed using the 7734 Cell Line. 
 1.5. “Affiliate” has the meaning set forth in the APA. 

1.6. “Agreement” has the meaning set forth in the preamble hereto. 

1.7. “APA” has the meaning set forth in the Recitals. 

1.8. “Assignment” has the meaning set forth in Section 7.6.2. 

1.9. “BioWa/Lonza License Agreement” has the meaning set forth in the Recitals. 

1.10. “Business Day” has the meaning set forth in the APA. 

1.11. “Effective Date” has the meaning set forth in the preamble hereto. 

1.12. “Law” has the meaning set forth in the APA. 

  
 2 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II)
WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 1.13. “Lonza” has the meaning set forth in the Recitals. 

1.14. “Lonza AG” has the meaning set forth in the Recitals. 

1.15. “Lonza License Agreement” has the meaning set forth in the Recitals. 

1.16. “MEDI-551” has the meaning set forth in the Recitals. 

1.17. “MEDI-7734” has the meaning set forth in the Recitals. 

1.18. “MedImmune” has the meaning set forth in the preamble hereto. 

1.19. “Notice” has the meaning set forth in Section 7.3.1. 

1.20. “Party” and “Parties” have the meanings set forth in the preamble hereto. 

1.21. “Product” means the 551 Product or the 7734 Product as applicable and “Products” means both of
them. 
 1.22. “Product Cell Line” means the 551 Cell Line or the 7734 Cell Line as applicable and “Product
Cell Lines” means both of them. 
 1.23. “Spinco” has the meaning set forth in the preamble hereto. 

1.24. “Tax” has the meaning set forth in the APA. 

1.25. “Third Party” has the meaning set forth in the APA. 

1.26. “Transaction Agreements” has the meaning set forth in the APA. 

ARTICLE 2 
 GRANT OF
RIGHTS 
 2.1. Grant. As of the Effective Date, subject to Section 2.2 and the other terms and conditions of this
Agreement, MedImmune hereby grants to Spinco an exclusive (as between MedImmune and Spinco) sublicense under the licenses granted to MedImmune under Sections 6.1 and 10.4 of the Lonza License Agreement, solely for the purpose of Exploiting the
Products as a therapeutic pharmaceutical product in humans or for diagnostic, veterinary or any other use worldwide in accordance with the terms and conditions of this Agreement. Spinco shall not grant any sublicense under the rights granted to it
by MedImmune hereunder without the prior written approval of MedImmune and, if required, Lonza; provided, that if Lonza has consented to such sublicense in writing Spinco shall provide a copy of such consent to MedImmune and MedImmune’s consent
shall not be required. 
 2.2. Application of Lonza License Agreement. The sublicenses granted by MedImmune in
Section 2.1 and any right of Spinco to grant a further sublicense thereunder shall be subject and subordinate to the terms and conditions of the Lonza License Agreement and shall be effective solely to the extent permitted under the terms of
the Lonza License Agreement. Without limitation of the foregoing, to the extent that the Lonza License Agreement requires that particular terms or conditions of the Lonza License Agreement be contained or incorporated in any agreement granting a
sublicense thereunder, such terms and conditions are hereby deemed to be incorporated herein by reference. 

  
 3 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II)
WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 2.3. Maintenance of the Lonza License Agreement. 

2.3.1. MedImmune covenants to Spinco that: 

(a) To the extent not expressly delegated to or assumed by Spinco as provided in this Agreement, MedImmune shall fulfill all of its material
obligations, including its payment obligations, under the Lonza License Agreement to the extent that failure to do so would have an adverse effect on or would reasonably be expected to adversely affect Spinco’s rights or obligations under this
Agreement; and 
 (b) MedImmune shall not amend, waive, take an action or omit to taking any action that would alter or otherwise modify
any of MedImmune’s rights under, or violate or breach, the terms of the Lonza License Agreement during the term of this Agreement, in each case in a manner that would have an adverse effect on or would reasonably be expected to adversely affect
Spinco’s rights or obligations under this Agreement and shall not terminate the Lonza License Agreement or the Product Schedule(s) applicable to the Products, in each case without Spinco’s prior written consent (such consent not to be
unreasonably withheld, conditioned or delayed); provided that MedImmune shall not be required to make any payments to Lonza with respect to the Exploitation of the Products if Spinco is in breach of its payment obligations hereunder and MedImmune
may terminate the Lonza License Agreement with respect to a Product if Spinco is in breach of its obligations under Article 3 and fails to remedy such breach within thirty [***] following its receipt of written notice thereof from MedImmune.
MedImmune shall promptly notify Spinco of any default under, termination or amendment of the Lonza License Agreement to the extent relevant to Spinco’s rights or obligations under this Agreement. 

2.3.2. MedImmune represents and warrants that as of the Effective Date: 

(a) MedImmune is entitled to grant the rights and licenses granted to Spinco under this Agreement; and 

(b) MedImmune has provided to Spinco an accurate, true and complete copy of the Lonza License Agreement, including all amendments thereto,
and except as set out in Schedule 4.4 to the APA, to MedImmune’s knowledge the Lonza License Agreement is in full force and effect, MedImmune has not received any notice that it is in breach of the Lonza License Agreement and none of the
parties to the Lonza License Agreement is in breach thereof. 
 2.4. Restrictions on Use and Transfer of Cell Lines. Any LB
System Materials included in the Product Cell Lines shall be deemed to be Confidential Information of Lonza. In addition, the Product Cell Lines are also subject to restrictions as set out in the BioWa License Agreement or the BioWa/Lonza License
Agreement (as applicable) and Article 4. Spinco may use the Product Cell Lines to express Products solely in accordance with the terms and conditions of this Agreement and for no other purpose. For clarity, Biological Materials (as defined in the
APA) shall not include any LB Materials or LB System Materials except if and to the extent that LB System Materials are incorporated into the Product Cell Line. 

  
 4 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II)
WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 2.5. No Other Rights Granted by MedImmune. Except as expressly provided herein
and without limiting the foregoing, MedImmune grants no other right or license not otherwise expressly granted herein. 
 ARTICLE 3

 ASSUMPTION OF LIABILITIES 

3.1. General. On and after the Effective Date and as between MedImmune and Spinco and subject to the Transaction Agreements (as
defined in the APA), Spinco shall assume responsibility for the Exploitation of the Products and MedImmune and its Affiliates shall have no rights with respect to the Exploitation of the Products except as expressly set forth in the Transaction
Agreements. Each Party shall use commercially reasonable efforts to take such actions as the other Party may reasonably require to ensure that the other Party can comply with its obligations under the Lonza License Agreement. 

3.2. Financial Obligations. 

3.2.1. Assumption of Liability. As consideration for MedImmune granting the sublicense to Spinco in accordance with
Section 2.1, Spinco shall be responsible for and shall pay to MedImmune for further payment to Lonza (or, if applicable, to reimburse MedImmune if MedImmune has made a payment to Lonza after the Effective Date that, as between the Parties
pursuant to this Agreement, is Spinco’s responsibility), or (if directed in writing by MedImmune) to Lonza, all amounts that are paid or payable by MedImmune to Lonza under the Lonza License Agreement with respect to the Exploitation of
Products by Spinco, its Affiliates or sublicensees after the Effective Date, including any royalty or fee payments due solely with respect to the Exploitation of the Products under Article 6 of the Lonza License Agreement. For clarity, MedImmune
represents and warrants that Spinco is not a Competing Contract Manufacturer as at the Effective Date. 
 3.2.2. Reductions
and Calculations. The payment obligations assumed by Spinco under Section 3.2.1 will be calculated in accordance with the Lonza License Agreement and subject to the same reductions, step-downs or any other deductions
and limitations to such reductions, step-downs or other deductions, to which MedImmune has a right under the Lonza License Agreement such that Spinco shall pay to MedImmune an amount that is equal to the amount that is paid or payable by MedImmune
to Lonza under the Lonza License Agreement solely with respect to Exploitation of Products by Spinco, its Affiliates or sublicensees.  

3.2.3. Payments and Reports. Unless otherwise directed by MedImmune, Spinco shall pay all amounts that become due for payment
in accordance with Section 3.2.1 and provide any required related reports under the Lonza License Agreement solely with respect to the Products to MedImmune or (if directed in writing by MedImmune) to Lonza, in each case in accordance with the
terms and conditions of Sections 9.2, 9.3, 9.4 and 9.5 and 

  
 5 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II)
WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 
Articles 6, 12 and 13 of the Lonza License Agreement (including as to currency of payment) as if Spinco were a party thereto in place of MedImmune and references to Lonza were to MedImmune;
provided, that Spinco shall pay all such amounts and provide such required reports to MedImmune at least [***] ([***]) [***] in advance of the due date for such payment or report under the Lonza License Agreement, so that MedImmune shall in turn
satisfy its payment and reporting obligations to Lonza under the Lonza License Agreement in accordance with the requirements thereof. Subject to the foregoing, MedImmune shall be responsible for the timely payment of any amounts due under the Lonza
License Agreement, and in the event that MedImmune has timely received the payment from Spinco but fails to make the corresponding payment with respect to a Product when due under the Lonza License Agreement, Spinco shall have the right to make such
payment on behalf of MedImmune. In such event, MedImmune shall promptly reimburse Spinco any such amounts paid by Spinco or, at Spinco’s election, Spinco may offset such amounts paid by Spinco against any future amounts payable to MedImmune
hereunder. 
 3.2.4. Records and Audit. Spinco shall keep records as described in Section 6.13 of the Lonza License
Agreement solely with respect to the Products and shall grant MedImmune rights to audit such records and books consistent with Lonza’s rights to audit MedImmune pursuant to such section and MedImmune shall have the right to disclose the results
of any such audit to Lonza. 
 3.2.5. Tax. For the avoidance of doubt, Article X of the APA shall govern all matters relating
to Tax with respect to the transactions contemplated by this Agreement. 
 3.2.6. Interest. If either Party fails to pay any
amount payable under this Agreement by the due date for such payment, then [***]. Interest shall be calculated on the basis of a year of 365 days and for the actual number of days elapsed, shall accrue from day to day, and shall be compounded
quarterly. 
 3.3. Compliance with Applicable Law. In exercising its rights and performing its obligations under this
Agreement, Spinco shall comply in all material respects with applicable laws, regulations and guidelines (including cGMP with respect to Products that will be administered in humans or animals). MedImmune shall perform its obligations under this
Agreement in accordance with applicable laws, regulations and guidelines. 
 ARTICLE 4 

CONFIDENTIALITY AND NON-DISCLOSURE 

4.1. Lonza’s Confidential Information. Spinco shall comply with Article 13 of the Lonza License Agreement as if it were a
Party thereto in place of MedImmune with respect to: (a) information identified by MedImmune as being Confidential Information of Lonza, including the Product Cell Lines; and (b) information disclosed by Lonza to Spinco. For clarity,
Spinco shall only have the right to use the Confidential Information described in the preceding sentence to Exploit the Products in accordance with the license granted under Section 2.1 and, pursuant to such license, as otherwise consistent
with Article 13 of the Lonza License Agreement. 

  
 6 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II)
WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 4.2. Permitted Use and Disclosures. Spinco shall be required to submit notice
to MedImmune under Section 13.3 of the Lonza License Agreement, should Spinco make a disclosure of Lonza’s Confidential Information that is reasonably necessary to comply with applicable governmental regulations, obtaining or enforcing a
Patent (as defined in the Lonza License Agreement) or otherwise for the purpose of submitting information to government authorities or conducting clinical trials, in each case with respect to the Product(s). 

4.3. Public Disclosure. Spinco shall not issue a press release or make any other public disclosure of the terms of the Lonza
License Agreement without the prior written approval of MedImmune. 
 4.4. Spinco Confidential Information. Information
disclosed by or on behalf of Spinco to MedImmune under this Agreement shall be treated as Spinco’s Confidential Information and subject to Section 7.2 of the APA; provided that MedImmune shall be entitled to disclose such information to
Lonza pursuant to the Lonza License Agreement. 
 4.5. Disclosures to Third Parties. Information disclosed by or on behalf of
Spinco to Third Parties as may be necessary or useful in connection with the Exploitation of the Product as contemplated by this Agreement shall be treated in accordance with Section 13.3.5 of the Lonza License Agreement. 

ARTICLE 5 
 INDEMNITY,
LIMITATIONS AND INSURANCE 
 5.1. Indemnification of MedImmune. Spinco shall indemnify, defend and hold each AZ
Indemnified Party (as defined in the APA) harmless from and against any and all Losses (as defined in the APA) arising from Third Party claims including any claims made by Lonza pursuant to Sections 11.3 or 11.4 of the Lonza License Agreement
incurred, resulting or arising from or relating to (a) any breach of or failure to perform any covenant or agreement made by Spinco in this Agreement; (b) the negligence or willful misconduct of Spinco, its Affiliates or sublicensees; or
(c) Exploitation of any Product by Spinco, its Affiliates or sublicensees, except in each case to the extent such claim is due to Sections 5.2(a)-(b); provided that, for clarity, if Spinco is in breach of its payment obligations hereunder any
failure by MedImmune to make payments to Lonza with respect to the Exploitation of Products shall not constitute negligence or willful misconduct of MedImmune.  

5.2. Indemnification of Spinco. MedImmune shall indemnify, defend, and hold each Spinco Indemnified Party (as defined in
the APA) harmless from and against any and all Losses (as defined in the APA) arising from Third Party claims incurred, resulting or arising from or relating to (a) any breach of or failure to perform any covenant or agreement made by MedImmune
in this Agreement; or (b) the negligence or willful misconduct of MedImmune, its Affiliates or sublicensees (other than Spinco or its Affiliates or sublicensees), except in each case (a) and (b) to the extent such claim is due to Sections
5.1(a)-(c). 
 5.3. Procedure. The Party seeking indemnification under Sections
5.1-5.2 shall (i) promptly notify the indemnifying Party in writing of the claim for which it seeks indemnification, (ii) give the indemnifying Party sole control of the defense and settlement

  
 7 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II)
WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 
thereof, and (iii) provide the indemnifying Party, at the indemnifying Party’s expense, with reasonable assistance and full information with respect to such claims; provided, however,
the indemnifying Party shall not enter into any settlement that admits fault, wrongdoing or damages, or otherwise requires any consideration other than money, without the indemnified Party’s written consent, such consent not to be unreasonably
withheld or delayed. The indemnifying Party shall have no obligations with respect to such claims if the indemnified Party makes any admission, settlement or other communication regarding such claim without the prior written consent of the
indemnifying Party. In addition, the indemnifying Party shall have no obligation to indemnify the indemnified Party for any costs or expenses incurred without the indemnifying Party’s prior written consent. 

5.4. Limitation of Liability. NOTWITHSTANDING ANYTHING TO THE CONTRARY CONTAINED IN THIS AGREEMENT, TO THE FULLEST EXTENT
PERMITTED BY APPLICABLE LAW AND EXCEPT AS A RESULT OF COMMON LAW FRAUD IN CONNECTION WITH MATTERS COVERED HEREIN OR A PARTY’S BREACH OF ITS CONFIDENTIALITY OBLIGATIONS HEREUNDER, AND EXCEPT WITH RESPECT TO ANY LIABILITY PURSUANT TO SECTIONS 5.1
OR 5.2, NEITHER SPINCO NOR MEDIMMUNE SHALL BE LIABLE TO THE OTHER OR THEIR AFFILIATES, FOR ANY CONSEQUENTIAL, INCIDENTAL, SPECIAL, EXEMPLARY, PUNITIVE, OR INDIRECT DAMAGES, INCLUDING FOR LOSS OF PROFITS, REVENUE OR INCOME, DIMINUTION IN VALUE OR
LOSS OF BUSINESS OPPORTUNITY (IN EACH CASE, WHETHER OR NOT FORESEEABLE AT THE EFFECTIVE DATE), OR FOR ANY DAMAGES CALCULATED BY REFERENCE TO A MULTIPLIER OF REVENUE, PROFITS, EBITDA OR SIMILAR METHODOLOGY, CONNECTED WITH OR RESULTING FROM ANY BREACH
OF THIS AGREEMENT, OR ANY ACTIONS UNDERTAKEN IN CONNECTION WITH, OR RELATED HERETO, INCLUDING ANY SUCH DAMAGES WHICH ARE BASED UPON BREACH OF CONTRACT, TORT (INCLUDING NEGLIGENCE AND MISREPRESENTATION), BREACH OF WARRANTY, STRICT LIABILITY, STATUTE,
OPERATION OF LAW OR ANY OTHER THEORY OF RECOVERY. 
 5.5. Disclaimer of Warranties. EXCEPT AS EXPRESSLY SET FORTH IN THIS
AGREEMENT OR ANY TRANSACTION AGREEMENT, MEDIMMUNE EXPRESSLY DISCLAIMS ANY AND ALL REPRESENTATIONS AND WARRANTIES, EXPRESS, IMPLIED, STATUTORY OR OTHERWISE, WITH RESPECT TO THE LICENSED INTELLECTUAL PROPERTY OR THIS AGREEMENT, INCLUDING ANY WARRANTY
OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, VALIDITY, OR NON-INFRINGEMENT OF INTELLECTUAL PROPERTY RIGHTS. 

5.6. Insurance. Spinco shall have and maintain such types and amounts of insurance covering its Exploitation of each
Product as (i) is normal and customary in the pharmaceutical industry generally for parties similarly situated; (ii) would normally be insured against by a prudent business in connection with the risks associated with this Agreement; and
(iii) is otherwise required by Law. Within [***] ([***]) [***] of written request by MedImmune, Spinco shall provide to MedImmune evidence of its relevant insurance coverage. 

  
 8 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II)
WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 ARTICLE 6 

TERM AND TERMINATION 

6.1. Term and Expiration. This Agreement shall commence on the Effective Date and, unless earlier terminated in accordance with
Section 6.2, shall continue in effect until expiration or termination of the Lonza License Agreement with respect to the Products. For the avoidance of doubt, when MedImmune’s license under the Lonza License Agreement with respect to a
Product becomes fully paid-up and perpetual, Spinco’s license granted under this Agreement with respect to such Product shall become fully paid-up and perpetual.

 6.2. Termination. 

6.2.1. Either Party may terminate this Agreement immediately upon written notice to the other Party if such other Party materially
breaches this Agreement, or such other Party, its Affiliates or sublicensees takes or fails to take any action that, if such action had been taken or failed to be taken by MedImmune, would constitute a material breach of the Lonza License Agreement
as further described in Section 12.2 of the Lonza License Agreement, and in either case fails to remedy such breach within thirty (30) days following its receipt of written notice thereof from such Party. Notwithstanding the foregoing, if
a Party disputes in good faith a breach alleged by the other Party pursuant to this Section 6.2.1 by written notice to such other Party within such [***] ([***])-[***] period, such other Party shall not have the right to terminate this
Agreement unless it has been determined that this Agreement was materially breached in accordance with Section 7.2.2, and such Party fails to comply with its obligations alleged to have been breached within [***] ([***]) [***] after such
determination. 
 6.2.2. Either Party may terminate this Agreement immediately upon written notice if the other Party
(a) voluntarily declares or seeks protection under bankruptcy or insolvency laws, (b) has an involuntary petition in bankruptcy filed against it, which petition is not dismissed within [***] ([***]) [***] following it filing, (c) has
its business placed in the hands of a receiver or trustee and the appointment of such receiver or trustee if not dissolved within [***] ([***]) [***], (d) ceases to exist as an active business or (e) suffers any other event described in
Section 12.3.2 of the Lonza License Agreement. 
 6.2.3. Spinco may terminate this Agreement for any reason upon thirty
(30) days prior written notice to MedImmune. 
 6.2.4. This Agreement shall automatically terminate in its entirety on
termination of the Lonza License Agreement or with respect to a Product on termination of the Lonza License Agreement or applicable Product Schedule with respect to such Product; provided, that if Spinco is not in breach of this Agreement, MedImmune
shall, at Spinco’s request, use reasonable efforts to assist Spinco in obtaining a direct license from Lonza with respect to the Products. 

6.2.5. Bankruptcy. All rights and licenses granted under or pursuant to this Agreement from MedImmune to Spinco are, and
shall otherwise be deemed to be, for purposes of Section 365(n) of the U.S. Bankruptcy Code or any non-U.S. equivalent thereof, licenses of right to “intellectual property” as defined under
Section 101 of the U.S. Bankruptcy 

  
 9 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II)
WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 
Code. MedImmune agrees that Spinco, as sublicensee of certain rights and licenses under this Agreement, shall retain and may fully exercise all of its rights and elections under the U.S.
Bankruptcy Code or any non-U.S. equivalent thereof; provided, that any such sublicense shall continue to be subject to the Lonza License Agreement. MedImmune further agrees that, in the event of the
commencement of a bankruptcy proceeding by or against MedImmune under the U.S. Bankruptcy Code or other applicable Law governing MedImmune, subject to Section 6.2.4, Spinco shall have the right to retain any and all rights and licenses granted
to it hereunder, to the maximum extent permitted by applicable law (such as under Sections 365(n)(1) and 365(n)(2) of the U.S. Bankruptcy Code or any non-U.S. equivalent thereof), unless MedImmune (or its
bankruptcy trustee) elects to assume this Agreement and continue to perform all of its obligations under this Agreement. 
 6.3.
Effect of Termination. On termination of this Agreement in its entirety or with respect to a Product, the licenses granted to Spinco in this Agreement with respect to such Product(s) shall terminate, Spinco shall comply with the terms of
Section 12.9, as applicable, of the Lonza License Agreement and the surviving provisions, as applicable, of the Lonza License Agreement, in each case solely with respect to the Products, the Product Cell Lines and related Confidential
Information as if it were a party thereto in place of MedImmune. 
 6.4. Accrued Rights. Termination or expiration of
this Agreement for any reason shall be without prejudice to any rights that shall have accrued to the benefit of a Party prior to such termination or expiration. Such termination or expiration shall not relieve a Party from obligations that are
expressly or by implication intended to come into or continue in force on termination or expiry of this Agreement, and [***] shall remain in full force and effect. 

ARTICLE 7 
 MISCELLANEOUS

 7.1. Independent Contractor. The Parties and each of their respective Affiliates shall each be an independent
contractor in the performance of its obligations hereunder. 
 7.2. Governing Law, Jurisdiction, Venue and Service. 

7.2.1. Governing Law. This Agreement shall be governed by and construed in accordance with the Laws of the State of New
York, excluding any conflicts or choice of Law rule or principle that might otherwise refer construction or interpretation of this Agreement to the substantive Law of another jurisdiction. 

7.2.2. Jurisdiction. The Parties hereby irrevocably and unconditionally consent to the exclusive jurisdiction of the courts of
the State of New York and the United States District Court for the Southern District of New York for any action, suit or proceeding (other than appeals therefrom) arising out of or relating to this Agreement, and agree not to commence any action,
suit or proceeding (other than appeals therefrom) related thereto except in such courts. The Parties irrevocably and unconditionally waive their right to a jury trial in connection with any litigation arising out of or relating to this Agreement or
the transactions contemplated hereby. 

  
 10 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II)
WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 7.2.3. Venue. The Parties further hereby irrevocably and unconditionally
waive any objection to the laying of venue of any action, suit or proceeding (other than appeals therefrom) arising out of or relating to this Agreement in the courts of the State of New York or in the United States District Court for the Southern
District of New York, and hereby further irrevocably and unconditionally waive and agree not to plead or claim in any such court that any such action, suit or proceeding brought in any such court has been brought in an inconvenient forum. 

7.2.4. Service. Each Party further agrees that service of any process, summons, notice or document by registered mail to its
address set forth in Section 7.3.2 shall be effective service of process for any action, suit or proceeding brought against it under this Agreement in any such court. 

7.3. Notices. 

7.3.1. Notice Requirements. All notices or other communications which are required or permitted hereunder (each, a
“Notice”) shall be in writing and sufficient if delivered personally or sent by nationally recognized overnight courier or by registered or certified mail, postage prepaid, return receipt requested, or by facsimile or email,
addressed to the Parties at their respective addresses specified in Section 7.3.2 or to such other address as the Party to whom notice is to be given may have furnished to the other Party in writing in accordance herewith. All such notices and
other communications required or permitted by this Agreement shall be deemed to have been duly given (a) if sent to a recipient at the proper address as determined pursuant to this Section 7.3.1 by registered or certified mail, return
receipt requested, five calendar days after being deposited in the United States mail, postage prepaid; (b) if sent by Express Mail, Federal Express or similar reputable overnight delivery service that maintains records of receipt for next
Business Day delivery, the next Business Day after being entrusted to such service, with delivery charges prepaid or charged to the sender’s account; (c) if sent by facsimile transmission or email, on the date of transmission with
electronic confirmation of transmission; and (d) if delivered by hand, on the date of delivery. 
 7.3.2. Address for
Notice. 
 If to MedImmune, to: 

MedImmune, LLC 
 950 Wind River
Lane 
 Gaithersburg, MD 20878 

Attention: General Counsel 
 With
a copy (which shall not constitute notice) to: 
 [***] 

  
 11 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II)
WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 If to Spinco, to: 

Viela Bio, Inc. 
 1 Medimmune Way

 Gaithersburg, MD 20878 

Attention: Bing Yao 
 With a copy
(which shall not constitute notice) to: 
 Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. 

701 Pennsylvania Ave., NW, Suite 900 

Washington, DC 20004 
 Attention:
Christopher Jeffers 
 7.4. No Benefit to Third Parties. With the exception of Sections 3.1 and 3.2.1 that are drafted for the
benefit of Lonza and, accordingly, may be enforced by Lonza, the covenants and agreements set forth in this Agreement are for the sole benefit of the Parties and their successors and permitted assigns, and, except for the rights of any indemnified
person under Article 5, such provisions shall not be construed as conferring any rights on any other persons. 
 7.5. Waiver and Non-Exclusion of Remedies. Any term or condition of this Agreement may be waived at any time by the Party that is entitled to the benefit thereof, but no such waiver shall be effective unless set forth in a
written instrument duly executed by or on behalf of the Party waiving such term or condition. The waiver by either Party of any right hereunder or of the failure to perform or of a breach by the other Party shall not be deemed a waiver of any other
right hereunder or of any other breach or failure by said other Party whether of a similar nature or otherwise. The rights and remedies provided herein are cumulative and do not exclude any other right or remedy provided by applicable Law or
otherwise available except as expressly set forth herein. 
 7.6. Assignment. 

7.6.1. No Party may assign or transfer this Agreement or any rights or obligations hereunder, directly or indirectly (by operation of
Law or otherwise), without the prior written approval of the other Party and any attempted assignment without such required approval shall be null, void and of no effect; provided, however, that (a) MedImmune may assign its rights, interests or
obligations hereunder to an Affiliate of MedImmune or to any successor in interest (whether by merger, acquisition, asset purchase or otherwise) to all or substantially all of the business to which this Agreement relates, in each case without
Spinco’s prior written approval and (b) Spinco may assign its rights, interests, and obligations hereunder (in whole and not in part) to a wholly owned Affiliate of Spinco without MedImmune’s prior written approval. In addition,
following the earlier to occur of (c) the consummation in full of the Milestone Closing (as defined in the Securities Purchase Agreement) and (d) the consummation of a 

  
 12 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II)
WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 
Qualified IPO (as defined in the Restated Certificate (as defined in the Securities Purchase Agreement)), Spinco may assign its applicable rights, interests, and obligations hereunder related to
one or both Products to a Third Party without MedImmune’s prior written approval, so long as (i) such assignment shall be in connection with the divestment by Spinco of all or substantially all of the assets relating to such Product or
Products (whether by asset purchase or exclusive out-license), (ii) in connection therewith, Spinco also assigns to such Third Party its applicable rights, interests, and obligations under the other
Transaction Agreements related to such Product or Products, and (iii) proper provision shall be made so that the successors and assigns of Spinco shall succeed to Spinco’s applicable rights and obligations set forth herein and therein.
Furthermore, if Spinco or any of its successors or assigns (e) consolidates with or merges into any other Person and shall not be the continuing or surviving corporation or entity of such consolidation or merger or (f) transfers, licenses
or conveys all or substantially all of its rights and assets to any Person, then, and in each such case, Spinco may assign its rights, interests and obligations hereunder (in whole and not in part) to such Person without the prior written approval
of MedImmune so long as in connection therewith Spinco (i) also assigns to such Person all of its applicable rights, interests, and obligations under the other Transaction Agreements, and (ii) ensures that proper provision shall be made so
that the successors and assigns of Spinco shall succeed to Spinco’s rights and obligations set forth in this Agreement. Notwithstanding anything to the contrary set forth herein, no assignment or succession pursuant to this Section 7.6.1
shall relieve the assigning Party or predecessor Party of its obligations hereunder. Upon any permitted assignment, the references in this Agreement to a Party shall also apply to any such assignee unless the context otherwise requires. 

7.6.2. Notwithstanding the foregoing, in the event a Party assigns its rights or obligations under this Agreement or otherwise makes
payments from a jurisdiction other than the jurisdiction in which such Party is organized (each, an “Assignment”), and immediately after such Assignment the amount of Tax required to be withheld on any payment pursuant to this
Agreement is greater than the amount of such Tax that would have been required to have been withheld absent such Assignment, then such increased withholding tax shall be borne by the Party making such Assignment. 

7.7. Amendment. Except as expressly provided herein, this Agreement may not be modified, amended, altered or supplemented except
upon the execution and delivery of a written agreement executed by both Parties. 
 7.8. Severability. If any provision of
this Agreement is held to be illegal, invalid or unenforceable under any present or future Law, and if the rights or obligations of either Party under this Agreement will not be materially and adversely affected thereby, (a) such provision
shall be fully severable, (b) this Agreement shall be construed and enforced as if such illegal, invalid or unenforceable provision had never comprised a part hereof, (c) the remaining provisions of this Agreement shall remain in full
force and effect and shall not be affected by the illegal, invalid or unenforceable provision or by its severance herefrom and (d) in lieu of such illegal, invalid or unenforceable provision, there shall be added automatically as a part of this
Agreement a legal, valid and enforceable provision as similar in terms to such illegal, invalid or unenforceable provision as may be possible and reasonably acceptable to the Parties. 

  
 13 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II)
WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 7.9. English Language. This Agreement shall be written and executed in, and
all other communications under or in connection with this Agreement shall be in, the English language. Any translation into any other language shall not be an official version thereof, and in the event of any conflict in interpretation between the
English version and such translation, the English version shall control. 
 7.10. Counterparts. This Agreement may be executed
in any number of counterparts, and each such counterpart hereof shall be deemed to be an original instrument, but all such counterparts together shall constitute but one agreement. Delivery of an executed counterpart of a signature page of this
Agreement by facsimile or other electronic transmission shall be effective as delivery of a manually executed original counterpart of this Agreement. 

7.11. Entire Agreement. This Agreement, along with the attached Schedule, together with the APA, the Transition Services
Agreement (together with the Schedules and Exhibits expressly contemplated thereby and attached thereto), the Disclosure Schedules, the other Transaction Agreements and the other agreements, certificates and documents delivered in connection with
the APA or otherwise in connection with the transactions contemplated hereby and thereby, contain the entire agreement between the Parties with respect to the transactions contemplated hereby or thereby and supersede all prior agreements,
understandings, promises and representations, whether written or oral, between the Parties with respect to the subject matter hereof and thereof. In the event of any inconsistency between any such Schedules and Exhibits and this Agreement, the terms
of this Agreement shall govern. In the event of any inconsistency between this Agreement and the other Transaction Agreements, the APA shall control. 

7.12. Construction. The Parties have participated jointly in the negotiation and drafting of this Agreement and, in the event an
ambiguity or question of intent or interpretation arises, this Agreement shall be construed as jointly drafted by the Parties and no presumption or burden of proof shall arise favoring or disfavoring any Party by virtue of the authorship of any
provision of this Agreement. Except where the context otherwise requires, wherever used, the singular includes the plural, the plural the singular, the use of any gender shall be applicable to all genders and the word “or” is used in the
inclusive sense “and/or”. The table of contents and captions of this Agreement are for convenience of reference only and in no way define, describe, extend or limit the scope or intent of this Agreement or the intent of any provision
contained in this Agreement. The term “including” or its variations as used herein does not limit the generality of any description preceding such term and shall be construed as “including, without limitation.” The language of
this Agreement shall be deemed to be the language mutually chosen by the Parties and no rule of strict construction shall be applied against either Party. Unless otherwise specified or where the context otherwise requires, (a) references in
this Agreement to any Article, Section, Schedule or Exhibit are references to such Article, Section, Schedule or Exhibit of this Agreement, and references to this “Agreement” are references to this Agreement and all exhibits and schedules
hereto; (b) references in any Section to any clause are references to such clause of such Section; (c) “hereof,” “hereto,” “hereby,” “herein” and “hereunder” and words of similar import when
used in this Agreement refer to this Agreement as a whole and not to any particular provision of this Agreement; (d) references to a person are also to its permitted successors and assigns; (e) references to a Law include any amendment or
modification to such Law and any rules, regulations or legally binding guidelines issued 

  
 14 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II)
WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 
thereunder, in each case, as in effect at the relevant time of reference thereto; (f) references to any agreement, instrument or other document in this Agreement refer to such agreement,
instrument or other document as originally executed or, if subsequently amended, replaced or supplemented from time to time, as so amended, replaced or supplemented and in effect at the relevant time of reference thereto; (g) “extent” in
the phrase “to the extent” means the degree to which a subject or other thing extends, and such phrase does not mean simply “if”; (h) references to monetary amounts are denominated in United States Dollars; and
(i) references to days (excluding Business Days) or months shall be deemed references to calendar days or months. 
 [SIGNATURE
PAGE FOLLOWS.] 

  
 15 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II)
WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 THIS AGREEMENT IS EXECUTED by the authorized representatives of the Parties as of the date first written
above. 
  

			
	MedImmune, LLC	  	Viela Bio, Inc.
		
	By: [***]	  	By: /s/ Zhengbin (Bing) Yao
		
	Name: [***]	  	Name: Zhengbin (Bing) Yao
		
	Title: [***]	  	Title: CEO

  

  
 SIGNATURE PAGE TO LICENSE
AGREEMENT 
 [*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT
MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 Schedule 1 

Lonza License Agreement 

LICENSES AND SERVICES AGREEMENT 

by and between 

ASTRAZENECA AB 
 and

 LONZA BIOLOGICS PLC 

DATE: 21 January 2005 

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 TABLE OF CONTENTS 
  

							
	1.	  	Interpretation and Definitions	  	 	1	 
			
	2.	  	Construction	  	 	7	 
			
	3.	  	Scope & Governance	  	 	8	 
			
	4.	  	Research and Evaluation License	  	 	8	 
			
	5.	  	Product Schedules	  	 	8	 
			
	6.	  	License to Exploit LB Technology for Products or End Products	  	 	9	 
			
	7.	  	Services	  	 	14	 
			
	8.	  	Delivery and Quality Control	  	 	17	 
			
	9.	  	Consideration for Services and Taxes	  	 	18	 
			
	10.	  	Intellectual Property Rights and Inventions	  	 	19	 
			
	11.	  	Warranties and Indemnities	  	 	20	 
			
	12.	  	Term & Termination	  	 	22	 
			
	13.	  	Confidentiality	  	 	25	 
			
	14.	  	Force Majeure	  	 	27	 
			
	15.	  	Severability	  	 	28	 
			
	16.	  	Variation and Amendments	  	 	28	 
			
	17.	  	Public Announcements	  	 	28	 
			
	18.	  	Agency, Partnership or Joint Venture Excluded	  	 	28	 
			
	19.	  	Assignment and Affiliates	  	 	29	 
			
	20.	  	Remedies and Waivers	  	 	29	 
			
	21.	  	Notices	  	 	29	 
			
	22.	  	Entire Agreement	  	 	30	 
			
	23.	  	Contracts (Rights of Third Parties) Act 1999	  	 	31	 
			
	24.	  	Governing Law & Disputes	  	 	31	 
			
	25.	  	Counterparts	  	 	31	 

 Exhibit 1 Form Side Letter 

Exhibit 2 Patents 
 Exhibit 3 Research Evaluation Agreement 

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 Page 1 of 63 
  

 This Licenses and Services Agreement (the “Agreement”) is made effective as of
21 January 2005 (the “Effective Date”) by and between 
  

	(1)	 ASTRAZENECA AB, a Swedish corporation having its principal place of business at
S-151 85 Södertälje, Sweden (“AstraZeneca”); and 

  

	(2)	 LONZA BIOLOGICS PLC, a company incorporated in England & Wales under no. 2742471 whose registered
office is situated at 228 Bath Road, Slough, SL1 4DX, United Kingdom (“Lonza Biologics”). 

 Recitals 

 

	(A)	 WHEREAS, AstraZeneca presently has, and expects to continue to research and develop new biopharmaceuticals
products and to develop both commercial and technical information Know-How and other Intellectual Property Rights in relation to such new biopharmaceutical products, and the manufacture and use of such
biopharmaceutical products. 

  

	(B)	 WHEREAS, Lonza Biologics has the expertise in the process development and production of monoclonal antibodies
for therapeutic use and has proprietary intellectual property rights relating to a [***] gene expression system and relating [***] media and feeds for manufacturing biopharmaceutical products (“LB Technology” as defined below).

  

	(C)	 WHEREAS, AstraZeneca wishes to use Lonza Biologics’ LB Technology under licenses in the research of
biopharmaceuticals and to the extent successful in such research to develop, manufacture, market and sell biopharmaceutical products as End Products (as defined below). 

 

	(D)	 WHEREAS, AstraZeneca and Lonza Biologics wish, by this Agreement, to establish the framework under which Lonza
Biologics grants such licenses and is able to offer services for such research and development of biopharmaceutical products using the LB Technology, which biopharmaceutical products the Parties from time to time hereunder may agree to become one of
“Products” (as hereinafter defined) within the scope of this Agreement. 

 Agreement 

NOW, THEREFORE, in consideration of the mutual covenants contained in this Agreement, and other good and valuable consideration, the receipt and sufficiency of
which are hereby acknowledged, the Parties, intending to be legally bound, agree as follows: 

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 Page 2 of 63 
  

	1.	 Interpretation and Definitions 

In this Agreement, including its Product Schedules incorporated herein pursuant to Section 5.1, the following expressions shall have the
following meanings, unless the context requires otherwise: 
  

	1.1	 “Affiliate(s)” means, with respect to a Person, any Person that controls, is controlled by or
is under common control with such first Person. For purposes of this definition only, “control” means (a) to possess, directly or indirectly, the power to direct the management or policies of a Person, whether through ownership of
voting securities, by contract relating to voting rights or corporate governance or otherwise, or (b) to own, directly or indirectly, more than fifty percent (50%) of the outstanding voting securities or other ownership interest of such Person.
The following companies (but not limited to) are Affiliates of AstraZeneca for the purposes of this Agreement: AstraZeneca AB, AstraZeneca UK Limited, AstraZeneca Pharmaceutical LP, AstraZeneca India Private Limited, AstraZeneca Canada Inc.,
AstraZeneca KK, and AstraZeneca Rheims SA. AstraZeneca will notify Lonza Biologics of any other Affiliate than those listed above which will use the licenses and sublicenses under this Agreement. 

 

	1.2	 “AstraZeneca Information” means all data or information related to or comprised in
Intellectual Property Rights as well as other proprietary or confidential information in relation to AstraZeneca’s general business operations, technology and products, the Products, the End Products or their manufacture which is owned by, or
which is in the possession of, AstraZeneca or its Affiliates and which AstraZeneca or its Affiliates are otherwise entitled to disclose. 

  

	1.3	 “AstraZeneca Material” means the material to be provided to Lonza Biologics by AstraZeneca as
set out in the relevant Product Schedule; being compounds, cells, cell lines, Cell Lines, DNA and RNA molecules, plasmids, proteins, crystals, coordinates, antibodies, antibody coding DNA sequences, antibody coding expression vectors and antibody
expressing transfected cell lines and other materials and any replications of any of the foregoing, that AstraZeneca provides to Lonza Biologics to enable Lonza Biologics to perform services under the Work Programme; provided, however, that
“AstraZeneca Materials” shall exclude all Programme IPR. 

  

	1.4	 “Background IPR” means any Intellectual Property Rights relating to the Confidential
Information, generated independently of the work under this Agreement owned or controlled by Lonza Biologics or AstraZeneca or to which Lonza Biologics or AstraZeneca has rights on the Effective Date or from time to time during the term of this
Agreement. 

  

	1.5	 “Business Day” means any day on which AstraZeneca and Lonza Biologics are open for business.

  

	1.6	 “Cell Line” means the cell line created under and specified in the relevant Product Schedule.

  

	1.7	 “Competing Contract Manufacturer” means any party who undertakes or performs more than fifty
percent (50%) of their business as a third party manufacturer of monoclonal antibodies or therapeutic proteins or any product of a similar nature to that which this Agreement relates. 

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 Page 3 of 63 
  

	1.8	 “Commencement of Phase 2 Clinical Study” means the date of the first administration of the
Product or End Product in a person in a Phase 2 Clinical Study. 

  

	1.9	 “Confidential Information” means all AstraZeneca Information and all Lonza Biologics
Information disclosed to a Receiving Party by a Disclosing Party pursuant to this Agreement in written, verbal or any other form. 

  

	1.10	 “Work Programme” means the services under a work programme to be undertaken by Lonza Biologics
for each Product as set out in Part B of the Product Schedule applicable to such Product. 

  

	1.11	 “Disclosing Party” means the Party (or the Affiliate of a Party) disclosing Confidential
Information. 

  

	1.12	 “Documents” mean reports, research notes, charts, graphs, comments, computations, analyses,
recordings, photographs, paper, notebooks, books, files, ledgers, records, tapes, discs, diskettes, CD-ROM, computer programs and documents thereof, computer information storage means, samples of material,
other graphic or written data and any other media on which Know-How can be permanently stored. 

  

	1.13	 “Effective Date” means the date specified on page 1 of this Agreement. 

 

	1.14	 “End Products” mean pharmaceutical dosage forms marketed by or on behalf or AstraZeneca or its
Affiliates, now or in the future, that comprise or utilise any of the Products in their manufacture. 

  

	1.15	 “Exploit” means to make, have made, import, use, sell, or offer for sale, including to
research, develop, register, modify, enhance, improve, manufacture, have manufactured, hold/keep (whether for disposal or otherwise), formulate, optimise, have used, export, transport, distribute, promote, market or have sold or otherwise dispose or
offer to dispose of, a product or process. For the avoidance of doubt “Exploit” does not include (i) performing modifications, enhancements or improvements to LB System Materials, or (ii) performing any analysis, tests, reverse
engineering, experiment or optimisation of the LB Media and Feeds Technology; provided however that AstraZeneca shall always be able to make spent media analysis. 

 

	1.16	 “First Commercial Sale” means the first sale for monetary value for use or consumption by the
general public of a Product (or End Product) in any country after Health Registration Approval for such Product (or End Product) has been obtained in such country. For the avoidance of doubt, sales prior to receipt of all Health Registration
Approvals necessary to commence regular commercial sales, such as so-called “treatment IND sales,” “named patient sales” and “compassionate use sales,” shall not be construed as a
First Commercial Sale. 

  

	1.17	 “GMP” or “cGMP” means Good Manufacturing Practices and General Biologics
Products Standards as promulgated under the US Federal Food Drug and Cosmetic Act at 21CFR (Chapters 210, 211, 600 and 610) and the Guide to Good Manufacturing Practices for Medicinal Products (EudraLex Vol 4, GMP Guide incl relevant Annexes as 13,
16, 18) as promulgated under European Directive 2003/94/EEC. For the avoidance of doubt, Lonza Biologics’ operational quality standards are defined in internal GMP policy documents and are based on cGMP. 

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 Page 4 of 63 
  

	1.18	 “Health Registration Approval” means, with respect to a country, any and all approvals,
licences, registrations or authorisations of any health authority necessary to commercially distribute, sell or market a Product (or End Product) in such country, including, where applicable, (a) pricing and reimbursement approval in such
country, (b) pre- and post-approval marketing authorisations (including any prerequisite manufacturing approval or authorisation related thereto), (c) labelling approval and (d) technical, medical
and scientific licences. 

  

	1.19	 “IND” means an Investigational New Drug application in USA or its foreign equivalent.

  

	1.20	 “Indirect Taxes” means value added taxes, sales taxes, consumption taxes and other similar
taxes. 

  

	1.21	 “Intellectual Property Rights” and “IPR” means
Know-How, Patents, trade marks, service marks, trade names, design rights, copyright (including rights in computer software) and any rights or property similar to any of the foregoing in any part of the world
whether registered or not registered together with the right to apply for the registration of any such rights, and all rights or forms of protection having equivalent or similar effect, in any part of the world. 

 

	1.22	 “Invention” means any Intellectual Property Rights (whether patentable or not) which
constitute an invention, improvement, discovery, extension of Know-How, upgrading or modification arising out of Lonza Biologics’ work in connection with each Work Programme or Lonza Biologics’
evaluation of AstraZeneca Information. 

  

	1.23	 “Know-How” means unpatented technical and other
information which is not in the public domain, including without limitation information comprising or relating to concepts, discoveries, data, designs, formulae, ideas, inventions, methods, models, assays, research plans, procedures, designs for
experiments and tests and results of experimentation and testing (including results of research or development), processes (including manufacturing processes, specifications and techniques), laboratory records, chemical, pharmacological,
toxicological, clinical, analytical and quality control data, trial data, case report forms, data analyses, reports, manufacturing data or summaries and information contained in submissions to and information from ethical committees and regulatory
authorities. Know-How includes Documents containing Know-How. The fact that an item is known to the public shall not be taken to exclude the possibility that a
compilation including the item, or a development relating to the item, is not known to the public. Know-How includes any rights including trade secrets, copyright, database or design rights protecting such Know-How. 

  

	1.24	 “Lonza Biologics Information” means all data and information related to or comprised in
Intellectual Property Rights as well as other proprietary or confidential information in relation to Lonza Biologics’ general business operations, development and manufacturing processes which is owned by Lonza Biologics or which is in its
possession and which it is otherwise entitled to disclose. 

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 Page 5 of 63 
  

	1.25	 “LB System Technology” means the [***] system of which Lonza Biologics is the proprietor or
licensee under patents set out in Exhibit 2 and relating Know-How. 

  

	1.26	 “LB Technology” means the LB System Technology, the LB Media and Feeds Technology, LB System
Materials and LB Materials. 

  

	1.27	 “LB Media and Feeds Technology” means the [***] media and feeds used in the LB System
Technology, which media and feeds Lonza Biologics is the proprietor or licensee under patents set out in Exhibit 2 and relating Know-How and instructions on use. 

 

	1.28	 “LB Materials” means all other materials provided and owned by Lonza Biologics, except the LB
System Materials. 

  

	1.29	 “LB System Materials” means the recipient cell lines and vectors containing the LB System
Technology, but excluding any gene proprietary to AstraZeneca inserted in the cell tine for the purposes of producing the Product. 

  

	1.30	 “Milestone” means such milestone relating to each Work Programme in relation to a Product as
may be set out in Part B of the Product Schedule applicable thereto or otherwise agreed between the Parties. 

  

	1.31	 “Net Sales” means the gross invoiced amount on sales of the Products (or End Products) by
AstraZeneca and its Affiliates to Third Parties (including Distributors) after deduction of (a) normal and customary trade, quantity or prompt settlement discounts (including chargebacks and allowances) actually allowed; (b) amounts repaid
or credited by reason of rejection, returns or recalls of goods, rebates or bona fide price reductions determined by AstraZeneca or its Affiliates in good faith; (c) rebates and similar payments made with respect to sales paid for by any
governmental or regulatory authority such as, by way of illustration and not in limitation of the Parties’ rights hereunder, Federal or state Medicaid, Medicare or similar state program in the United States or equivalent governmental program in
any other country; (d) [***] of the gross invoiced amount as an allowance for transportation costs, distribution expenses, special packaging and related insurance charges; (e) excise taxes, Indirect Taxes, customs duties, customs levies
and import fees imposed on the sale, importation, use or distribution of the Products; and (f) any other similar and customary deductions that are consistent with generally accepted accounting principles, or in the case of non-United States sales, other applicable accounting standards. Net Sales shall be calculated using AstraZeneca’s internal audited systems used to report such sales as adjusted for any of items (a) to (f)
above not taken into account in such systems. Sales between AstraZeneca, its Affiliates and sub licensees shall not be subject to royalties hereunder. Royalties shall be calculated on AstraZeneca’s and its Affiliates’ sale of the Products
(or End Product) to a Third Party (including Distributors). Royalties shall be payable only once for any given batch of the Products (or End Product). 

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 Page 6 of 63 
  

 For purposes of determining Net Sales, the Product (or End Product) shall he deemed to be
sold when invoiced and a “sale” shall not include, and no royalties shall be payable on, transfers by AstraZeneca, its Affiliates or sub licensees of free samples of Products (or End Product) or clinical trial materials or other transfers
or dispositions for charitable, promotional, pre-clinical, clinical, manufacturing, testing or qualification, regulatory or governmental purposes. 

 

	1.32	 “Party” means AstraZeneca or Lonza Biologics as the context requires and
“Parties” mean both AstraZeneca and Lonza Biologics. 

  

	1.33	 “Patents” means (a) all national, regional and international patents and patent
applications, including provisional patent applications, (b) all patent applications filed either from such patents, patent applications or provisional applications or from an application claiming priority from either of these, including
divisionals, continuations, continuations-in-part, provisionals, converted provisionals, and continued prosecution applications, (c) any and all patents that have
issued or in the future issue from the foregoing patent applications ((a) and (b)), including utility models, petty patents and design patents and certificates of invention, (d) any and all extensions or restorations by existing or future
extension or restoration mechanisms, including revalidations, reissues, re-examinations and extensions (including any supplementary protection certificates and the like) of the foregoing patents or patent
applications ((a), (b) and (c)), and (e) any similar rights, including so-called pipeline protection, or any importation, revalidation, confirmation or introduction patent or registration patent or patent
of additions to any such foregoing patent applications and patents. 

  

	1.34	 “Phase 2 Clinical Study” means a clinical study done in persons with signs or symptoms of the
disease for which the Product or End Product is intended, and which purpose is to gain evidence of efficacy and to establish the proper dose and dosing intervals. 

 

	1.35	 “Person” means an individual, sole proprietorship, partnership, limited partnership, limited
liability partnership, corporation, limited liability company, business trust, joint stock company, trust, incorporated association, joint venture or similar entity or organization, including a government or political subdivision, department or
agency of a government. 

  

	1.36	 “Process” means the process for the production of the Product from the Cell Line, including
any improvements or modifications thereto from time to time. 

  

	1.37	 “Product” means the product(s) identified in Part A of the Product Schedule applicable
thereto. 

  

	1.38	 “Programme IPR” means Programme IPR General Application and Programme IPR AstraZeneca
Application. 

  

	1.39	 “Programme IPR General Application” means any Intellectual Property Rights relating to
Inventions and when the Inventions as such, that meets each of the following three criteria: 

  

	 	1.39.1	 arises from or is based upon the Lonza Biologics’ Background IPR, Lonza Biologics Information, or LB
Technology; and 

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 Page 7 of 63 
  

	 	1.39.2	 consists of subject matter of general applicability to the current business of Lonza Biologics; and

  

	 	1.39.3	 is reasonably necessary or useful to Lonza Biologics for applications that are unrelated to the AstraZeneca
Background IPR, and, when used for such applications, does not reveal or disclose any information about AstraZeneca Information, AstraZeneca Background IPR, AstraZeneca Materials or Services performed under this Agreement. 

 

	1.40	 “Programme IPR AstraZeneca Application” means any Intellectual Property Rights relating to
Inventions and when the Inventions as such relates to AstraZeneca Information, AstraZeneca Background IPR or AstraZeneca Materials. 

  

	1.41	 “Receiving Party” means the Party (or the Affiliate of a Party) to whom Confidential
Information is disclosed. 

  

	1.42	 “Services” mean the services or activities to be provided by Lonza Biologics or Products to be
manufactured under the individual Product Schedules. 

  

	1.43	 “Specification” means specification of the Product or other product to he performed or
supplied set out in the relevant Product Schedule. 

  

	1.44	 “Strategic Partner” means a Third Party with whom AstraZeneca or its Affiliates have a
collaboration arrangement to identify a therapeutic target, collaborate in performance of research and development of a Product or a product of which the Strategic Partner is the proprietor, except for Competing Contract Manufacturer.

  

	1.45	 “Third Party” means any Person other than the Parties or their respective Affiliates.

  

	2.	 Construction 

 

	2.1	 Except where the context requires otherwise, whenever used the singular includes the plural, the plural
includes the singular, the use of any gender is applicable to all genders and the word “or” has the inclusive meaning represented by the phrase “and/or”, unless it is obvious from the context that the meaning is solely
“or”. Whenever this Agreement refers to a number of days, unless otherwise specified, such number refers to calendar days. The headings of this Agreement are for convenience of reference only and do not define, describe, extend or limit
the scope or intent of this Agreement or the scope or intent of any provision contained in this Agreement. The term “including” or “includes” as used in this Agreement means including, without limiting the generality of any
description preceding such term. The wording of this Agreement shall be deemed to be the wording mutually chosen by the Parties and no rule of strict construction shall be applied against any Party. 

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 Page 8 of 63 
  

	2.2	 References to recitals, Sections and Product Schedules are to the recitals and Sections of and Product
Schedules to this Agreement. References in this Agreement to “Product Schedules” refer to the Product Schedules incorporated into this Agreement pursuant to Section 5.1 and the expressions “Work Programme”,
“Milestones” (and such other expressions as relate to the Products case-by-case) relate to the relevant Products described in the Product Schedule applicable
thereto. 

  

	2.3	 To the extent that there is conflict between or ambiguity relating to, on the one hand, any or all of the
Product Schedules and, on the other, the remainder of this Agreement, the wording of the relevant Product Schedule or Product Schedules shall prevail. 

  

	3.	 Scope & Governance 

 

	3.1	 The Parties agree to collaborate on the terms of this Agreement in which AstraZeneca and its Affiliates are
granted licenses for research of products and use in development, manufacture and sale of Products or End Products and Lonza Biologics undertakes to provide Services, all under LB Technology. Licenses to the LB Technology to Exploit for Products or
End Products and Services will be for such Products or End Products as arc listed in the Product Schedules (as amended from time to time), unless different terms are specified in this Agreement or the Work Programme for each particular Product.

  

	4.	 Research and Evaluation License 

 

	4.1	 AstraZeneca and its Affiliates are hereby granted a worldwide, research and evaluation license on the terms and
conditions as set out in the Research Evaluation Agreement (REA) in Exhibit 3. 

  

	5.	 Product Schedules 

 

	5.1	 Each time that the Parties agree that a new product should be added to and come within the scope of this
Agreement either (i) for the Product to be covered by the LB Technology License or parts thereof in conjunction with Services to be provided by Lonza Biologics, or (ii) for the Product to be covered by the LB Technology License or parts
thereof but without any Services being provided by Lonza Biologics, the Parties shall prepare and agree, in duplicate, a Product Schedule for such product. Each such Product Schedule shall he consecutively numbered and shall contain at least the
following sections (in case of (ii) above, the sections Parts B-E below may be filled in as not applicable); 

  

	 	5.1.1	 Part A: description of the Product; and 

 

	 	5.1.2	 Part B: description of the Work Programme and Specification intended for the Product and if any, a
listing of the AstraZeneca Material to be transferred; and 

  

	 	5.1.3	 Part C: provisions regarding any financial consideration in relation to the Product including any agreed
provisions relating to the termination or cancellation of the relevant Work Programme; and 

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 Page 9 of 63 
  

	 	5.1.4	 Part D: (if agreed at the date of execution of the relevant Product Schedule) the principal supply terms
agreed for the supply of the Product following the Work Programme. 

  

	 	5.1.5	 As Appendix to the Product Schedule: Quality Agreement, to be updated and agreed at least [***] ([***])
[***] prior to the commencement of any Services requiring cGMP compliance performed by Lonza Biologics. 

 To the extent
that there is conflict between or ambiguity relating to, on the one hand, the quality requirements in the Quality Agreement and, on the other, the Product Schedule Part B, the wording of the Quality Agreement shall prevail. 

 

	5.2	 With effect from the date upon which the Parties have signed a new Product Schedule pursuant to the above
provisions (or such earlier date as may be stated in such Product Schedule): 

  

	 	5.2.1	 that Product Schedule shall form part of this Agreement; and 

 

	 	5.2.2	 the Product referred to therein shall be one of the Products for the purposes of this Agreement, and the Work
Programme and provisions regarding any consideration in relation to that Product set out in such new Product Schedule shall, with immediate effect, be the Work Programme and financial consideration. 

 

	5.3	 Each time that the Parties agree that a Product Schedule should he amended or updated to reflect progress of
the relevant Work Programme or changes to the relevant Product or End Product, the Parties shall prepare and agree, in duplicate, a revised Product Schedule for the relevant Product. Once the Parties have signed and dated a revised Product Schedule
pursuant to the above provisions, in duplicate, that Product Schedule shall, with immediate effect, form part of this Agreement and shall supersede the previous version of such Product Schedule or as otherwise is set out in the revised Product
Schedule. 

  

	6.	 License to Exploit LB Technology for Products or End Products 

 

	6.1	 Lonza Biologics hereby grants to AstraZeneca and its Affiliates, a worldwide, perpetual and irrevocable (save
for AstraZeneca’s breach of the Agreement or Product Schedule but always relating to a specific Product as set out in Section 12.2), non-exclusive right, licence or sublicense under Lonza
Biologics’ right, title and interest in and to 

  

	 	6.1.1	 the LB System Technology including the Cell Line and vector containing the Product gene derived from the LB
System Materials, and 

  

	 	6.1.2	 the LB Media and Feeds Technology 

to Exploit and otherwise use the LB System Technology and the LB Media and Feeds Technology in conjunction with a Product or End Product as a
therapeutic pharmaceutical product in humans or for diagnostic, veterinary or any other use, License to use the LB Material may be granted as agreed in each Product Schedule. 

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 Page 10 of 63 
  

 For the avoidance of doubt, the LB Media and Feeds Technology can only be used in conjunction
with the LB System Technology, and may not be used in conjunction with any other gene expression system or for any other purpose whatsoever. 
  

	6.2	 AstraZeneca shall have the right to grant sublicenses under its license or sublicense in Section 6.1 (i)
to Strategic Partners to the LB System Technology including the Cell Line and vector containing the Product gene derived from the LB System Materials and the LB Media and Feeds Technology and (ii) to Competing Contract Manufacturers or to Third
Parties to the LB System Technology including the Cell Line and vector containing the Product gene derived from the LB System Materials. 

  

	6.3	 When AstraZeneca or Strategic Partners manufactures the Product (or End Product) being a therapeutic
pharmaceutical product in humans, AstraZeneca shall pay annual license fees as set out below for such licenses granted under Sections 6.1 and 6.2 payable from the Commencement of Phase 2 Clinical Study until the expiry of the last patent under the
LB System Technology in Exhibit 2, during such calendar years 

  

	 	6.3.1	 Product (or End Product) no 1 [***] (£[***]) 

 

	 	6.3.2	 Products (or End Products) no 2-4 [***] (£[***])

  

	 	6.3.3	 Product (or End Product) no 5 - onwards [***] ([***]) 

For avoidance of doubt, the first Product (or End Product) manufactured by AstraZeneca or a Strategic Partner to reach the Commencement of
Phase 2 Clinical Study shall be considered to be the Product (or End Product) no 1 according to subsection 6.3.1, the second Product (or End Product) manufactured by AstraZeneca or a Strategic Partner to reach Commencement of Phase 2 Clinical Study
shall be considered to be Product (or End Product) no 2 according to subsection 63.2 and so forth. 
  

	6.4	 When AstraZeneca or Strategic Partners manufactures the Product (or End Product) being a therapeutic
pharmaceutical product in humans using the LB System Technology and the LB Media and Feeds Technology, AstraZeneca shall be invoiced a one-off license fee per Product, for Product (or End Product) no 1 of
[***] (£[***]), Products (or End Products) no 2-4 [***] (£[***]), and Product (or End Product) no 5 - onwards [***] (£[***]) on the date of the first administration in humans. Lonza Biologics
shall immediately credit such invoices with an equivalent amount. Such invoices on Products may be sent and credited until the expiry of the last patent under the LB System Technology and the LB Media and Feeds Technology in Exhibit 2.

  

	6.5	 In addition, when AstraZeneca or Strategic Partners manufacture the Product (or End Product) using the LB
System Technology, AstraZeneca shall pay Lonza Biologics a running royalty of 

  

	 	6.5.1	 [***] ([***]) on Net Sales on each Product (or End Product) manufactured by AstraZeneca or a Strategic Partner
during the Royalty Patent Team; and thereafter 

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 Page 11 of 63 
  

	 	6.5.2	 [***] ([***]) on Net Sales on each Product (or End Product) manufactured by AstraZeneca or a Strategic Partner
during the Royalty Know-How Term. 

  

	6.6	 In addition, when AstraZeneca or Strategic Partners manufactures the Product (or End Product) using the LB
Media and Feeds Technology, AstraZeneca shall pay Lonza Biologics a running royalty of [***] ([***]) on Net Sales on each Product (or End Product) manufactured by AstraZeneca or a Strategic Partner utilizing such LB Media and Feeds Technology during
the Royalty Patent Term of LB Media and Feeds Technology, 

  

	6.7	 In case AstraZeneca sublicense the LB System Technology for the manufacturing of Products (or End Product)
being a therapeutic pharmaceutical product in humans to Competing Contract Manufacturers or Third Parties, AstraZeneca shall pay annual sublicense fee of [***] (£[***]) for the duration of such sublicense arrangements, but in no event is such
sublicense fee due or payable prior to the date of the first Product to be manufactured according to GMP requirements by such third party and not after the expiry of the last patent to expire under the LB System Technology. 

 

	6.8	 In the event that AstraZeneca Sublicense the LB System Technology as set out in Section 6.7, AstraZeneca
shall, in lieu of royalty according to Section 6.4, pay Lonza Biologics a running royalty of [***] ([***]) on Net Sales on each Product (or End Product) manufactured by such third party during the term of such sublicense arrangement according
to and within the Royalty Patent Term. 

  

	6.9	 In the event Lonza Biologics manufactures the Product for AstraZeneca, AstraZeneca shall pay Lonza Biologics in
respect of the LB System Technology, LB Media and Feeds Technology and LB Materials a running royalty of 

  

	 	6.9.1	 [***] ([***]) on Net Sales on each Product (or End Product) manufactured by Lonza Biologics during the Royalty
Patent Term; and thereafter 

	 	

	 	6.9.2	 [***] ([***]) on Net Sales on each Product (or End Product) manufactured by Lonza Biologics during the Royalty Know-How Term. 

 For avoidance of doubt, no annual or
one-off license fees are due in case Lonza Biologics manufactures the Product. 
  

	6.10	 Royalty Terms: 

 

	 	6.10.1	 Royalty Patent Term: AstraZeneca’s obligation to pay royalties shall commence, on a country-by-country basis, with respect to each separate Product (or End Product), on the date of First Commercial Sale of such Product (or End Product) in such country. The
obligation shall expire, on a country-by-country basis, with respect to each separate Product (or End Product), the expiration date in such country of the last to expire
of any issued Patent on the LB System Technology in Exhibit 2; or 

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 Page 12 of 63 
  

	 	6.10.2	 Royalty Know-Flow Term: AstraZeneca’s obligation to pay royalties shall commence, on a country-by-country basis, with respect to each separate Product (or End Product), on the date after the expiry date in such country of the last to expire or any issued Patent
on the LB System Technology in Exhibit 2. The obligation shall expire, on a country-by-country basis, with respect to each separate Product (or End Product), [***]
([***]) [***] after the commencement date of such royalty for each Product (or End Product). 

  

	 	6.10.3	 Royalty Patent Term of LB Media and Feeds Technology: AstraZeneca’s obligation to pay royalties
shall commence, on a country-by-country basis, with respect to each separate Product (or End Product), on the date of First Commercial Sale of such Product (or End
Product) in such country. The obligation shall expire at the expiration date of the last to expire of any issued Patent for the LB Media and Feeds Technology in Exhibit 2. 

 

	 	6.10.4	 Upon termination of the royalty obligations of AstraZeneca under this Section with respect to a Product (or End
product) in any country, the licence grants to AstraZeneca in this Article shall become fully paid-up, perpetual and irrevocable with respect to such country. 

 

	6.11	 Royalty Payments. The royalties shall be calculated quarterly as of the last day of March, June,
September and December respectively, for the calendar quarter ending on that date. AstraZeneca shall pay the royalties in conjunction with the delivery of a written report to Lonza Biologics within [***] ([***]) days after the end of each calendar
quarter that shows, with respect to each country and each Product (or End Product), the sales volume and Net Sales during such calendar quarter. 

  

	6.12	 Currency. AZ payments required under this Agreement shall be made in GBP, except for royalty payments,
which shall be made in U.S. Dollars. For the purpose of computing the Net Sales of Products (or End Product) sold in a currency other than U.S. Dollars, such currency shall be converted from local currency to U.S. Dollars by AstraZeneca in
accordance with the rates of exchange for the relevant month for converting such other currency into U.S. Dollars used by AstraZeneca’s internal accounting systems, which are independently audited on an annual basis. 

 

	6.13	 Records Retention. 

 

	 	6.13.1	 Until the third (3rd) anniversary of January 31 of the calendar year in which a Product (or End Product)
is sold, AstraZeneca shall keep or cause to be kept accurate records or books of account in accordance with applicable generally accepted accounting principles showing the information that is necessary for the accurate determination or the royalties
due hereunder with respect to the sale of such Product (or End Product), 

  

	 	6.13.2	 Upon the written request of Lonza Biologics, AstraZeneca shall permit a certified public accountant or a person
possessing similar professional status and associated with an independent accounting firm acceptable to the Parties to 

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 Page 13 of 63 
  

	 	
inspect during regular business hours and no more than once a year and going back no more than [***] ([***]) [***] preceding the current year, all or any part of AstraZeneca’s records and
books necessary to check the accuracy of the royalties paid. The accounting firm shall enter into appropriate obligations with AstraZeneca to treat all information it receives during its inspection in confidence. The accounting firm shall disclose
to Lonza Biologics and AstraZeneca only whether the royalty reports are correct and details concerning any discrepancies, but no other information shall be disclosed to Lonza Biologics. The charges of the accounting firm shall be paid by Lonza
Biologics, except that if the royalties have been understated by more than [***] ([***]), the charges shall be paid by AstraZeneca. 

  

	6.14	 Taxes General on License Fees and Royalties. The license fees and royalties payable by AstraZeneca to
Lonza Biologics pursuant to this Agreement (“Payments”) shall not be reduced on account of any taxes unless required by Applicable Law. Lonza Biologics alone shall be responsible for paying any and all taxes (other than withholding taxes
required by Applicable Law to be paid by AstraZeneca) levied on account of, or measured in whole or in part by reference to, any Payments it receives. AstraZeneca shall deduct or withhold from the Payments any taxes that it is required by Applicable
Law to deduct or withhold. Notwithstanding the foregoing, if Lonza Biologics is entitled under any applicable tax treaty to a reduction of rate of, or the elimination of, applicable withholding tax, it may deliver to AstraZeneca or the appropriate
governmental authority (with the assistance of AstraZeneca to the extent that this is reasonably required and is expressly requested in writing) the prescribed forms necessary to reduce the applicable rate of withholding or to relieve AstraZeneca or
its obligation to withhold tax, and AstraZeneca shall apply the reduced rate of withholding, or dispense with withholding, as the case may be, provided that AstraZeneca has received evidence, in a form satisfactory to AstraZeneca, of Lonza
Biologics’ delivery of all applicable forms (and, if necessary, its receipt of appropriate governmental authorization) at least [***] ([***]) [***] prior to the time that the Payments are due. If, in accordance with the foregoing, AstraZeneca
withholds any amount, it shall pay to Lonza Biologics the balance when due, make timely payment to the proper taxing authority of the withheld amount, and send to Lonza Biologics proof of such payment within [***] ([***]) [***] following that
payment. For purposes of this Agreement, the stated amount of the Payments payable by AstraZeneca includes any sales tax that Lonza Biologics maybe required to collect. 

 

	6.15	 Lonza Biologics hereby undertakes and agrees that at its own cost and expense it will: 

 

	 	6.15.1	 prosecute or procure prosecution or such of the Patents of the LB Technology which arc patent applications
diligently to grant so as to secure the best commercial advantage obtainable so far as it is reasonable to do so with reference to Lonza Biologics’ commercial considerations; and 

 

	 	6.15.2	 pay or procure payment of all renewal fees in respect of the Patents of the LB Technology valid and subsisting
for the full term thereof and in particular will procure such renewal of the registrations thereof as may be necessary from time to time so far as it is reasonable to do so with particular reference to commercial considerations.

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 Page 14 of 63 
  

	 	6.15.3	 Lonza Biologics undertakes and agrees to take all such steps and proceedings and to do all other acts and
things as may in Lonza Biologics’ sole discretion be necessary to restrain any third party infringement or improper or unlawful use or to defend any challenge to validity of the Patents of LB Technology and AstraZeneca shall permit Lonza
Biologics to have the sole conduct of any such steps and proceedings including the right to settle them whether or not AstraZeneca is a party to there. 

  

	7.	 Services 

 

	7.1	 Immediately following the date of the Product Schedule or such other date as is agreed by the Parties,
AstraZeneca shall supply to Lonza Biologics the AstraZeneca Information, together with full details of any hazards relating to the AstraZeneca Materials, their storage and use. On review of this AstraZeneca Information, the AstraZeneca Materials
shall be provided to Lonza Biologics, unless Lonza Biologics terminate the Work Programme within [***] ([***]) [***] from disclosure of such AstraZeneca Information on the ground that it finds that the AstraZeneca Materials mean unacceptable risks
to safety or health of the Lonza Biologics’ staff or facilities or unacceptable risks to Regulatory requirements for production of human medicinal products in such facilities. 

 

	7.2	 Lonza Biologics hereby agrees to use its reasonable endeavours and due skill and care and to provide
appropriate resources (i) to progress each Work Programme, (ii) to attain the Milestones and objectives of such Work Programme and (iii) to achieve the timescales. Such Milestones and objectives shalt include both technical and
commercial aspects of the Work Programme. 

  

	7.3	 Each Party shall cooperate with any and all reasonable requests for assistance from the other Party with
respect to the activities under the Work Programme, including by making its employees, consultants and other scientific staff available upon reasonable notice during normal business hours at their respective places of employment to consult with such
other Party on issues arising in connection with the Work Programme. 

  

	7.4	 Lonza Biologics shall manufacture cGMP Product according to the Quality Agreement to meet the Specifications
set out in the Product Schedule in relation to microbiological or viral contaminants except such microbiological or viral contaminants as are agreed in the Product Schedule to be “report results”. In relation to other requirements in the
Specifications Lonza Biologics shall use its reasonable endeavours and due skill and care to meet such requirements. 

  

	7.5	 Owing to the unpredictable nature of the biological processes involved in the Services (being of R&D nature
and not commercial scale manufacturing), the timescales set down for the performance of the Services (including without limitation the dates for production and Delivery of Product) and the quantities of Product for Delivery set out in the Product
Schedules are estimated only. 

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 Page 15 of 63 
  

	7.6	 Lonza Biologics shall comply with the International Committee for Harmonization regulatory guidelines (in force
from time to time) applicable, as interpreted by Lonza Biologics to be approved by AstraZeneca, to the Services as set out in the relevant Product Schedule. 

  

	7.7	 Lonza Biologics shall: 

 

	 	7.7.1	 at all times use all reasonable endeavours to keep the Cell Line and AstraZeneca Materials secure and safe from
loss and damage in such manner as Lonza Biologics stores its own material of similar nature i.e. among the highest professional standards in the industry; 

  

	 	7.7.2	 not part with possession of the Cell Line and AstraZeneca Materials or the Product, save for the purpose of
tests at subcontracted testing laboratories provided however that Lonza Biologics shall always keep the control of the Cell Line, AstraZeneca Materials or the Product; and 

 

	 	7.7.3	 procure that all subcontracted testing laboratories are subject to obligations of confidentiality and non-use substantially in the form of those obligations of confidentiality and non-use imposed on Lonza Biologics under this Agreement. 

 

	7.8	 Each Work Programme shall be monitored jointly by one nominee of Lonza Biologics and one nominee of AstraZeneca
(together “the Technical Representatives”) by regularly reviewing relevant parts of the Product Schedule for that Product and agreeing in good faith to reasonable changes that reflect progress of the Work Programme. 

 

	7.9	 The Technical Representatives shall for each Work Programme; 

 

	 	7.9.1	 establish and periodically review the content of the Work Programme, the goals of the Services, the
collaboration and the Milestones; and 

  

	 	7.9.2	 co-ordinate activities required to progress the Services, the
collaboration and the Work Programme (although, for the avoidance of doubt, the day to day management of the Work Programme shall be within the control of Lonza Biologics); and 

 

	 	7.9.3	 monitor the progress of the Services, the collaboration and the performance by the Parties of their obligations
hereunder; and 

  

	 	7.9.4	 meet on a quarterly basis or at such other intervals as the Parties shall agree (it being acknowledged that
such meetings may take place by telephone conference). 

  

	7.10	 At each meeting between them, the Technical Representatives shall nominate one of them to provide to both
Parties, within [***] ([***]) [***] after such meeting, written minutes of the matters discussed and agreed upon at such meeting. The Technical Representatives shall use all reasonable endeavours to agree such minutes within [***] ([***]) [***]
after the date of the relevant meeting, either by signing off or approve via email. If neither Technical Representative raises any objection before the expiry of such period, the minutes shall be deemed to have been accepted by both Technical
Representatives. 

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 Page 16 of 63 
  

	7.11	 In the event that unanimous consent cannot be reached between the Parties in respect of any material aspect of
a Work Programme other than for reasons set out in Section 12.4, the matter in question shall be referred to the Vice President of Global Process R&D, AstraZeneca and Head of the Slough site of Lonza Biologics and in the event that they are
unable to reach agreement at or prior to the ensuing meeting of the Technical Representatives either Party may terminate the Work Programme in question on [***] ([***]) [***] written notice; if terminated by AstraZeneca then the consequences in
Section 12.5 shall apply and if terminated by Lonza Biologics then the consequences in Section 12.4 shall apply. 

  

	7.12	 In performing its obligations under this Agreement, Lonza Biologics must ensure that all of its activities for
AstraZeneca comply with all applicable legislation, and directives, including, but not limited to the following: 

  

	 	7.12.1	 in respect of Transmissible Spongiform Encephalopathy (“TSE”): European Community Directive
1999/82/EC: This Directive formalises the arrangements laid down in CPMR/BWP/1230/98 and subsequent up dates “Notes for Guidance on Minimising Risk of Transmitting Animal Spongiform: Encephalopathy agents via Medicinal Products”.

  

	 	7.12.2	 in respect of Genetically Modified Organisms (“GMO”) EU directive 98/81/EC and its amendment
90/219/EEC and relevant national legislation, as applicable from time to time. 

  

	 	7.12.3	 in respect to GMP manufacture of active pharmaceutical ingredient: at the date of initiation of GMP manufacture
of active pharmaceutical ingredient Lonza Biologics must be able to provide documented evidence for a positive outcome of a GMP inspection of the facilities and processes applied for bulk drug manufacture. This inspection must be conducted by a
competent authority and based on EU requirements (EU Annex 18 to EU Guide to Good Manufacturing Practice). 

  

	7.13	 AstraZeneca does business with parties who conduct themselves in a manner consistent with AstraZeneca’s
policies concerning “Corporate Responsibility” as in effect from time to time. AstraZeneca shall provide Lonza Biologics with the most recent version of such policies. Lonza Biologics represents and warrants that Lonza Biologics will
perform this Agreement in material compliance with all applicable laws and regulations, including, without limitations, laws and regulations relating to safety, health, the environment, fair labour practices and unlawful discrimination. AstraZeneca
and Lonza Biologics shall, at a mutually convenient time and place, meet to discuss the performance of services and sharing of best practices in order to identify and pursue opportunities for continuous improvements with regard to Corporate
Responsibility objectives in the context of this Agreement. 

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 Page 17 of 63 
  

	8.	 Delivery and Quality Control 

 

	8.1	 The Product shall be delivered according to the delivery term set out in the relevant Product Schedule. Risk
and title to Product pass to AstraZeneca upon delivery according to the agreed delivery term Subject to Section 8.2, Lonza Biologics shall deliver to AstraZeneca the Certificate of Analysis not later than the date of delivery.

  

	8.2	 At AstraZeneca’s request, Lonza Biologics will deliver Product in quarantine prior to delivery of the
Certificate of Analysis. Such request shall he accompanied by AstraZeneca’s written acknowledgement that the Product has been delivered without the transmittal to AstraZeneca of a Certificate of Analysis, that accordingly the Product cannot be
administered to humans until transmittal of the Certificate of Analysis, and that AstraZeneca nevertheless accepts full risk of loss, title and ownership of the Product. The delivery of Product in quarantine shall be subject to such testing
requirements as Lonza Biologics may reasonably require, and the [***] ([***]) [***] period referred to in Section 8.6 shall run from receipt of the delivery in quarantine to AstraZeneca of the Product. 

 

	8.3	 Unless otherwise agreed, Lonza Biologics shall package and label Product manufactured according to GMP
requirements, for delivery in accordance with its standard operating procedures or as agreed in the Specification. 

  

	8.4	 AstraZeneca shall diligently examine the Product as soon as practicable after receipt. Notice of all claims
arising out of visible damage to or total or partial loss of Product shall be given in writing to Lonza Biologics within [***] ([***]) [***] of receipt by AstraZeneca, unless another timeframe is agreed in the relevant Product Schedule.

  

	8.5	 AstraZeneca shall make damaged Product and associated packaging materials available for inspection.

  

	8.6	 Following receipt of Product or any sample thereof, AstraZeneca may carry out any of the tests outlined or
referred to in the Specifications set out in the relevant Product Schedule. If such tests show that the Product fails to meet the Specifications relating to microbiological or viral contaminants as referred to in Section 7.4 above, AstraZeneca
shall give Lonza Biologics written notice thereof within [***] ([***]) [***] from the date of receipt and shall return such Product to Lonza Biologics’ premises for further testing. If Product returned to Lonza Biologics fails to meet such
Specifications and such failure is not due (in whole or in part) to acts or omissions of AstraZeneca or any third party after delivery, Lonza Biologics shall at AstraZeneca’s discretion (i) refund that part of the Price that relates to the
manufacture of such Product or (ii) replace such Product at its own cost and expense; and in all events remunerate AstraZeneca for any direct costs in connection therewith. In the event AstraZeneca requires Lonza Biologics to replace such
Product, Lonza Biologics shall use all reasonable endeavours to do so with the minimum delay having regard to its commitments to Third Parties in the timing of such replacement. 

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 Page 18 of 63 
  

	8.7	 If there is any dispute concerning whether Product returned to Lonza Biologics is damaged or fails to meet
Specification relating to microbiological or viral contaminants or whether such failure is due (in whole or in part) to acts or omissions of AstraZeneca or any third party after delivery, such dispute shall be referred for decision to an independent
expert (acting as an expert and not as an arbitrator) to be appointed by agreement between Lonza Biologics and AstraZeneca or, in the absence of agreement by the President for the time being of the Association of the British Pharmaceutical Industry.
The decision of such independent expert shall be in writing and, save for manifest error on the face of the decision, shall be binding on both Lonza Biologics and AstraZeneca. In the event that the independent expert decides there was no damage or
defect in the Product in question, the costs of the independent expert shall be borne by AstraZeneca. In all other circumstances, the costs of the independent expert shall be borne by Lonza Biologics. 

 

	8.8	 The remedies set out in this Article shall be the sole remedies available to AstraZeneca in respect of Product
that is damaged or fails to meet Specification, unless breach of warranty. 

  

	9.	 Consideration for Services and Taxes 

 

	9.1	 In consideration for the work to be undertaken by Lonza Biologics and the rights granted to AstraZeneca
hereunder, AstraZeneca agrees to pay to Lonza Biologics, at the times and in the manner set out in Part C of the relevant Product Schedule: 

  

	 	9.1.1	 such sums as are set out in Part C of the relevant Product Schedule in relation to each Work Programme; and

  

	 	9.1.2	 such costs as are agreed in the event of cancellation of the Work Programme prior to commercialization of any
Product (excluding, for the avoidance of doubt, items such as loss of alternative opportunities and the like) or as are set out in Sections 12.4, 12.5 and 12.6, except where cancellation results from a breach by Lonza Biologics entitling AstraZeneca
to terminate this Agreement in accordance with Section 12.3. 

  

	9.2	 All amounts payable under this Agreement shall (unless otherwise stated) be exclusive of Value Added Tax (VAT)
and Duty where applicable. Where VAT and Duty are chargeable on any supply or deemed supply under this Agreement the Party which is obliged to pay for such supply or deemed supply shall in addition pay at the prevailing rate such VAT and Duty as are
properly chargeable thereon. 

  

	9.3	 In the event that Lonza Biologics is obliged to pay taxes or duty on importation of goods provided by
AstraZeneca or a Third Party acting on behalf of AstraZeneca, such costs, including those associated with associated import requirements such as import clearance and import licences, shall be recovered From AstraZeneca. 

 

	9.4	 Either Party may withhold from any payment to the other Party income withholding tax as required by law in
relation to any royalty payments under this Agreement. If applicable laws require that such taxes be withheld the relevant Party shall deduct these 

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 Page 19 of 63 
  

	 	
taxes from the remittance payments, make timely payment of these taxes to the proper taxing authority and send confirmation to the other Party within [***] following payment. Both Parties agree
to co-operate to reduce any such taxes where legally permissible under any applicable double taxation agreement. 

  

	9.5	 Both Parties agree to co-operate fully to reduce any such taxes and
duty as are referred to in this Section where legally permissible. 

  

	10.	 Intellectual Property Rights and Inventions 

Inventions 
  

	10.1	 Lonza Biologics shall promptly notify AstraZeneca of any Programme IPR or Invention arising from work performed
in carrying out any Work Programme or evaluating any Confidential Information disclosed to it by AstraZeneca. 

  

	10.2	 Except as provided in Section 10.3, Lonza Biologics shall own all right, title and interest in Programme
IPR General Application. 

  

	10.3	 Except for and not including Programme IPR General Application, AstraZeneca shall own all right, title, and
interest in, Programme IPR AstraZeneca Application, including without limitation relating to the Product and all improvements to AstraZeneca Background IPR. Lonza Biologics hereby assigns to AstraZeneca and shall continue to assign to AstraZeneca
all of its right, title and interest in any Programme IPR AstraZeneca Application. Lonza Biologics shall promptly disclose to AstraZeneca in writing all Programme IPR AstraZeneca Application. Lonza Biologics shall execute any documents required to
confirm AstraZeneca’s ownership of the Programme IPR AstraZeneca Application, and any documents required to apply for, maintain and enforce any patents or other rights in the Programme IPR AstraZeneca Application. Upon AstraZeneca’s
request and at AstraZeneca’s reasonable expense, and at no cost to Lonza Biologics, Lonza Biologics shall assist AstraZeneca as may be necessary to apply for, maintain and enforce any patents or other rights in the Programme IPR AstraZeneca
Application. 

  

	10.4	 In addition to the Licenses granted in Articles 4 and 6, Lonza Biologics hereby grants AstraZeneca a non-exclusive, world-wide, fully paid-up, irrevocable and transferable license, with the right to grant and authorize sublicenses, under and to all Programme IPR General
Application, to the extent such Programme IPR General Application is useful or beneficial to research, develop, conduct clinical trials for, formulate, manufacture, test, seek regulatory approval for, market, commercialize, make, have made, use,
sell, import, and distribute any product, which AstraZeneca or its Affiliates own, license or otherwise in the possession of AstraZeneca with the right to use. 

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 Page 20 of 63 
  

	11.	 Warranties and Indemnities 

 

	11.1	 Lonza Biologics represents and warrants to AstraZeneca that: 

 

	 	11.1.1	 the Services shall be performed in accordance with Sections 7.2, 7.4, 7.6, 7.7, and 7.12;

  

	 	11.1.2	 unencumbered title (save for any intellectual property rights which may exist) to Product will he conveyed to
AstraZeneca upon delivery: 

  

	 	11.1.3	 as of the date of this Agreement and at all times throughout the term of this Agreement, Lonza Biologics’ Know-How and Patents and the LB Technology are or will be owned by or licensed to Lonza Biologics or its legal successors, or Lonza Biologics is otherwise entitled to use them for the purposes of providing Services
and the licenses granted to AstraZeneca and its Affiliates under this Agreement and during the term of this Agreement, Lonza Biologics shall not do, omit, fail or otherwise cause anything which would adversely affect their ownership, licenses or
entitlement to use the same for those purposes; 

  

	 	11.1.4	 Lonza Biologics has the necessary corporate authorisations to enter into this Agreement; 

 

	 	11.1.5	 as of the date of this Agreement to the best of Lonza Biologics’ knowledge and belief, the use by Lonza
Biologics of the LB Technology and the Process (excluding any modifications or steps made or developed by AstraZeneca, the AstraZeneca Materials, AstraZeneca information and AstraZeneca Patents) and Lonza Biologics’ Patents and Lonza
Biologics’ Know-How for the performance of the Services or granting and use of the licenses to the LB System Technology and/or the LB Media and Feeds Technology as provided herein will not infringe any
rights (including without limitation any intellectual or industrial property rights) vested in any Third Party; and 

  

	 	11.1.6	 Lonza Biologics will promptly notify AstraZeneca in writing if it receives or is notified of a claim from a
Third Party that the use by Lonza Biologics of the LB Technology or Lonza Biologics’ Know-How or Patents for Services or granted licenses infringes any intellectual property rights vested in such Third
Party. 

  

	11.2	 AstraZeneca represents and warrants to Lonza Biologics that: 

 

	 	11.2.1	 AstraZeneca bus the right to enter into this Agreement; 

 

	 	11.2.2	 AstraZeneca has and shall at all times throughout the term of this Agreement have the [***];

  

	 	11.2.3	 any of the AstraZeneca Materials, AstraZeneca Information and AstraZeneca Background IPR not owned by
AstraZeneca are licensed to AstraZeneca under a licence which will permit their use by Lonza Biologics to perform the Services; 

  

	 	11.2.4	 to the best of AstraZeneca’s knowledge and belief, the use by Lonza Biologics of the expression of the
Product in the Cell Line, AstraZeneca Materials, AstraZeneca Information and AstraZeneca Background IPR for the Services (including without limitation the manufacture of the Product) will not infringe any

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 Page 21 of 63 
  

	 	
intellectual property rights of any Third Party (provided, however, that Lonza Biologics shall waive any breach of this warranty which arises if a court of competent jurisdiction determines that
the use by Lonza Biologics of the expression of the Product in the Cell Line, AstraZeneca Materials, AstraZeneca Information or AstraZeneca Background IPR for the Services infringes the intellectual property rights of a Third Party, provided that
and for so long as AstraZeneca actually indemnifies Lonza Biologics pursuant to Sections 11.3 and 11.4); and 

  

	 	11.2.5	 AstraZeneca will promptly notify Lonza Biologics in writing if it receives or is notified of a claim from a
Third Party that the expression of the Product in the Cell Line, AstraZeneca Materials, AstraZeneca Information or the AstraZeneca Background IPR and that the use by Lonza Biologics thereof for the provision of the Services infringes any
intellectual property rights of such Third Party, 

  

	11.3	 Subject to Section 11.5, each Party shall be liable for and hereby agrees to indemnify and hold harmless
the other Party, its Affiliates and its and its Affiliates’ officers, employees and contractors from and against any and all direct damage, losses or expenses (including death or personal injury of or to persons, damage to plant, property or
the environment and reasonable legal and other profession fees) (collectively “Losses”) resulting directly or indirectly from: 

  

	 	11.3.1	 breach of contract, or 

 

	 	11.3.2	 negligence or willful misconduct, or 

 

	 	11.3.3	 breach of the warranties above (as the case maybe); 

of the indemnifying Party or its Affiliates, agents or sub-licensees except to the extent that the
Party seeking indemnification has contributed to, or failed to reasonably mitigate, those Losses. 
  

	11.4	 AstraZeneca shall farther indemnify and maintain Lonza Biologics promptly indemnified against any Losses in
respect of any product liability in respect of Product, unless such liability is caused by the negligent act or omission of Lonza Biologics in providing the Services. 

 

	11.5	 Neither Party shall be liable to the other under this Agreement for any indirect or consequential loss or
damage. 

  

	11.6	 Notwithstanding the above, Lonza Biologics’ aggregate liability for direct damages arising under each
Product Schedule for the Services provided under such Product Schedule shall be limited to [***] ([***]) times the value of such Product Schedule. For the avoidance of doubt, the limitation shall not apply to a) any breach of confidentiality or b)
breach of any warranty in Section 11.1 but not subsection 11.1.1, c) negligent or intentionally wrongful acts or omissions, and d) physical injury or death. 

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 Page 22 of 63 
  

	11.7	 Notwithstanding the above, AstraZeneca’s aggregate liability for direct damages arising under each Product
Schedule for the performances under such Product Schedule, shall be limited to [***] ([***]) times the value of such Product Schedule. For the avoidance of doubt, the limitation shall not apply to a) any breach of confidentiality, b) breach of any
warranty in Section 11.2, c) negligent or intentionally wrongful acts or omissions, d) product liability under Section 11.4, e) physical injury or death and f) any third party claim that the development and/or manufacture of any Product
infringes any third party intellectual property rights. 

  

	12.	 Term & Termination 

 

	12.1	 This Agreement shall come into full force and effect on the Effective Date and each Product Schedule shall come
into full force and effect on the Product Schedule Effective Date. Subject to the provisions for early termination set out herein, this Agreement or each Product Schedule individually shall continue until terminated by AstraZeneca in writing with
six (6) months notice period. 

  

	12.2	 Lonza Biologics may terminate the relevant Product Schedule forthwith by notice in writing to AstraZeneca upon
the occurrence of AstraZeneca committing a material breach of Product Schedule (which shall include a breach of the warranties set out in this Agreement) which in the case of a breach capable of remedy is not remedied within [***] ([***]) [***] of
the receipt by AstraZeneca of notice identifying the breach and requiring its remedy 

  

	12.3	 AstraZeneca may terminate the Agreement or the relevant Product Schedule forthwith by notice in writing to
Lonza Biologics upon the occurrence of any of the following events: 

  

	 	12.3.1	 if Lonza Biologics commits a material breach of the Agreement (which shall include a breach of the warranties
set out in this Agreement) which in the case of a breach capable of remedy is not remedied within [***] ([***]) [***] of the receipt by the other of notice identifying the breach and requiring its remedy; or 

 

	 	12.3.2	 if Lonza Biologics ceases for any reason to carry on business or compounds with or convenes a meeting of its
creditors or has a receiver or manager appointed in respect of all or any part of its assets or is the subject of an application for an administration order or of any proposal for a voluntary arrangement or enters into liquidation (whether
compulsorily or voluntarily) or undergoes any analogous act or proceedings under foreign law. 

  

	12.4	 If it becomes apparent to either Loom Biologics or AstraZeneca at any stage in the provision of Services that
it will not be possible to complete the Services for scientific or technical reasons, a [***] ([***]) [***] period shall be allowed for good faith discussion and attempts to resolve such problems. If such problems are not resolved within such
period, Lonza Biologics and AstraZeneca shall each have the right to terminate the Work Programme in the relevant Product Schedule forthwith by notice in writing. In the event of such termination, AstraZeneca shall pay to Lonza Biologics a
termination sum calculated by reference to all the Services performed by Lonza Biologics prior to such 

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 Page 23 of 63 
  

	 	
termination (including a pro rata proportion of the Price for any stage of the Services which is in process at the date of termination including any cGMP manufacturing stage) and all expenses
reasonably incurred and specified by Lonza Biologics in giving effect to such termination, including the costs of terminating any commitments entered into under the Agreement, such termination sum not to exceed the amount payable under 12.5 if
terminated according to Section 12.5, or the Price whichever is lowest. 

  

	12.5	 AstraZeneca may in its sole discretion terminate the Services in a Work Programme in a Product Schedule at any
time for any reason by giving not less than [***] ([***]) [***] notice in writing to Lonza Biologics. In the event of termination pursuant to this Section 12.5, AstraZeneca shall pay Lonza Biologics a termination sum calculated in accordance
with the below: 

  

	 	12.5.1	 Lonza Biologics’ costs for providing such Services incurred up to the date of termination, which would
normally be chargeable under the relevant Product Schedule; and 

  

	 	12.5.2	 in the event notice to terminate Services or a Work Programme pursuant to this Section 12.5 is issued to
Lonza Biologics: 

  

	 	(i)	 more than [***] ([***]) [***] after Lonza Biologics has notified AstraZeneca of the productivity of the Cell
Line at the stage of transfectants, e.g. in the case of Product Schedule No.1, this would mean more than [***] ([***]) [***] after the end of Stage la (i.e, delivery of relevant samples), but before Lonza Biologics’ then estimated start date
for any stage of those Services which include manufacturing of a cGMP batch; or 

  

	 	(ii)	 after AstraZeneca provides a Cell Line at the start of the Work Programme, but less than [***] prior to Lonza
Biologics’ then estimated start date for any stage of those Services which includes manufacturing of a cGMP batch, 

AstraZeneca shall pay Lonza Biologics a sum equal to [***] ([***]) of the price of that stage(s) which include manufacturing of a cGMP batch,
which payment shall fall due to Lonza Biologics after the date of termination and [***] ([***]) [***] from AstraZeneca’s receipt of an invoice of such payment. 
  

	 	12.5.3	 in the event notice to terminate Services or a Work Programme pursuant to this Section 12.5 is issued to
Lonza Biologics during the course of any stage that includes manufacturing of a cGMP batch, AstraZeneca shall pay Lonza Biologics a sum equal to [***] ([***]) of the price of that stage, which payment shall fall due to Lonza Biologics after the date
of termination and [***] ([***]) [***] from AstraZeneca’s receipt of an invoice of such payment. 

  

	12.6	 [***] 

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 Page 24 of 63 
  

	12.7	 If the Parties enter into a new Product Schedule within [***] ([***]) [***] from the date of payment of any
amount under Subsections 12.5.2 and 12.5.3, then AstraZeneca shall be entitled to deduct an amount equivalent to [***] ([***]) of the amount paid tinder Subsections 12.5.2 and 12.5.3 for any Services to be performed under the new Product Schedule.

  

	12.8	 For the avoidance of doubt activities relating to manufacturing of a cGMP batch shall be deemed to commence
with the date of removal of the vial of cells from frozen storage for the performance of the manufacturing of a cGMP hatch. 

  

	12.9	 Upon the termination of this Agreement or a Product Schedule for whatever reason: 

 

	 	12.9.1	 Lonza Biologics shall promptly return to AstraZeneca all AstraZeneca Information and shall dispose of or return
to AstraZeneca all remaining AstraZeneca Materials and any materials therefrom, as directed by AstraZeneca; 

  

	 	12.9.2	 AstraZeneca shall promptly return to Lonza Biologics all Lonza Biologics
Know-How it has received from Lonza Biologics relating to this Agreement or the relevant Product Schedule, whichever is terminated; 

 

	 	12.9.3	 AstraZeneca shall not thereafter use or exploit the Lonza Biologics Patents or the Lonza Biologics Know-How in any way whatsoever relating to this Agreement or the relevant Product Schedule, whichever is terminated unless the license to LB Technology or parts thereof is or is made perpetual according to this
Agreement; 

  

	 	12.9.4	 Lonza Biologics and AstraZeneca shall do all such acts and things and shall sign and execute all such deeds and
documents as the other may reasonably require to evidence compliance with this Section 12.9. 

  

	12.10	 Termination of this Agreement for whatever reason shall not affect the accrued rights of either Lonza Biologics
or AstraZeneca arising under or out of this Agreement and all provisions, which are expressed to survive the Agreement shall remain in full force and effect. 

  

	12.11	 The provisions of [***] shall survive termination of this Agreement howsoever occasioned.

  

	13.	 Confidentiality 

 

	13.1	 Save as otherwise provided in this Agreement any Confidential Information including the Cell Line which is
disclosed by or on behalf of one Party to the other at any time after the date of this Agreement shall remain the property of the Disclosing Party and the Receiving Party undertakes: 

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 Page 25 of 63 
  

	 	13.1.1	 to use the Confidential Information solely and exclusively for the purpose of this Agreement (or such other
purpose as is agreed in writing between the Parties at the time of disclosure), and not to use the Confidential Information for any other purpose whatsoever, including but not limited to the development, manufacture. marketing, sale or licensing of
any process or product or any other commercial purpose anywhere in the world, unless the Parties enter into an agreement specifying otherwise; and 

  

	 	13.1.2	 to maintain the confidentiality of the Confidential Information and not to disclose it directly or indirectly
to any other Person, save as permitted by Sections 13.2 and 13.3; and 

  

	 	13.1.3	 at the request of the Disclosing Party, to return, delete or destroy all copies of the Confidential
Information, in whatever form it is held, provided that the Receiving Party may retain one copy of the Confidential Information for the sole purpose of determining its obligations under this Agreement but may make no further use of such Confidential
Information whatsoever. 

  

	13.2	 Notwithstanding Section 13.1, the Receiving Party may disclose Confidential information to any of its
Affiliates, and its and its Affiliates’ directors, employees and professional advisers, who need to know the Confidential Information in order to fulfil the purpose of this Agreement, provided that the Receiving Party shall procure that each
such person to whom Confidential information is to be disclosed is made aware of the obligations contained in this Agreement prior to such disclosure; and adheres to such terms of this Agreement as if it were a Party to it. 

 

	13.3	 Permitted Disclosures. Each Party may disclose Confidential Information to the extent that such
disclosure is: 

  

	 	13.3.1	 made in response to a valid order of a court of competent jurisdiction or other competent authority; provided,
however, that the Receiving Party shall first have given notice to the Disclosing Party and given the Disclosing Party a reasonable opportunity to quash any such order or obtain a protective order requiring that the Confidential Information and
documents that are the subject of such order be held in confidence by such court or authority or, if disclosed, be used only for the purpose for which the order was issued; and provided further that if such order is not quashed or a protective order
is not obtained, the Confidential Information disclosed in response to such court or governmental order shall be limited to that information that is legally required to be disclosed in response to such court or governmental order;

  

	 	13.3.2	 made by AstraZeneca or its Affiliates or sublicensees to a regulatory authority as may be necessary or useful
in connection with any filing, application or request for a Health Registration Approval; provided, however, that reasonable measures shall be taken to assure confidential treatment of such information, to the extent such protection is available;

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 Page 26 of 63 
  

	 	13.3.3	 made by the Receiving Party to a patent authority as may be necessary or useful for purposes of obtaining or
enforcing a Patent; provided, however, that reasonable measures shall be taken to assure confidential treatment of such information, to the extent such protection is available; or 

 

	 	13.3.4	 otherwise required by law, provided, however, that the Receiving Party shall (a) provide the Disclosing
Party with reasonable advance notice of and an opportunity to comment on any such required disclosure, (b) if requested by the Disclosing Party, seek confidential treatment with respect to any such disclosure to the extent available, and
(c) use good faith efforts to incorporate the comments of the Disclosing Party in any such disclosure or request for confidential treatment; or 

  

	 	13.3.5	 made by AstraZeneca or its Affiliates or sublicensees to Third Parties as may be necessary or useful in
connection with the Exploitation of the Products as contemplated by this Agreement, including subcontracting or sublicensing transactions in connection therewith, provided such Third Parties are subject to obligations of confidentiality
substantially equivalent to those entered into between AstraZeneca and Lonza Biologics under this Agreement. 

Notwithstanding the foregoing, in the event that either Party is required by Applicable Law or the requirements of a national securities
exchange or another similar regulatory body to disclose this Agreement, in whole or in part, the Parties shall reasonably agree on a redacted version of this Agreement as necessary to protect the Confidential information of the Parties prior to
making such disclosure. 
  

	13.4	 The provisions of Section 13.1 shall not apply to any Confidential Information which the Receiving Party
can demonstrate to the reasonable satisfaction of the Disclosing Party: 

  

	 	13.4.1	 was already in the possession of the Receiving Party or any of its Affiliates and at the Receiving Party’s
or any of its Affiliates’ free use and disposal or in the public domain (through in each case no fault of the Receiving Party or any of its Affiliates or no breach of this Agreement by the Receiving Party) prior to its disclosure by the
Disclosing Party hereunder; or 

  

	 	13.4.2	 is purchased or otherwise legally acquired by the Receiving Party or any of its Affiliates at any time from a
Third Party having good title thereto and the right to disclose the same; or 

  

	 	13.4.3	 comes into the public domain, otherwise than through the fault of the Receiving Party or any of its Affiliates;
or 

  

	 	13.4.4	 is independently generated by the Receiving Party or any of its Affiliates without any recourse or reference to
the Confidential Information disclosed by the Disclosing Party as can be reasonably evidenced by the Receiving Party. 

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 Page 27 of 63 
  

	13.5	 Without the prior written consent of the other Party, neither Party shall disclose to any Third Party either
the fact that of the existence of this Agreement, the disclosures contemplated in this Agreement are taking place or have taken place or any of the terms, conditions of the status thereof at any time or any other facts in respect of a possible
transaction between the Parties, save as set out in Article 17. 

  

	13.6	 The obligations of each Party in this Article 13 shall survive: 

 

	 	13.6.1	 with respect to Know-How relating LB Technology or Product, until the
relevant Know-How satisfies the terms of Section 13.4.3 above, but in no event longer than [***] ([***]) [***] from the date of the disclosure; and 

 

	 	13.6.2	 in relation to any other Confidential Information, for a period of [***] ([***]) [***] from the date upon which
disclosure of such Confidential Information was made. 

  

	14.	 Force Majeure 

 

	14.1	 In this Agreement, “force majeure” shall mean any cause preventing either Party From performing any
or all of its obligations which arises from or is attributable to acts, events, omissions or accidents beyond the reasonable control of the Party so prevented including, without limitation, strikes, lock-outs or other industrial disputes (whether
involving the workforce of the Party so prevented or of any third Party), act of God, war, riot, civil commotion, malicious damage, compliance with any law or Governmental order, rule, regulation or direction, accident, breakdown of plant or
machinery, fire, flood or storm. 

  

	14.2	 If either Party is prevented or delayed in the performance of any of its obligations under this Agreement by
force majeure, that Party shall forthwith serve notice in writing on the other Party specifying the nature and extent of the circumstances giving rise to force majeure, and shall subject to service of such notice and to Section 14.4, have no
liability in respect of the performance of such of its obligations as are prevented by the force majeure event during the continuation of such events, and for such time after they cease as is necessary for that Party, using all reasonable
endeavours, to recommence its affected operations in order for it to perform its obligations. 

  

	14.3	 If either Party is prevented from performance of its obligations for a continuous period in excess of [***]
([***]) [***], the other Party may terminate this Agreement forthwith on service of written notice upon the Party so prevented, in which case neither Party shall have any liability to the other except that rights and liabilities which accrued prior
to such termination shall continue to subsist. 

  

	14.4	 The Party claiming to be prevented or delayed in the performance of any of its obligations under this Agreement
by reason of force majeure shall use all reasonable endeavours to bring the force majeure event to a close or to find a solution by which the Agreement may be performed despite the continuation of the force majeure event. 

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 Page 28 of 63 
  

	15.	 Severability 

 

	15.1	 Should any provision of this Agreement, be held to be illegal, invalid or unenforceable in any respect by any
judicial or other competent authority under the law of any jurisdiction: 

  

	 	15.1.1	 such provision shall, so far as it is illegal, invalid or unenforceable in any jurisdiction, be given no effect
by the Parties and shall be deemed not to be included in this Agreement in that jurisdiction; and 

  

	 	15.1.2	 the other provisions of this Agreement shall be binding on the Parties in that jurisdiction as if such
provision were not included herein; and 

  

	 	15.1.3	 the legality, validity and enforceability of the provision in any other jurisdiction shall not be affected or
impaired; and 

  

	 	15.1.4	 the Parties agree to negotiate in good faith to amend such provision for incorporation herein in such
reasonable manner as most closely achieves the intention of the Parties without impairing the Parties’ original interests and without rendering such provision invalid or unenforceable. 

 

	16.	 Variation and Amendments 

This Agreement may only be varied or amended in accordance with Section 5.1 or otherwise by agreement in writing and signed by or on
behalf of the Parties. 
  

	17.	 Public Announcements 

 

	17.1	 Save as expressly permitted by the terms of this Agreement, neither Party shall make any announcement about the
existence of this Agreement, the subject matter of this Agreement or the Work Programme without the prior written consent of the other. 

  

	17.2	 If any announcement concerning the existence of this Agreement, the subject matter of this Agreement or any
ancillary matter is required of a Party by law or any securities exchange or regulatory or governmental body to which either Party is subject, the announcement shall only be made if reasonably practicable after agreement with the other Party as to
the terms of and timetable for publication of any announcement and the consent of the other Party shall not be unreasonably withheld or delayed. 

  

	18.	 Agency, Partnership or Joint Venture Excluded 

 

	18.1	 Nothing in this Agreement shall be construed so as to constitute either Party to be the agent of the other.

  

	18.2	 Nothing in this Agreement and no action taken by the Parties pursuant to this Agreement shall constitute a
partnership, joint venture association or other co-operative entity of any kind between the Parties. 

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 Page 29 of 63 
  

	19.	 Assignment and Affiliates 

 

	19.1	 Save as specified in Section 19.2, neither Party shall without the prior written consent of the other
Party (such consent not to be unreasonably withheld or delayed) assign, transfer, charge or deal in any other manner with this Agreement or any of its rights under it, or purport to do any of the same, nor
sub-contract any or all of its obligations under this Agreement. 

  

	19.2	 Either Party shall be entitled to assign its rights under this Agreement to an Affiliate provided that such
Party shall procure that any such Affiliate to whom it assigns any of its rights under this Agreement shall assign such rights back to such Party immediately before ceasing to be an Affiliate of such Party. Any assignment made pursuant to this
Section 19.2 shall be on the condition that no such assignment shall relieve the relevant Party of any of its obligations under this Agreement. 

  

	19.3	 If any Affiliate of AstraZeneca wishes to disclose Confidential Information to Lonza Biologics or otherwise
enter into an Agreement with Lonza Biologics in the same terms as this Agreement, it may do so by sending to Lonza Biologics a letter substantially in the form of the drag set out in the Exhibit to this Agreement, and having attached to it one or
more Product Schedules in the same form as the Product Schedule(s), or by separate agreement in writing between such Affiliate and Lonza Biologics. Lonza Biologics shall not be obligated to enter into an agreement with an Affiliate of AstraZeneca.

  

	20.	 Remedies and Waivers 

 

	20.1	 No delay or omission on the part of any Party to this Agreement in exercising any right, power or remedy
provided by law or under this Agreement shall: 

  

	 	20.1.1	 impair such right, power or remedy; or 

 

	 	20.1.2	 operate as a waiver thereof. 

 

	20.2	 The single or partial exercise of any right, power or remedy provided by law or under this Agreement shall not
preclude any other or further exercise thereof or the exercise of any other right, power or remedy. 

  

	20.3	 The rights, powers and remedies provided in this Agreement are cumulative and not exclusive of any rights,
powers and remedies provided by law. 

  

	21.	 Notices 

 

	 	21.1.1	 All notices and other communications given or made in relation to this Agreement: 

 

	 	21.1.2	 shall be in English and in writing; and 

 

	 	21.1.3	 shall be delivered by hand or sent by registered post (airmail if abroad) or facsimile; and

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 Page 30 of 63 
  

	 	21.1.4	 shall be delivered or sent to the Party concerned at the relevant address or facsimile number, shown in
Section 21.2 subject to such amendments as may be notified from time to time in accordance with this Section by the relevant Party to the other Party by no less than three (3) Business Days’ notice; and 

 

	 	21.1.5	 shall be deemed to have been duly given or made if addressed in the aforesaid manner: 

 

	 	a)	 if delivered by hand, upon delivery; or 

 

	 	b)	 if posted by registered post, at the earlier of the time of delivery and 10.00 a.m., on the second Business Day
after posting (or the fifth Business Day after posting if sent by airmail); or 

  

	 	c)	 if sent by facsimile, when the sender’s facsimile system generates a message confirming successful
transmission or the total number of pages of the notice unless, within eight (8) business hours after that transmission, the recipient informs the sender that the recipient has not received the entire notice. The facsimile must be followed up
by a paper copy by post within five (5) Business Days; 

 provided that if any notice or other communication would
otherwise become effective on a non-Business Day or after 5.00 p.m. on a Business Day, it shall instead be deemed to be given or made at 10.00 a.m. on the next Business Day. 

 

	21.2	 The initial details for the purposes of Section 21.1 are: 

For AstraZeneca 

Västra Mälarehamnen 9, 

5-151 85 Södertälje, 

Sweden 
 Facsimile: +46 (0) 8 553
290 00 
 For the attention of: Assistant General Counsel 

with a copy to; Director of Bio Process R&D 

For Lonza Biologics 
 Lonza
Biologics Plc 
 228 Bath Road, Slough, S11 4DX 

Facsimile: +44 1753 777001 
 For
the attention of: Head of Legal Services 
  

	22.	 Entire Agreement 

 

	22.1	 This Agreement (together with the Product Schedules incorporated herein from time to time), together with any
Confidentiality Agreement between the Parties, represents the entire agreement between the Parties in relation to the subject matter of this Agreement and supersedes any previous agreement or arrangement between the Parties in relation to the
subject matter, whether written or oral or which might be construed from the conduct of the Parties, Accordingly, all other conditions, representations and warranties which would otherwise be implied (by law or otherwise) shall not form part of this
Agreement. 

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 Page 31 of 63 
  

	23.	 Contracts (Rights of Third Parties) Act 1999 

A person who is not a Party to this Agreement shall have no rights under the Contracts (Rights of Third Parties) Act 1999 to enforce any terms
of this Agreement. This Section does not affect any right or remedy of any person, which exists or is available otherwise than pursuant to that Act. 
  

	24.	 Governing Law & Disputes 

This Agreement shall be governed by and construed in accordance with the laws of England and Wales. The Parties hereby submit to the non-exclusive jurisdiction of the courts of England and Wales over any claim or matter arising under or in connection with this Agreement. 
  

	25.	 Counterparts 

This Agreement is executed in two (2) counterparts, each of which when executed and delivered shall be deemed to constitute an original.
This Agreement shall become effective when one or more counterparts have been signed by each of the Parties and such a counterpart (so signed) has been delivered to the other Party. 

Execution 
 THIS AGREEMENT IS EXECUTED by the
authorised representatives of the Parties as of the date first written above. 
  

									
	 STONED far and on behalf of

AstraZeneca AB (publ)
	 		 	 SIGNED for and on behalf of

Lonza Biologics Plc

			
	 /s/ [***]
	 		 	 /s/ [***]

	Signature	 		 	Signature
					
	Name: [***]	 	 	 		 	Name: [***]	 	 

									
					
	Title:	 	Executive Vice President
Global Discovery Research	 		 	Title:	 	Director

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 Page 1 of 63 
  

 Exhibit 1 

to Licenses and Services Agreement 
 Form of side letter for
Affiliates of AstraZeneca 
 [On the letterhead of the AstraZeneca Affiliate which is not Party to the original Licenses and Services Agreement]

 [Name and address of Lonza Biologics Plc] 
 [Date]

 Dear Sirs 
 Licenses and Services Agreement dated
[    ] 2005 between AstraZeneca AB and Lonza Biologics Plc (“the Agreement”). 
 With effect From the date upon which you
countersign this letter, or such earlier date as may be specified in the attached Product Schedule, you agree that you and we shall be deemed to have entered an agreement in the form of the Agreement, save that references in the Agreement to: 

“AstraZeneca” shall be deemed to be references to us; 

“Parties” and to all other terms shall be construed accordingly; 

‘‘Product Schedule(s)” shall be deemed to be references to the attached Product Schedule and to any amendments to that Product Schedule, or
additional Product Schedules to this letter, agreed in writing between us from time to time; and 
 “Product(s)” shall be deemed to be references
to the Product(s) listed in the attached Product Schedule and in any amendments to such Product Schedule, or in any additional Product Schedules; agreed in writing between us from time to time. 

The address for service of notices on us is as follows: 

[                     ] 

[Drafting note: consider any other provisions, which may need to be amended] 

Yours faithfully 
  

					
	AstraZeneca	 		 	 Agreed and accepted for and on behalf of

Lonza Biologics Plc

			
	   
	 		 	   

	Signature	 		 	Signature

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 Page 2 of 63 
  

									
					
	 Name:
	 	 	 		 	 Name:
	 	 

									
					
	 Title:
	 	 	 		 	 Title:
	 	 
					
		 		 		 	 Date:
	 	 

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 Page 1 of 63 
  

 Exhibit 2 

Patents 
 1. [***] 

[***] 
  

									
	 Territory
	  	 Application

Date
	  	 Application No.
	  	 Patent No.
	  	 Expiry Date

	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]

 *[***] 
 2. [***] 

[***] 
  

					
	 Territory
	  	 Patent Application or *

Patent Number
	  	 Patent Expiry Date

	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]

 +[***] 
 3. [***] 

[***] 
  

					
	 Territory
	  	 Patent Application

or * Patent Number
	  	 Patent Expiry Date

	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 Page 2 of 63 
  

					
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]

 *[***] 
 l[***] 

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 Page 3 of 63 
  

 AMENDMENT No. 1 

This Amendment No. 1 (“Amendment”) to the Licenses and Services Agreement dated 21 January 2005 by and between 

(1) AstraZeneca AB, a company incorporated in Sweden under no. 556011-7482 with offices at S-151 85
Sodertalje, Sweden (“AstraZeneca”); and 
 (2) Lonza Sales AG, a company incorporated and registered in Switzerland whose
registered office is at Muenchensteinerstrasse 38, CH-4002, Basel, Switzerland (“Lonza”) 

(the “Agreement”) is made effective as of the 20 March 2009 (“Amendment Effective Date”). 

Recitals 
 (A) WHEREAS,
AstraZeneca and Lonza Biologics Plc (a company incorporated in England under company number 02742471, whose registered office is situated at 228 Bath Road, Slough, Berkshire, SL1 4DX) (“Lonza Biologics”) entered into the Agreement. 

(B) WHEREAS, in a Novation Agreement dated 1 January 2007 between AstraZeneca and Lonza Biologics, the Agreement was novated from Lonza
Biologics to Lonza. 
 (C) WHEREAS, the Parties desire to amend, modify and restate certain terms its and conditions of the Agreement. 

Agreement 
 NOW, THEREFORE,
in consideration of the mutual covenants contained in this Amendment, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound, agree as follows: 

 

	26.	 Definitions 

  

	 	26.1	 Any capitalized term not separately defined in this Amendment shall have the meaning ascribed to it in the
Agreement. 

  

	27.	 Modifications 

 

	 	27.1	 Exhibit 2 of the Agreement shall be amended to include the content of Schedule 1 to this Agreement.

  

	 	27.2	 Section 1.7 of the Agreement shall be amended to read as follows: 

 

	 	“1.7	 “Competing Contract Manufacturer” means any Third Party who undertakes or performs more than
fifty percent (50%) of their business as a third party manufacturer of monoclonal antibodies or therapeutic proteins or any product of a similar nature to that which this Agreement relates.” 

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 Page 4 of 63 
  

	 	27.3	 Section 5.1 of the Agreement shall be amended to read as follows: 

 

	 	“5.1	 Each time AstraZeneca wishes a new product to be added to and come within the scope of this Agreement for the
Product to be covered by the licence to the LB Technology herein or parts thereof but without any Services being provided by Lonza Biologics, AstraZeneca shall prepare, in duplicate, a Product Schedule for such product. Each such Product Schedule
shall be consecutively numbered and shall contain a description of the Product. 

 Each time the Parties agree that a new
product should be added to and come within the scope of this Agreement for the Product to be covered by the licence to the LB Technology herein or parts thereof in conjunction with Services to be provided by Lonza Biologics, the Parties shall
prepare and agree, in duplicate, a Product Schedule for such product. Each such Product Schedule shall be consecutively numbered and shall contain at least the following sections: 

 

	 	5.1.1	 Part A: description of the Product; and 

 

	 	5.1.2	 Part B: description of the Work Programme and Specification intended for the Product and if any, a listing of
the AstraZeneca Material to be transferred; and 

  

	 	5.1.3	 Part C: provisions regarding any financial consideration in relation to the Product including any agreed
provisions relating to the termination or cancellation of the relevant Work Programme; and 

  

	 	5.1.4	 Part D: (if agreed at the date of execution of the relevant Product Schedule) the principal supply terms agreed
for the supply of the Product following the Work Programme. 

  

	 	5.1.5	 As Appendix to the Product Schedule: Quality Agreement, to be updated and agreed at least [***] ([***]) [***]
prior to the commencement of any Services requiring cGMP compliance performed by Lonza Biologics. 

 To the extent that
there is a conflict between or ambiguity relating to, on the one hand, the quality requirements in the Quality Agreement and, on the other, the Product Schedule Part B, the wording of the Quality Agreement shall prevail.” 

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 Page 5 of 63 
  

	 	27.4	 Section 6.3 of the Agreement shall be amended to read as follows: 

 

	 	“6.3	 When AstraZeneca or Strategic Partners manufacture(s) the Product (or End Product) being a therapeutic
pharmaceutical product in humans, AstraZeneca, shall pay annual license fees as set out below for such licenses granted under Sections 6.1 and 6.2 payable from the Commencement of Phase 2 Clinical Study until the expiry of the last relevant patent
(depending on which cell line is used for such Product) under the LB System Technology in Exhibit 2 during such calendar years: 

  

	 	6.3.1	 Product (or End Product) no 1: [***] (£[***]) 

 

	 	6.3.2	 Products (or End Products) no 2-4: [***] (£[***])

  

	 	6.3.3	 Product (or End Product) no 5 — onwards: [***] (£[***]). 

For avoidance of doubt, the first Product (or End Product) manufactured by AstraZeneca or a Strategic Partner to reach the Commencement of
Phase 2 Clinical Study shall be considered to be the Product (or End Product) no 1 according to subsection 6.3.1, the second Product (or End Product) manufactured by AstraZeneca or a Strategic Partner to reach Commencement of Phase 2 Clinical Study
shall be considered to be Product (or End Product) no 2 according to subsection 6.3.2 and so forth.” 
  

	 	27.5	 Section 6.4 of the Agreement shall be amended to read as follows: 

 

	 	“6.4	 When AstraZeneca or Strategic Partners manufactures the Product (or End Product) being a therapeutic
pharmaceutical product in humans using the LB System Technology and the LB Media and Feeds Technology, AstraZeneca shall be invoiced a one-off license fee per Product, for Product (or End Product) no 1 of
[***] (£[***]), Products (or End Products) no 2-4 [***] (£[***]), and product (or End product) no 5 — onwards [***] (£[***]) on the date of the first administration in humans. Such
invoices on Products may be sent until the expiry of the last relevant patent under the LB System Technology and the LB Media and Feeds Technology in Exhibit 2, depending on which cell line is used for such Product.” 

 

	 	27.6	 Section 6.7 of the Agreement shall be amended to read as follows: 

 

	 	“6.7	 In case AstraZeneca sublicense the LB System Technology for the manufacturing of Products (or End Product)
being a therapeutic pharmaceutical product in humans to Competing Contract Manufacturers or Third Parties, AstraZeneca shall pay annual sublicense fee of GBP [***] (£[***]) per Product for the duration of such sublicense arrangements, but in
no event is such sublicense fee due or payable prior to the date of the first Product to be manufactured according to GMP requirements by such third party and not after the expiry of the last relevant patent to expire (depending on which cell line
is used for such Product) under the LB System Technology in Exhibit 2.” 

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 Page 6 of 63 
  

	 	27.7	 Subsections 6.10.1, 6.10.2 and 6.10.3 of the Agreement shall be amended to read as follows:

  

	 	“6.10.1	 Royalty Patent Term: AstraZeneca’s obligation to pay royalties shall commence, on a country-by-country basis, with respect to each separate Product (or End Product), on the date of First Commercial Sale of such Product (or End Product) in such country. The
obligation shall expire, on a country-by-country basis, with respect to each separate Product (or End Product), on the expiration date in such country of the last to
expire of any relevant issued Patent (depending on which cell line is used for such Product) in Exhibit 2; or 

  

	 	6.10.2	 Royalty Know-How Term: AstraZeneca’s obligation to pay
royalties shall commence, on a country-by-country basis, with respect to each separate Product (or End Product), on the date after the expiry date in such country of the
last to expire of any relevant issued Patent (depending on which cell line is used for such Product) on the LB System Technology in Exhibit 2. The obligation shall expire, on a
country-by-country basis, with respect to each separate Product (or End Product), [***] ([***]) [***] after the commencement date of such royalty for each Product (or
End Product). 

  

	 	6.10.3	 Royalty Patent Term of LB Media and Feeds Technology: AstraZeneca’s obligation to pay royalties
shall commence, [***], on the date of First Commercial Sale of such Product (or End Product) in such country. The obligation shall expire at the [***] in Exhibit 2.” 

 

	 	27.8	 The first paragraph of Section 2.1 of the Research Evaluation Agreement (Exhibit 3 to the Agreement) shall
be amended to read as follows: 

  

	 	“2.1	 Following the signature of this Agreement by both parties, but only upon AstraZeneca’s request, Biologics
shall arrange for supply Ex Works Biologics’ premises, Slough, Berkshire, (Incotemis 2000) to AstraZeneca two (2) sets of the following:” 

  

	 	27.9	 Section 5.2 of the Research Evaluation Agreement (Exhibit 3 to the Agreement) shall be amended to read as
follows: 

  

	 	“5.2	 In consideration of the rights to carry out the Research Evaluation granted by Biologics to AstraZeneca and its
Affiliates, AstraZeneca shall be invoiced by Biologics the amount of [***] (£[***]) upon signature by both parties of this Agreement.” 

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 Page 7 of 63 
  

	 	27.10	 Section 5.3 of the Research Evaluation Agreement (Exhibit 3 to the Agreement) shall be amended to read as
follows: 

  

	 	“5.3	 At every extension of the duration of the Research Evaluation as provided in Clause 3, Biologics shall invoice
AstraZeneca [***] (£[***]) for the extended Research Evaluation period for [***] ([***]) [***] following the initial [***] following the initial [***] ([***]) month period and each further [***] ([***]) month period of the Research
Evaluation.” 

  

	28.	 Product Aggregation 

 

	 	28.1	 Notwithstanding anything to the contrary in the Agreement, the Parties acknowledge and agree that the method of
determining whether a Product (or End Product) is: 

  

	 	28.1.1	 Product (or End Product) number 1; 

 

	 	28.1.2	 Product (or End Product) number 2-4; 

 

	 	28.1.3	 Product (or End Product) number 5; 

shall be based not upon the number of Products (or End Products) manufactured by the AstraZeneca Affiliate in question, but upon the number of
Products (or End Products) manufactured by all of the AstraZeneca Affiliates, in aggregate. 
 For clarity, at Clause 6.3.3 this means that
if MedImmune, Inc. manufactures four (4) Products (or End Products), and subsequently MedImmune Limited manufactures one (1) Product (or End Product), then because this latter Product would be Product number 5, neither MedImmune Limited
nor MedImmune, Inc. (nor any other member of the AstraZeneca group) shall be liable for an annual licence fee for such Product (or End Product). 
  

	29.	 Amendment Effective Date 

 

	 	29.1	 This Amendment shall become effective on the Amendment Effective Date. 

 

	30.	 Affiliates 

  

	 	30.1	 Each agreement (if any) executed before the Amendment Effective Date by Lonza and an Affiliate of AstraZeneca,
which agreement is substantially the same as the Agreement (including without limitation each agreement based on the letter contained in the Exhibit to the Agreement), shall be deemed to be amended in line with this Amendment, as if it had been
executed after the Amendment Effective Date. 

  

	31.	 Entire Agreement 

 

	 	31.1	 This Amendment, together with the Agreement, constitutes the entire agreement between the Parties with respect
to the subject matter of the Agreement. The Agreement together with this Amendment supersedes all prior agreements, whether written or oral, with respect to the subject matter of the Agreement, as

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 Page 8 of 63 
  

	 	
amended. Each Party confirms that it is not relying on any representations, warranties or covenants of the other Party except as specifically set out in the Agreement as amended. Nothing in this
Amendment is intended to limit or exclude any liability for fraud. The Parties hereby agree that subject to the modifications specifically stated in this Amendment, all terms and conditions of the Agreement shall remain in full force and effect.

  

	32.	 Governing Law & Disputes 

 

	 	32.1	 This Amendment shall be governed by and construed in accordance with the laws of England and Wales. The Parties
hereby submit to the non-exclusive jurisdiction of the courts of England and Wales over any claim or matter arising under or in connection with this Agreement. 

Execution 
 THIS AMENDMENT
IS EXECUTED by the authorised representatives of the Parties as of the date first written above. 
  

					
	 SIGNED for and on behalf of 
AstraZeneca AB (publ):
	 		 	SIGNED for and on behalf of 
Lonza Sales AG:
			
	 [***]
	 		 	[***]
	 Signature
	 		 	Signature:
	 Name: [***]
	 		 	 Name: [***]

	 Title: Authorised Signatory
	 		 	
Title:                         
                                         
                    

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 Page 9 of 63 
  

 SCHEDULE 1 
  

			
	4.	  	
	Lonza Reference:	  	[***]
	Priority Date:	  	[***]
	Title:	  	[***]
	Inventors:	  	[***]
		  	[***]

  

					
	 Territory
	  	 Patent Number
	  	 Patent Expiry Date

	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]

  

	+	 Includes Austria, Belgium, France, Germany, Greece, Italy, Luxembourg, Netherlands, Spain, Sweden, Switzerland
and United Kingdom 

  

			
	5.	  	
	Lonza Reference:	  	[***]
	Priority Dates:	  	[***]
	Title:	  	[***]
	Inventors:	  	[***]
		  	[***]

  

					
	 Territory
	  	 Patent Number
	  	 Patent Expiry Date

	[***]*	  	[***]	  	[***]
	[***]*	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]+*	  	[***]	  	[***]
	[***]*	  	[***]	  	[***]
	[***]*	  	[***]	  	[***]
	[***]	  	[***]	  	[***]

  

	+	 Includes Austria, Belgium, France, Germany, Italy, Luxembourg, Netherlands, Sweden and Switzerland

  

	*	 Patent has now expired in these countries 

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.EX-10.14

 Exhibit 10.14 

ASSET PURCHASE AGREEMENT 

BY AND BETWEEN 

MEDIMMUNE, LLC, 

MEDIMMUNE LIMITED, 

ASTRAZENECA COLLABORATION VENTURES, LLC, 

AND 
 VIELA BIO, INC.

 DATED AS OF FEBRUARY 23, 2018 

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 TABLE OF CONTENTS 

 

									
	 	 	 	 	 	  	Page	 
		
	 ARTICLE I PURCHASE PRICE
	  	 	2	 
				
		 	 1.1
	 	 Purchase Price
	  	 	2	 
		
	 ARTICLE II PURCHASE AND SALE
	  	 	2	 
				
	       
	 	 2.1
	 	 Acquired Assets
	  	 	2	 
				
		 	 2.2
	 	 Excluded Assets
	  	 	3	 
				
		 	 2.3
	 	 Assumption of Assumed Liabilities
	  	 	4	 
				
		 	 2.4
	 	 Excluded Liabilities
	  	 	5	 
				
		 	 2.5
	 	 Non-Assignable Assets
	  	 	6	 
		
	 ARTICLE III CLOSING
	  	 	6	 
				
		 	 3.1
	 	 Closing
	  	 	6	 
				
		 	 3.2
	 	 Deliveries by Medi LLC at the Closing
	  	 	7	 
				
		 	 3.3
	 	 Deliveries by Spinco at Closing
	  	 	8	 
				
		 	 3.4
	 	 Additional Closing Deliveries
	  	 	9	 
		
	 ARTICLE IV REPRESENTATIONS AND WARRANTIES OF THE AZ PARTIES
	  	 	9	 
				
		 	 4.1
	 	 Organization and Good Standing
	  	 	9	 
				
		 	 4.2
	 	 Authorization of Agreement
	  	 	9	 
				
		 	 4.3
	 	 Conflicts; Consents of Third Parties
	  	 	10	 
				
		 	 4.4
	 	 Acquired Assets
	  	 	10	 
				
		 	 4.5
	 	 No Other Representations or Warranties
	  	 	13	 
		
	 ARTICLE V REPRESENTATIONS AND WARRANTIES OF SPINCO
	  	 	13	 
				
		 	 5.1
	 	 No Representations or Warranties
	  	 	13	 
		
	 ARTICLE VI CONDUCT OF BUSINESS
	  	 	13	 
				
		 	 6.1
	 	 Conduct of Business Pending the Closing
	  	 	13	 
		
	 ARTICLE VII COVENANTS
	  	 	14	 
				
		 	 7.1
	 	 Cooperation; Filings and Approvals; Consents
	  	 	14	 
				
		 	 7.2
	 	 Confidentiality
	  	 	14	 
				
		 	 7.3
	 	 Preservation of Records
	  	 	15	 
				
		 	 7.4
	 	 Publicity
	  	 	15	 
				
		 	 7.5
	 	 Employee Matters
	  	 	15	 
				
		 	 7.6
	 	 Intentionally Omitted
	  	 	16	 
				
		 	 7.7
	 	 Misallocated Assets
	  	 	16	 

  
 i 

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 TABLE OF CONTENTS 

(continued) 
  

									
	 	 	 	  	 	  	Page	 
				
		 	 7.8
	  	 Third Party Agreement Transfer Liability
	  	 	17	 
				
		 	 7.9
	  	 Non-Competition
	  	 	17	 
				
		 	 7.10
	  	 Certain Cellective Agreements.
	  	 	19	 
				
		 	 7.11
	  	 Certain other MEDI-551 Agreements
	  	 	20	 
				
		 	 7.12
	  	 MEDI1116 License Agreement.
	  	 	22	 
				
		 	 7.13
	  	[***]	  	 	23	 
		
	 ARTICLE VIII CONDITIONS TO CLOSING
	  	 	23	 
				
	       
	 	 8.1
	  	 Conditions Precedent to Obligation of the Parties
	  	 	23	 
				
		 	 8.2
	  	 Conditions Precedent to Obligation of Spinco
	  	 	24	 
				
		 	 8.3
	  	 Conditions Precedent to Obligation of the AZ Parties
	  	 	24	 
				
		 	 8.4
	  	 Frustration of Closing Conditions
	  	 	25	 
		
	 ARTICLE IX INDEMNIFICATION
	  	 	25	 
				
		 	 9.1
	  	 Survival
	  	 	25	 
				
		 	 9.2
	  	 Indemnification by the AZ Parties
	  	 	25	 
				
		 	 9.3
	  	 Indemnification by Spinco
	  	 	26	 
				
		 	 9.4
	  	 Indemnification Procedures
	  	 	26	 
				
		 	 9.5
	  	 Limitations on Indemnified Costs
	  	 	28	 
				
		 	 9.6
	  	 Exclusive Remedy
	  	 	29	 
		
	 ARTICLE X TAX MATTERS
	  	 	29	 
				
		 	 10.1
	  	 Tax Matters; Cooperation
	  	 	29	 
				
		 	 10.2
	  	 Transfer Taxes
	  	 	30	 
				
		 	 10.3
	  	 Purchase Price Allocation
	  	 	30	 
				
		 	 10.4
	  	 Withholding Taxes
	  	 	30	 
		
	 ARTICLE XI MISCELLANEOUS
	  	 	31	 
				
		 	 11.1
	  	 Expenses
	  	 	31	 
				
		 	 11.2
	  	 Governing Law
	  	 	31	 
				
		 	 11.3
	  	 Dispute Resolutions
	  	 	31	 
				
		 	 11.4
	  	 Entire Agreement
	  	 	31	 
				
		 	 11.5
	  	 Amendments and Waivers
	  	 	31	 
				
		 	 11.6
	  	 Notices
	  	 	32	 
				
		 	 11.7
	  	 Severability
	  	 	33	 

  
 ii 

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 TABLE OF CONTENTS 

(continued) 
  

											
		 		 		  		  	 	Page	 
					
		 	       
	 	 11.8
	  	 Specific Performance
	  	 	33	 
					
		 		 	 11.9
	  	 No Third-Party Beneficiaries; No Successor Liability
	  	 	34	 
					
		 		 	 11.10
	  	 Assignment
	  	 	34	 
					
		 		 	 11.11
	  	 Neutral Construction
	  	 	35	 
					
		 		 	 11.12
	  	 Counterparts
	  	 	35	 

  
 iii 

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

			
	Exhibits	  	
		
	Exhibit A	  	Certain Definitions; Interpretive Matters
	Exhibit B	  	Form of Transition Services Agreement
	Exhibit C	  	Form of Clinical Supply Agreement
	Exhibit D	  	Form of Sublicense Agreements
	Exhibit E	  	Form of Master Supply and Development Services Agreement
	Exhibit F	  	Form of Affiliate Lease Agreement
	Exhibit G	  	Form of License Agreement
	Exhibit H	  	Form of MRC Payment Agreements
	Exhibit I	  	Form of Services Agreement
		
	Schedules	  	
		
	Schedule 2.1(b)(i)	  	Assigned Intellectual Property
	Schedule 2.1(b)(iii)	  	Assigned Contracts
	Schedule 2.1(b)(vii)	  	Acquired Personal Property
	Schedule 4.3(a)	  	AZ Consents
	Schedule 4.4	  	Acquired Assets
	Schedule 7.5(a)	  	AZ Employees
	Schedule 7.9	  	Covered Autoimmune Diseases
	Schedule 7.12	  	[***] License Term Sheet
	Schedule 10.3	  	Purchase Price Allocation

  
 iv 

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 ASSET PURCHASE AGREEMENT 

This ASSET PURCHASE AGREEMENT is entered into as of February 23, 2018 (this “Agreement”), by and between MEDIMMUNE,
LLC, a Delaware limited liability company (“Medi LLC”), MEDIMMUNE LIMITED, a United Kingdom company (“Medi Ltd”), and ASTRAZENECA COLLABORATION VENTURES, LLC, a Delaware limited liability company
(“AZCV”), and VIELA BIO, INC., a Delaware corporation (“Spinco”). Each of Medi LLC, Medi Ltd and AZCV are sometimes referred to herein individually as an “AZ Party” and collectively as the
“AZ Parties.” Each of the AZ Parties and Spinco are sometimes referred to herein individually as a “Party” and collectively as the “Parties.” Capitalized terms used herein and not otherwise defined
shall have the meanings set forth in Exhibit A. 
 W I T N E S E T H: 

WHEREAS, the AZ Parties have established research, development and/or manufacturing programs for [***], collectively, the
“Programs”) aimed at treating inflammation and autoimmune disorders; provided that the programs for [***] and [***] (the “[***] Collaboration Programs”) are being pursued in collaboration with [***] pursuant to the
Collaboration Agreement, dated as of March 30, 2012, as amended (the “[***] Collaboration Agreement”), between AZCV and[***] (such collaboration, the “[***] Collaboration”); 

WHEREAS, AstraZeneca UK Limited, an Affiliate of the AZ Parties (“AZUK”), formed Spinco, and AZUK and a group
of investors have provided equity financing to Spinco in order to consummate the transactions contemplated hereby and to enable Spinco to research, develop, manufacture and commercialize the Products and to perform its obligations and receive
certain benefits under the Services Agreement with respect to the [***] Collaboration Products (the “Spinco Business”), on the terms and subject to the conditions set forth in the Series A Preferred Stock Purchase Agreement, dated
as of the date hereof (the “Securities Purchase Agreement”), by and among Spinco and each of the investors party thereto (collectively, the “Investors”); 

WHEREAS, the AZ Parties (other than AZCV) have agreed to sell to Spinco, and Spinco has agreed to purchase from the AZ Parties, assets
owned by the AZ Parties and exclusively related to the Programs on the terms and subject to the conditions set forth herein; 

WHEREAS, in connection with the foregoing, AZCV and Spinco have agreed to enter into the Services Agreement pursuant to which AZCV will
delegate to Spinco, and Spinco will agree to accept and perform, certain of AZCV’s obligations under the [***] Collaboration Agreement with respect to the[***] Collaboration Products and, in connection therewith, AZCV will transfer to Spinco
the net economic benefits AZCV receives from the [***] Collaboration with respect to the AZCV Collaboration Products, on the terms and subject to the conditions set forth in the Services Agreement; 

WHEREAS, the AZ Parties have agreed to (i) sublicense to Spinco certain Patents and Know-How related to the Programs that have been
licensed by Medi LLC or one of its Affiliates from Third Parties and (ii) license to Spinco certain Patents and Know-How of Medi LLC and its Affiliates related (but not exclusively) to the Products, in each case pursuant to separate agreements
further described in Section 3.2; and 

  

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 WHEREAS, in connection with the Transactions, the Parties and/or their respective
Affiliates will enter into the other Transaction Agreements at the Closing, on the terms and subject to the conditions of this Agreement. 

NOW, THEREFORE, in consideration of the foregoing and the mutual representations, warranties, covenants and agreements contained
herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and intending to be legally bound hereby, the Parties hereby agree as follows: 

ARTICLE I 
 PURCHASE
PRICE 
 1.1    Purchase Price. In consideration of the conveyance to Spinco of all right, title and interest
in and to the Acquired Assets, the non-competition covenants set forth in Section 7.9 and the other rights granted to Spinco hereunder and under the Services Agreement, and subject to
the terms and conditions hereof, at the Closing, Spinco shall pay a purchase price in cash of $142,253,240 in the aggregate (the “Purchase Price”) as follows: (a) to Medi LLC, an amount equal to [***], (b) to Medi Ltd an
amount equal to [***], and (c) to AZCV, an amount equal to [***], by wire transfer of immediately available funds pursuant to written instructions furnished to Spinco by the AZ Parties at least [***] prior to the Closing. 

ARTICLE II 
 PURCHASE
AND SALE 
 2.1    Acquired Assets. 

(a)    On the terms and subject to the conditions set forth in this Agreement, at the Closing, the AZ Parties (other than
AZCV) shall sell, assign, transfer, convey and deliver to Spinco, and Spinco shall receive, acquire and accept, all right, title and interest of the AZ Parties in, to and under the Acquired Assets (including the Assigned Intellectual Property), free
and clear of all Liens except for Permitted Liens. 
 (b)    “Acquired Assets” means the following
assets at the Closing:  
 (i)    the Assigned Intellectual Property: 

(ii)    intentionally omitted; 

(iii)    the Assigned Contracts; 

  
 2 

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 (iv)    all Regulatory Materials and other Governmental
Approvals and all pending applications therefor or renewals thereof, in each case to the extent transferable to Spinco and exclusively relating to the Products or the Programs and complete and accurate electronic copies of such materials, approvals
and applications; provided that such transfer shall not be deemed to be an assignment of any Know-How contained in such materials, timing of the transfer of Regulatory Materials shall be in accordance
with the TSA, the AZ Parties shall not be required to transfer copies of any Excluded Manufacturing Know-How (and such information shall be redacted from such electronic copies), and the AZ Parties shall be
entitled to retain copies of the transferred Regulatory Materials and Governmental Approvals as necessary to comply with applicable Law and its internal document retention policies subject to the AZ Parties’
non-use and confidentiality obligations set forth in Section 7.2; 

(v)    all Biological Materials; provided that Biological Materials subject to the Assigned Contracts and
the In-License Agreements shall only be transferred and used in accordance with the terms of those agreements; 

(vi)    all Inventory; 

(vii)    those items of tangible personal property listed on Schedule 2.1(b)(vii) (the
“Acquired Personal Property”); and 
 (viii)    all Documents to the extent exclusively
relating to the Products or the Programs, but excluding personnel files for employees or former employees (whether or not Transferred Employees); provided that the AZ Parties and their Affiliates shall be entitled to retain copies of the
foregoing as necessary to comply with applicable Law and its internal document retention policies subject to the AZ Parties’ non-use and confidentiality obligations set forth in
Section 7.2. 
 2.2    Excluded Assets. 

(a)    Notwithstanding anything to the contrary in this Agreement, nothing herein contained shall be deemed to sell,
transfer, assign or convey to Spinco the Excluded Assets, and the AZ Parties and their Affiliates shall retain all right, title and interest to, in and under the Excluded Assets and Spinco shall not acquire any of the Excluded Assets. 

(b)    “Excluded Assets” means each of the following assets at the Closing: 

(i)    all cash and cash equivalents, securities, negotiable instruments, accounts receivable, notes and
other amounts receivable of the AZ Parties or their Affiliates; 
 (ii)    any rights to Tax refunds,
credits, deductions, allowances or other Tax benefits of the AZ Parties or their Affiliates; 

(iii)    the company seal, minute books, charter documents, stock or equity record books and such other
books and records as pertain to the organization, existence or capitalization of the AZ Parties and their Affiliates, as well as any other records or materials relating to the AZ Parties or their Affiliates generally and not exclusively related to
the Acquired Assets or the operations of the Programs; 

  
 3 

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 (iv)    all right, title and interest in and to the
names “AstraZeneca” and “AZ” and “MedImmune”; 
 (v)    all tangible
personal property of the AZ Parties or any of their Affiliates, other than the tangible personal property expressly included in the Acquired Assets; 

(vi)    Excluded Manufacturing Know-How and all other intangible
property of the AZ Parties or any of their Affiliates, other than the Assigned Intellectual Property; 

(vii)    all real property owned or leased by the AZ Parties or any of their Affiliates; 

(viii)    all rights which accrue or will accrue to the AZ Parties or any of their Affiliates under this
Agreement, any of the other Transaction Agreements, the Securities Purchase Agreement or any of the agreements contemplated thereunder; 

(ix)    (A) all attorney-client privilege and attorney work-product protection of AZ or its
Affiliates, (B) all Documents subject to the attorney-client privilege or work-product protection described in the foregoing clause (A), and (C) all Documents maintained by the AZ Parties or their Affiliates in connection
with the Transactions and the transactions contemplated under the Securities Purchase Agreement, in each case (A)-(C) above to the extent such items do not constitute Acquired Assets; 

(x)    Tax Returns of the AZ Parties and their Affiliates; 

(xi)    all Employee Benefit Plans and any assets relating thereto; 

(xii)    all current and prior insurance policies of the AZ Parties and their Affiliates and all rights of
any nature with respect thereto, including all insurance recoveries thereunder and rights to assert claims with respect to any such insurance recoveries; 

(xiii)    all assets, rights, and claims of AZCV and its Affiliates in the [***] Collaboration or otherwise
owned by AZCV and its Affiliates relating thereto; and 
 (xiv)     all other assets, properties,
contractual rights, goodwill, and other intangible assets, rights and claims of the AZ Parties and their Affiliates not included in the Acquired Assets and not exclusively used or held for use in the Programs. 

2.3    Assumption of Assumed Liabilities. 

(a)    On the terms and subject to the conditions set forth in this Agreement, as of the Closing, Spinco shall assume and
be responsible for, and shall timely perform, satisfy and discharge in accordance with their terms, the Assumed Liabilities. 

  
 4 

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 (b)    “Assumed Liabilities” means each of the
following Liabilities of the AZ Parties and their Affiliates at the Closing: 
 (i)    all Liabilities of
the AZ Parties and their Affiliates arising under or in connection with the Assigned Contracts from and after the Closing, excluding for clarity the Excluded Liabilities set forth in Section 2.4(b)(ii) below; 

(ii)    all Liabilities of the AZ Parties and their Affiliates arising out of or relating to actions by
Spinco or its Affiliates commenced after the Closing, irrespective of the legal theory asserted, arising from the administration, manufacture, advertising, marketing, distribution, sale or use of the Products or conduct of the Programs during the
period of time on or after the Closing; 
 (iii)    all Liabilities of the AZ Parties and their
Affiliates resulting from the hiring and/or employment of the Transferred Employees by Spinco or its Affiliates from and after the Closing (except to the extent otherwise expressly set forth herein, including in
Section 2.4(b)(iv)); and 
 (iv)    without duplication of the other provisions
of this Section 2.3(b), all Liabilities arising from and after the Closing of whatever kind and nature to the extent relating specifically to the Products or the Programs or arising in connection with the use, ownership or
operation of the Acquired Assets by Spinco or its Affiliates from and after the Closing, other than Liabilities of the AZ Parties and their Affiliates arising out of their breach or termination of the Transaction Agreements and only to the extent
expressly provided therein. 
 2.4    Excluded Liabilities. 

(a)    Spinco shall not assume or be liable for any Excluded Liabilities. 

(b)    “Excluded Liabilities” means all Liabilities of the AZ Parties and their Affiliates at the
Closing, other than the Assumed Liabilities, including the following: 
 (i)    all Liabilities to the
extent not related to the Products, the Programs or the Acquired Assets; 
 (ii)    all Liabilities
relating to or arising out of the Excluded Assets; 
 (iii)    all Liabilities relating to the Assigned
Contracts to the extent such obligations (A) arise before the Closing Date, or (B) arise from or relate to any breach by the AZ Parties or their Affiliates of any provision of any of such contracts; 

(iv)    except to the extent specifically provided in Section 7.5, all
Liabilities arising out of, relating to or with respect to (A) the Transferred Employees, or termination by the AZ Parties or their Affiliates of employment or services of any individual on or before the Closing Date (including all Liabilities
for the compensation of Transferred Employees for services prior to the Closing Date); (B) workers’ compensation 

  
 5 

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 
claims that relate to the period before the Closing, irrespective of whether such claims are made prior to or after the Closing Date; (C) any Employee Benefit Plan and any funding or other
obligations relating to any of the foregoing; (D) any retention payments, severance payments, or such payments arising out of or related to the consummation of the Transactions contemplated in this Agreement, but excluding any equity grants or
other benefits provided for in the Spinco offer letters or employment agreements, or otherwise promised by Spinco; or (E) any obligations under the Worker Adjustment and Retraining Notification Act (“WARN Act”) or similar state
or local Laws that arise before the Closing Date or in connection with the consummation of the Transactions due to termination of employment by the AZ Parties or their Affiliates; and 

(v)    all other Liabilities arising out of or relating to the Products, the Programs or the Acquired
Assets, to the extent such Liabilities relate to the period of time prior to Closing. 
 2.5    Non-Assignable Assets. Notwithstanding anything to the contrary in this Agreement, nothing in this Agreement or the consummation of the Transactions shall be construed as an attempt or agreement to assign any
Acquired Asset, including any Contract, Permit, certificate, approval, authorization or other right, which by its terms or by Law is non-assignable without the consent of a Third Party or a Governmental
Authority or is terminable or cancelable by a Third Party or a Governmental Authority in the event of an assignment (any such Acquired Asset, a “Non-assignable Asset”) unless and until
such consent shall have been obtained. The AZ Parties shall use all commercially reasonable efforts to obtain any such consents with respect to the Acquired Assets promptly, and shall cooperate as reasonably requested by Spinco in any efforts made
by Spinco to obtain such consent. To the extent permitted by applicable Law, in the event such consent to the assignment thereof cannot be obtained, at Spinco’s request, such Non-assignable Asset shall be
held, as of and from the Closing Date, by the applicable AZ Party in trust for Spinco and the covenants and obligations under any Non-assignable Asset that is a Contract, Permit, certificate, approval or
authorization shall be performed by Spinco in the applicable AZ Party’s name and all benefits and Liabilities existing thereunder after Closing shall be for Spinco’s account. The AZ Parties shall take or cause to be taken, at Spinco’s
expense, such reasonably necessary actions in its name or otherwise as Spinco may reasonably request so as to provide Spinco with the benefits of any Non-assignable Assets and to effect collection of money or
other consideration that becomes due and payable under Non-assignable Assets, and the AZ Parties or their applicable Affiliate shall promptly pay over to Spinco all money or other consideration received by it
in respect of all Non-assignable Assets. 
 ARTICLE III 

CLOSING 

3.1    Closing. Subject to the terms and conditions of this Agreement, the closing of the Transactions (the
“Closing”) shall take place on the date of this Agreement immediately following the consummation of the transactions contemplated by the Securities Purchase Agreement at the offices of Covington & Burling LLP, 620 Eighth
Avenue, New York, New York 10018 as soon as practicable following the satisfaction or waiver of all conditions contained in 

  
 6 

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 
Article VIII (except for those conditions which by their terms are to be satisfied at the Closing but subject to the satisfaction or waiver of such conditions), or on such other date,
place and time as the Parties may agree in writing (the “Closing Date”). 
 3.2    Deliveries by
Medi LLC at the Closing. At the Closing, Medi LLC shall deliver, or cause to be delivered, to Spinco, as applicable, the following: 

(a)    the certificates required by Section 8.2(a) and Section 8.2(b);

 (b)    the Transition Services Agreement, substantially in the form attached hereto as Exhibit B (the
“Transition Services Agreement”), executed by a duly authorized officer of Medi LLC; 
 (c)    the
Clinical Supply Agreement, substantially in the form attached hereto as Exhibit C (the “Clinical Supply Agreement”), executed by a duly authorized officer of Medi LLC or its applicable Affiliate; 

(d)    the sublicense agreements substantially in the forms attached hereto as Exhibit
D-1, D-2 and D-3 (collectively, the “Sublicense Agreements”), executed by a duly authorized officer of Medi LLC
or its applicable Affiliate, pursuant to which Medi LLC or its applicable Affiliate will grant sublicenses under the BioWa License Agreement, the BioWa/Lonza License Agreement and the Lonza License Agreement, on the terms and subject to the
conditions set forth therein; 
 (e)    the Master Supply and Development Services Agreement, substantially in the form
attached hereto as Exhibit E (the “Development Services Agreement”), executed by a duly authorized officer of Medi LLC or its applicable Affiliate; 

(f)    the Affiliate Lease Agreement, substantially in the form attached hereto as Exhibit F (the “Affiliate Lease
Agreement”), executed by a duly authorized officer of Medi LLC or its applicable Affiliate; 
 (g)    the
License Agreement, substantially in the form attached hereto as Exhibit G (the “License Agreement”), executed by a duly authorized officer of Medi LLC or its applicable Affiliate, pursuant to which Medi LLC or its applicable
Affiliate will license to Spinco certain Know-How and Patents of Medi LLC and its Affiliates related (but not exclusively) to the Programs and Products and reasonably necessary for exploitation of the Products
by Spinco, on the terms and subject to the conditions set forth herein; 
 (h)    the Payment Agreements for [***] and
[***], substantially in the forms attached hereto as Exhibit H (the “MRC Payment Agreements”), executed as a deed by Medi LLC or its applicable Affiliate, pursuant to which Spinco will make payments to Medi LLC’s Affiliate
MedImmune Limited on the terms and subject to the conditions set forth herein; 
 (i)    an assignment and assumption
agreement and bill of sale, in a form reasonably agreed among the Parties (the “Assignment and Assumption and Bill of Sale”), executed by a duly authorized officer of the applicable AZ Parties; 

  
 7 

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 (j)    the Services Agreement, substantially in the form attached hereto
as Exhibit I, with such changes as are mutually agreed by AZCV and the Investors after the execution and delivery of the Securities Purchase Agreement by the Parties thereto (the “Services Agreement”); 

(k)    a certificate from each of Medi LLC and AZCV (or its owner if it is a disregarded entity for U.S. federal income
Tax purposes), in form and substance as prescribed by Treasury Regulations Section 1.1445-2(b), stating that each is not a “foreign person” within the meaning of Code Section 897; and 

(l)    in respect of the Acquired Assets, such other documents, deeds, assignments and instruments of transfer as shall be
necessary and reasonably requested by Spinco to effect the transfer of the Acquired Assets to Spinco and to carry out the intent of the Transactions and as shall be sufficient to convey to and vest in Spinco all of the right, title and interest of
the AZ Parties to the Acquired Assets. 
 3.3    Deliveries by Spinco at Closing. At Closing, Spinco shall
deliver, or cause to be delivered, to the AZ Parties, as applicable, the following: 
 (a)    the certificates required
by Section 8.3(a); 
 (b)    the Purchase Price by wire transfer of immediately available
funds in accordance with Section 1.1; 
 (c)    the Transition Services Agreement, executed by
a duly authorized officer of Spinco; 
 (d)    the Clinical Supply Agreement, executed by a duly authorized officer of
Spinco; 
 (e)    the Sublicense Agreements, executed by a duly authorized officer of Spinco; 

(f)    the Development Services Agreement, executed by a duly authorized officer of Spinco; 

(g)    the Affiliate Lease Agreement, executed by a duly authorized officer of Spinco; 

(h)    the License Agreement, executed by a duly authorized officer of Spinco; 

(i)    the MRC Payment Agreements, executed as a deed by Spinco; 

(j)    the Assignment and Assumption and Bill of Sale, executed by a duly authorized officer of Spinco; and 

(k)    the Services Agreement, executed by a duly authorized officer of Spinco. 

  
 8 

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 3.4    Additional Closing Deliveries. From time to time following
the Closing, at the reasonable request of the AZ Parties or Spinco, such other Party shall, and shall cause its respective Affiliates to, execute, acknowledge and deliver all such further conveyances, notices, assumptions, releases and acquittances
and such other instruments, and shall take such further actions, as may be necessary to assure fully (a) to Spinco and its successors and assigns, all of the properties, rights, titles, interests, estates, remedies, powers and privileges
intended to be conveyed to Spinco under this Agreement and the other Transaction Agreements, and (b) to the Parties and their respective Affiliates, and their respective successors and assigns, the assumption of the Liabilities intended to be
assumed by Spinco under this Agreement and the other Transaction Agreements, and to otherwise make effective the Transactions. 
 ARTICLE
IV 
 REPRESENTATIONS AND WARRANTIES OF THE AZ PARTIES 

The AZ Parties hereby represent and warrant to Spinco on the date hereof and as of the Closing Date as follows: 

4.1    Organization and Good Standing. The AZ Parties and Spinco are each an entity duly organized, validly
existing and in good standing under the applicable Laws of the state of its organization and each of the AZ Parties has all requisite corporate or similar power and authority to own, lease and operate the Acquired Assets owned by it as currently
conducted. Each of the AZ Parties is duly qualified or authorized to do business as a foreign entity and is in good standing under the applicable Laws of each jurisdiction in which it owns or leases real property related to the Acquired Assets and
each other jurisdiction in which the conduct of its business or the ownership of its properties related to the Acquired Assets requires such qualification or authorization, except, in each case, where the failure to be so qualified or in good
standing as has not been and would not reasonably be expected to be, individually or in the aggregate, a Material Adverse Effect. Spinco was formed on December 11, 2017 and, from the date of, and until the consummation of the transaction
contemplated by, the Securities Purchase Agreement, Spinco was a direct, wholly owned subsidiary of AZUK, the authorized capital stock of Spinco consisted of [***] per share of common stock, Spinco had no subsidiaries and no liabilities (other than
as set forth in the Transaction Agreements and the Securities Purchase Agreement and the other agreements contemplated thereby). 

4.2    Authorization of Agreement. The AZ Parties and their Affiliates have all requisite power and authority to
execute and deliver this Agreement, each other Transaction Agreement and each other agreement, document, instrument or certificate contemplated by this Agreement or any other Transaction Agreement, in each case, to which it is a party (collectively,
the “AZ Documents”), to perform its respective obligations hereunder and thereunder and to consummate the Transactions. The execution, delivery and performance by the AZ Parties and their Affiliates of each of the AZ Documents and
the consummation of the Transactions, in each case, to which it is party, have been duly authorized and approved by all requisite corporate or similar action on the part of the AZ Parties and their Affiliates. Each of the AZ Documents has been, or
will be at or prior to the Closing, duly and validly executed and delivered by the AZ Party or its Affiliate that is a party thereto and (assuming the due authorization, execution and delivery 

  
 9 

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 
by the other parties thereto) each of the AZ Documents, when so executed and delivered, will constitute the legal, valid and binding obligations of the AZ Party or its Affiliate that is a party
thereto, enforceable against it in accordance with its terms, subject to the effect of any applicable Laws relating to bankruptcy, reorganization, insolvency, moratorium, fraudulent conveyance or preferential transfers, or similar Laws relating to
or affecting creditors’ rights generally and subject, as to enforceability, to the effect of general principles of equity (regardless of whether such enforceability is considered in a proceeding in equity or at Law). 

4.3    Conflicts; Consents of Third Parties. 

(a)    Assuming the receipt of the consents identified on Schedule 4.3(a), none of the execution and delivery of
this Agreement or the other AZ Documents by the AZ Party or its Affiliate that is party thereto, the consummation of the Transactions or the compliance by such AZ Party or the applicable Affiliate with any of the provisions hereof or thereof
conflicts with or will conflict with, or result in any violation of, or constitute a breach of, or conflict with or default (with or without notice or lapse of time, or both) under, or result in the loss of any benefit under, or permit the
acceleration of any obligation under, or give rise to a right of termination, modification or cancellation under, or give rise to any obligation of, such AZ Party or the applicable Affiliate to make any payment under, or to the increased,
additional, accelerated or guaranteed rights or entitlements of any Person under, or result in the creation of any Liens (other than Permitted Liens) upon any of the properties or assets of the AZ Parties or its Affiliates used or held for use in
the Programs under any provision of: (i) the certificate of incorporation and by-laws or comparable organizational documents of any AZ Party or any of its Affiliates; (ii) any Contract or Permit to
which any AZ Party or any of its Affiliates is a party or by which any of the properties or assets of any AZ Party or any of its Affiliates used or held for use in the Programs are bound; (iii) any Order of any Governmental Authority applicable
to any AZ Party or any of its Affiliates or by which any of the properties or assets of any AZ Party or any of its Affiliates used or held for use in the Programs are bound; or (iv) any applicable Law, except, in the case of clauses
(ii), (iii) and (iv) above, where such conflict, violation or default would not have or would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect. 

(b)    Except for any such filings, notices, Permits, authorizations, registrations, consents or approvals, the failure to
make or obtain would not have and would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect, no consent, waiver, approval, Order, Permit or authorization of, or declaration or filing with, or notification
to, any Governmental Authority (a “Governmental Approval”) is required for any AZ Party or any of its Affiliates in connection with the execution and delivery of this Agreement or the other AZ Documents, the compliance by such
AZ Party or such Affiliate with any of the provisions hereof and thereof, the consummation of the Transactions or the taking by such AZ Party or such Affiliate of any other action contemplated hereby or thereby. 

4.4    Acquired Assets. Except as set forth on Schedule 4.4, 

(a)    The AZ Parties own and have good title to, the Acquired Assets, free and clear of all Liens other than Permitted
Liens. Other than any Permitted Liens and except as set forth in the Assigned Contracts and the In-License Agreements, none of the AZ Parties or their 

  
 10 

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 
Affiliates has granted to any Third Party any interest, right to use, license, or entered into any covenants not to sue, releases for infringement, or waivers of claims for infringement, in, of
or with respect to the Acquired Assets. None of the AZ Parties or its Affiliates has received any written notice from any other Person challenging its ownership or rights to use any Acquired Assets and there are no pending actions or claims against
any AZ Party or its Affiliates challenging such ownership or rights. 
 (b)    There are no actions, suits, (to
AZ’s Knowledge) investigations by a Governmental Authority, claims, or proceedings (other than proceedings before a patent office in connection with the prosecution of the Assigned Intellectual Property) pending, or, to AZ’s Knowledge,
threatened, relating in any way to the Acquired Assets that would materially and adversely affect the conduct of the Programs, including any that would reasonably be expected to impair in any material respect any AZ Party’s ability to assign,
transfer, convey and deliver, or that otherwise materially and adversely affects, the Acquired Assets. 
 (c)    Other
than any Permitted Liens and except as set forth in the [***] Collaboration Agreement, there are no existing Contracts to which any AZ Party or any of its Affiliates is a party, pursuant to which a Third Party is granted an option to acquire any
interest in the Acquired Assets. 
 (d)    None of the Assigned Patents has ever been found invalid or unenforceable, in
whole or in part, for any reason in any administrative, arbitration, judicial or other proceeding (other than in proceedings before a patent office in connection with the prosecution of the Assigned Patents) to which any AZ Party or its Affiliate is
or was a party. None of the AZ Parties or its Affiliates has received any written notice from any other Person that any issued patents within the Assigned Patents are not valid and enforceable. 

(e)    None of the AZ Parties or its Affiliates has engaged in, and (to AZ’s Knowledge) none of its agents or
representatives have engaged in, any conduct, or omitted to perform any necessary act, the result of which has invalidated or would reasonably be expected to invalidate any of the Assigned Patents. 

(f)    None of the Assigned Patents is or has been involved in any reexamination, reissue, interference proceeding, or any
similar proceeding, and no such proceedings are pending or, to AZ’s Knowledge, threatened. 
 (g)    The AZ Parties
and their Affiliates have not received any written notice that any maintenance fees and annuities due on the Assigned Patents have not been timely paid except to the extent such failure to timely pay has not resulted in the final abandonment of any
Assigned Patent. 
 (h)    To AZ’s Knowledge, the practice of the inventions, discoveries, technology or ideas
claimed in the Assigned Patents does not and will not infringe upon (including inducing or contributing to the infringement of) or misappropriate any intellectual property rights of any Third Party, and the AZ Parties and their Affiliates have not
received any written notice alleging the foregoing. 

  
 11 

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 (i)    None of the AZ Parties, any of their Affiliates, nor their
respective agents and advisors, has (i) put a Third Party on notice of actual or potential infringement of any of the Assigned Patents or (ii) initiated any enforcement action with respect to any of the Assigned Patents. 

(j)    None of the AZ Parties or any of their Affiliates has received any written communication from any Governmental
Authority relating to any violation of any applicable Law in connection with the Acquired Assets. 
 (k)    The Programs
and Products existing as of the date hereof have been conducted and developed, and the Biological Materials have been manufactured, processed, tested and stored, in accordance with all applicable Laws, rules and regulations, in all material
respects. No Person involved in development of any data included in the Regulatory Materials has been convicted of (or investigated for) any crime or engaged in any conduct that would reasonably be expected to result in exclusion under 42 U.S.C. Section 1302a-7 or any similar state law or regulation or been debarred by the FDA under Article 306 or the Federal Food Drug and Cosmetic Act, 21 U.S.C. Section 335a(a) or (b). 

(l)    None of the AZ Parties or their Affiliates has received (a) any FDA Form 483 “Inspectional
Observations”, or similar notice from any Governmental Authority, relating to the Programs, Products or the facilities in which the Products are manufactured; (b) any FDA Notices of Adverse Findings, or similar notice from any other
Governmental Authority, with respect to the Products or the Programs; or (c) any “warning letters,” or “untitled letters,” or other similar Governmental Authority notice of inspectional observations or legal deficiencies or
other written correspondence from the FDA or any other Governmental Authority asserting a violation of applicable Law concerning the Programs or the Products. There has not been a recall or market withdrawal or replacement of any Product by, or on
behalf of, any AZ Party or any of its Affiliates, whether voluntary or involuntary. The AZ Parties and their Affiliates are, and at all times have been, in compliance with all adverse event reporting requirements applicable to the Products. 

(m)    Neither any AZ Party nor any of its Affiliates has made any false statements on, or omissions from, the
applications, reports and other submissions or communications (written or oral) to the FDA or any other Governmental Authority with respect to the Programs, the Product(s) or their manufacture or any other records, reports and documentation prepared
or maintained to comply with the requirements of applicable Law. None of the AZ Parties or any of their Affiliates is the subject of any pending or, to AZ’s Knowledge, threatened investigation by any Governmental Authority with respect to the
Programs, or the Products, including by (a) the FDA pursuant to its “Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities” Final Policy set forth in 56 Fed. Reg. 46191 (September 10, 1991) and any
amendments thereto; (b) the Federal Trade Commission (“FTC”); or (c) any other Governmental Authority that has jurisdiction over the Programs under any similar policy. 

(n)    The Assigned Contracts are in full force and effect and, to AZ’s Knowledge, no party to the Assigned Contracts
is in material breach thereof. 

  
 12 

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 (o)    To AZ’s Knowledge, the Acquired Assets (including for this
purpose the Duke License Agreement and the DFCI License Agreement), along with the Licensed Intellectual Property, the Transferred Employees and the rights of Spinco under the Transaction Agreements, comprise all of the material assets and rights
that are necessary for Spinco to conduct the Programs from and after the Closing, where applicable, during the period contemplated by such Transaction Agreements in all material respects as currently conducted by the AZ Parties and their Affiliates
as of the Closing Date. The Assigned Patents, the Patents subject to the Assigned Contracts, the Duke License Agreement and the DFCI License Agreement and the Patents within the Licensed Intellectual Property comprise all of the Patents owned or
controlled by the AZ Parties or their Affiliates that claim or cover the Products or uses of the Products (but for clarity not methods of manufacturing the Products) as of the date hereof. 

4.5    No Other Representations or Warranties. Except for the representations and warranties contained in this
Article IV, Spinco acknowledges that none of the AZ Parties or any of their Affiliates nor any other Person on behalf of any AZ Party or any of its Affiliates has made, and Spinco has not relied upon, any representation or warranty, whether
express or implied, with respect to the Programs, any AZ Party or its Affiliates or their respective businesses, affairs, assets, Liabilities, financial condition, results of operations, future operating or financial results, estimates, projections,
forecasts, plans or prospects (including the reasonableness of the assumptions underlying such estimates, projections, forecasts, plans or prospects) or with respect to the accuracy or completeness of any other information provided or made available
to Spinco by or on behalf of the AZ Parties in connection with the Transactions. 
 ARTICLE V 

REPRESENTATIONS AND WARRANTIES OF SPINCO 

5.1    No Representations or Warranties. Without limiting the representations and warranties made by AZ with
respect to Spinco in Article IV, the AZ Parties acknowledge that Spinco is not making any representation or warranty hereunder. 

ARTICLE VI 
 CONDUCT OF
BUSINESS 
 6.1    Conduct of Business Pending the Closing. During the period from the date of this Agreement
to the Closing, except (1) as required by applicable Law, (2) as otherwise contemplated or required by this Agreement or (3) with the prior written consent of Spinco (which consent shall not be unreasonably withheld, conditioned or
delayed), Medi LLC shall, and shall cause its Affiliates, to: 
 (a)    conduct the Programs only in the Ordinary Course
of Business; and 
 (b)    use its commercially reasonable efforts to (A) preserve the present business operations
and goodwill of the Programs, (B) preserve the present relationships with material suppliers and other Persons having material business dealings with Medi LLC and its Affiliates in connection with the Programs, and (C) maintain all assets
and properties included in the Acquired Assets in their current condition, normal wear and tear excepted; 

  
 13 

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 provided, however, that notwithstanding the foregoing or anything else to the contrary herein,
Medi LLC shall have full and sole discretion to make any and all personnel decisions prior to Closing with respect to the AZ Employees (whether Transferred Employees or otherwise) as determined by Medi LLC, including hiring, terminating, and
compensating such AZ Employees, subject to Section 7.5(e). 
 ARTICLE VII 

COVENANTS 

7.1    Cooperation; Filings and Approvals; Consents. 

(a)    Subject to the terms and conditions of this Agreement, each of the Parties shall cooperate with the other and use
(and shall cause their respective Affiliates to use) reasonable best efforts to promptly (i) take, or cause to be taken, all actions and do, or cause to be done, all things necessary, proper or advisable to cause the conditions set forth in
Article VIII to be satisfied as promptly as practicable and to consummate and make effective the Transactions, including preparing and filing promptly all documentation to effect all necessary filings, notices, petitions, statements,
registrations, submissions of information, applications and other documents, and (ii) obtain all approvals, consents, registrations, Permits, authorizations and other confirmations from any Governmental Authority necessary, proper or advisable
to consummate the Transactions. The Parties shall not, and shall cause their respective Affiliates not to, knowingly take any action after the date of this Agreement that would reasonably be expected to result in not obtaining, any approvals,
consents, registrations, Permits, authorizations and other confirmations from any Governmental Authority necessary, proper, or advisable to be obtained prior to the Closing in order to consummate the Transactions. 

(b)    Each of the Parties shall use commercially reasonable efforts to take, or cause to be taken, all actions and do, or
cause to be done, all things necessary, proper or advisable to, in the most expeditious manner practicable, (i) provide all notices to and obtain all consents, waivers and approvals of and notices to any Person (other than a Governmental
Authority) required to consummate the Transactions, including the notices, consents and approvals referred to in Section 4.3, and (ii) take such other actions as may be reasonably required in order to carry out the
intent of this Agreement; provided, however, that, in each case, notwithstanding anything to the contrary in this Agreement, no Party shall be obligated to pay any consideration to any Person from whom consent or approval is requested
in order to obtain such consent or approval. 
 7.2    Confidentiality. For a period of [***], each Party shall
not, and shall cause its Affiliates not to, directly or indirectly, disclose, reveal, divulge or communicate to any Person other than the other Party or any of their respective Affiliates or Representatives, or, subject to the proviso set forth
herein, use or otherwise exploit for the benefit of any Person other than the other Party or any of their respective Affiliates or Representatives, any Confidential Information of the other Party without the prior written consent of such other
Party. Neither Party shall have any 

  
 14 

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 
obligation to keep confidential any Confidential Information if and to the extent disclosure thereof is specifically required by applicable Law; provided, however, that in the event
disclosure is required by applicable Law, the disclosing Party shall, to the extent reasonably possible and permissible under applicable Law, provide the other Party of such requirement prior to making any disclosure so that the other Party may seek
an appropriate protective order. For purposes of this Agreement, “Confidential Information” means all confidential and proprietary information of such Party; provided, however, that Confidential Information of a Party
shall not include, and there shall be no obligation hereunder with respect to, information that (i) is generally available to the public on the date of this Agreement, (ii) becomes generally available to the public other than as a result
of a disclosure by the receiving Party or any of its Affiliates in breach of this Section 7.2, (iii) is or becomes available to the receiving Party or any of its respective Affiliates from a source that is not known by
such Person to be bound by an obligation of confidentiality or (iv) is independently developed by the receiving Party or any of its respective Affiliates after Closing without the use of, or reference to, the disclosing Party’s
Confidential Information. For clarity, from and after Closing, the Acquired Assets that consist of Confidential Information shall be the Confidential Information of Spinco. 

7.3    Preservation of Records. Each Party agrees that it shall, and shall cause its respective Affiliates to,
preserve and keep the records held by it relating to the Programs and the Acquired Assets for a[***] and shall make such records and personnel available to the other Party as may be reasonably required by such other Party in connection with, among
other things, any insurance claims by, Legal Proceedings (other than Legal Proceedings between the Parties related to this Agreement, the other Transaction Agreements or the Transactions) or Tax audits against or governmental investigations of Medi
LLC or Spinco or any of their respective Affiliates or in order to enable Medi LLC (and its applicable Affiliates) or Spinco to comply with their respective obligations under this Agreement and the other Transaction Agreements and each other
agreement, document or instrument contemplated hereby or thereby. Notwithstanding the foregoing, neither Medi LLC nor Spinco shall be required to, or to cause its respective Affiliates to, provide access to or disclose information where such access
or disclosure would jeopardize the attorney-client privilege of such Party or its Affiliates or contravene any applicable Law. 

7.4    Publicity. Neither Party nor their respective Affiliates shall issue any press release or public
announcement concerning this Agreement, the other Transaction Agreements or the Transactions or make any other public disclosure containing the terms of this Agreement without obtaining the prior written approval of the other Party (not to be
unreasonably withheld) unless, in the judgment of the disclosing Party, disclosure is otherwise required by applicable Law. 

7.5    Employee Matters. 

(a)    Transferred Employees. At least [***] prior to the Closing, Spinco delivered, in writing, an offer of
employment (on an “at will” basis) to commence employment upon the Closing with Spinco to each AZ Employee, and each such AZ Employee will be required to execute a proprietary information, confidentiality and assignment agreement as a term
and condition of their employment with Spinco. Notwithstanding the foregoing, Bing Yao, Jorn Drappa, and Aaron Ren have been offered an employment agreement with a [***] term, and will be required to enter into a restricted covenant agreement with non-competition agreement and 

  
 15 

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 
customer non-solicitation obligations for the period of employment and[***] following termination of employment, and employee non-solicitation obligations for the period of employment and [***] years following termination of employment. AZ Employees who accept such offer on or prior to the Closing Date and commence employment with Spinco
upon the Closing are referred to as “Transferred Employees.” Subject to applicable Law, the provisions of this Section 7.5, and the provisions of any employment letters or agreements between Spinco and the
applicable Transferred Employee, after the Closing Date, Spinco shall have the right to dismiss any Transferred Employee at any time, with or without cause, and to change the terms and conditions of their employment (including their position and
compensation and any employee benefits provided to them). 
 (b)    Procedure. Pursuant to the
“Procedure” provided in section 4 of Revenue Procedure 2004-53, 2004-2 C.B. 320, each of Spinco and Medi LLC (or the applicable member of the AZ Group) shall
file a Form W-2 with respect to any Transferred Employees for the calendar year in which the Closing occurs. The AZ Parties and Spinco shall cooperate, and to the extent reasonably requested, provide
information to each other in complying with any Law with respect to Taxes, and with respect to the reduction of any withholding Taxes where available. 

(c)    Employee Benefits. Transferred Employees shall cease to be covered under the Employee Benefit Plans
effective as of Closing. 
 (d)    COBRA. The AZ Group shall be exclusively responsible for complying with COBRA
with respect to its employees (including the Transferred Employees) and their qualified beneficiaries by reason of any such employees’ termination of employment with the AZ Group, and Spinco shall not have any Liability to provide rights under
COBRA on account of any such termination of employment. 

(e)    Non-Solicitation. From the Closing to the [***] of the Closing Date,
Medi LLC and its Affiliates shall not, directly or indirectly, solicit, entice, or attempt to solicit or entice any then-current employee of Spinco to terminate employment with Spinco. This provision shall not be violated by (i) general
solicitations or advertisements, including in newspapers, websites and other media, not specifically targeted at employees of Spinco or (ii) soliciting or hiring any former employee of Spinco. 

(f)    No Third Party Beneficiary. The provisions of this Section 7.5 are solely for the
benefit of the Parties, and no other Person (including any AZ Employee or any beneficiary or dependent thereof) shall be regarded for any purpose as a third party beneficiary of this Agreement, and no provision of this
Section 7.5 shall create such rights in any such Person. 
 7.6    Intentionally
Omitted. 
 7.7    Misallocated Assets. If, following the Closing, any right, property or asset not forming
part of the Acquired Assets is found to have been transferred to Spinco in error, either directly or indirectly, Spinco shall (a) transfer at no cost to Medi LLC, such right, property or asset (and any related Liability) as soon as practicable
to one or more of Medi LLC and its Affiliates designated by Medi LLC and (b) prior to such transfer, ensure that Spinco shall where permitted 

  
 16 

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 
by the terms on which it has the right to such asset, hold the asset (or part thereof), and any monies, goods or other benefits arising after the Closing by virtue of it, as agent of and trustee
for Medi LLC and its Affiliates and allow Medi LLC and its Affiliates from and after the Closing to have full enjoyment and use of such asset and Medi LLC and its Affiliates shall bear all burdens relating to such asset. If, following the Closing,
any right, property or asset forming part of the Acquired Assets is found to have been retained by Medi LLC or any of its Affiliates in error, either directly or indirectly, Medi LLC shall (i) transfer, or shall cause its Affiliates to
transfer, at no cost to Spinco, such right, property or asset (and any related Liability) as soon as practicable to Spinco and (ii) prior to such transfer, ensure that Medi LLC or its applicable Affiliate shall where permitted by the terms on
which Medi LLC or its applicable Affiliate has the right to such asset, hold the asset (or part thereof), and any monies, goods or other benefits arising after the Closing by virtue of it, as agent of and trustee for Spinco and allow Spinco from and
after the Closing to have full enjoyment and use of such asset and Spinco shall bear all burdens relating to such asset. For the avoidance of doubt, the Parties understand and agree that (x) the Excluded Assets are not intended to, and shall
not, be transferred to Spinco and Medi LLC or its applicable Affiliate shall retain such rights, properties and assets, and (y) the Acquired Assets are intended to, and shall, be transferred to Spinco and Spinco shall acquire such rights,
properties and assets. 
 7.8    Third Party Agreement Transfer Liability. To the extent Medi LLC or any of its
Affiliates incur any out-of-pocket costs or expenses associated with the act of assigning any Assigned Intellectual Property or assigning any Assigned Contracts, in each
case to Spinco, Medi LLC shall bear such costs. 

7.9    Non-Competition. 

(a)    Subject to the terms of this Section 7.9, from the Closing Date until the [***] of the
Closing Date (the “Restricted Period”), Medi LLC shall not, and Medi LLC shall cause its Affiliates not to, either itself or with or through any Affiliate or Third Party: (i) initiate or conduct any Clinical Study with respect
to any Competing Product, or (ii) market, sell or otherwise commercialize, a Competing Product anywhere in the world (the activities described in the foregoing clauses (i) and (ii) are collectively referred to herein as “Competing
Activities”). Notwithstanding expiration of the Restricted Period, Medi LLC shall not, and shall cause its Affiliates not to, either itself or through any Affiliates or Third Party, initiate or conduct any activity that would, had it been
undertaken during the Restricted Period, constitute a Competing Activity, with any Product or any compound or molecule derived from the selected, pre-optimized lead antibody, antibody fragment or peptide (as
applicable) from which such Product was derived. 
 (b)    Notwithstanding the covenants set forth above in
Section 7.9(a), during the Restricted Period, neither Medi LLC nor any of its Affiliates shall be prohibited from: 

(i)    acquiring and continuing to hold any securities of any person to the extent such acquisitions are
for passive investment purposes only and do not result in AstraZeneca or any of its Affiliates owning in the aggregate more than [***] of all issued and outstanding capital; 

  
 17 

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 (ii)    acquiring (through merger, stock purchase,
purchase of assets or otherwise) ownership of, or any equity interest in (to the extent not otherwise permitted by Section 7.9(b)(i)), and continuing to hold, any business or person engaged in any Competing Activities so
long as (A) such Competing Activities accounted for less than [***] of such acquired business’ or person’s consolidated annual revenues during the fiscal year prior to such acquisition being made or (B) to the extent such
Competing Activities account for [***] or more of such acquired business’ or person’s consolidated annual revenues during the fiscal year prior to such acquisition being made, within[***] of the closing of such an acquisition, Medi LLC or
such Affiliate either divests Competing Activities acquired pursuant to such acquisition or ceases such Competing Activities, in either case such that, following such divestures and cessations, any remaining Competing Activities so acquired in the
aggregate accounted for less than [***] of such acquired business’ or person’s consolidated annual revenues during the fiscal year prior to such acquisition being made, during the remainder of the Restricted Period; or 

(iii)    undertaking the [***] Collaboration Programs, conducting Clinical Studies (or other Development
activities) or marketing, selling or otherwise commercializing [***] Collaboration Products, in each case pursuant to the [***] Collaboration Agreement. 

(c)    Nothing in this Section 7.9 shall restrict the activities of any Person (or any of its
Affiliates) who engages in a business combination transaction resulting in the acquisition (by merger, tender offer, purchase or otherwise) of any capital stock or assets of AstraZeneca plc and who prior to entering into or commencing such business
combination transaction is not an Affiliate of AstraZeneca plc. 
 (d)    Nothing in this
Section 7.9 shall restrict the activities of any Person (or any of its Affiliates) who engages in a business combination transaction with AstraZeneca plc pursuant to which (1) at least [***] of any consideration paid
to the stockholders of AstraZeneca plc and/or such person, as applicable, as a result of such transaction, consists of common equity of the resulting parent company, and (2) the market capitalization of the resulting parent entity immediately
following the consummation of such business combination is at least [***] of the market capitalization of AstraZeneca plc prior to the public announcement of such business combination (with such market capitalization of AstraZeneca plc being
determined by reference to the average trading price over the last [***] where AstraZeneca plc’s stock price was unaffected as a result of such possible business combination). 

(e)    Nothing in this Section 7.9 shall restrict the activities of any acquired business or
person described in Section 7.9(b)(ii). 
 (f)    For clarity, nothing in this Agreement or
any Transaction Agreement shall prevent or restrict Medi LLC or any of its Affiliates from Developing, commercializing or otherwise exploiting (i) [***] in any disease area, (ii) any medicinal product (other than with respect to Products as
expressly transferred hereunder) for the treatment, prevention or diagnosis of any diseases in the therapeutic areas of oncological, [***], or (iii) [***] (or any other Licensed Product as defined in the [***] License Term Sheet) in accordance with
this Agreement and/or the [***] License Agreement. 

  
 18 

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 (g)    Notwithstanding anything herein to the contrary, it is understood
and agreed that the remedy of indemnity payments pursuant to Article IX and other remedies at law would be inadequate in the case of any breach of the covenants contained in Section 7.9(a). Spinco shall be entitled
to seek equitable relief, including the remedy of specific performance, with respect to any breach or attempted breach of such covenants. If a final and non-appealable judicial determination is made that any
provision of Section 7.9(a) constitutes an unreasonable or otherwise unenforceable restriction with respect to any particular jurisdiction, the provisions of Section 7.9(a) will not be rendered
void but will be deemed to be modified solely with respect to the applicable jurisdiction to the minimum extent necessary to remain in force and effect for the greatest period and to the greatest extent that such court determines constitutes a
reasonable restriction under the circumstances. 
 7.10    Certain Cellective Agreements.  

(a)    Cellective Agreements. Reference is made to (i) the Agreement and Plan of Merger, dated as of
September 13, 2005 (the “Cellective Merger Agreement”), by and among (A) MedImmune, Inc., a Delaware corporation (“MedImmune, Inc.”) and predecessor in interest to Medi LLC, (B) Trifecta Merger Sub,
Inc., (C) Cellective Therapeutics, Inc. (which was subsequently merged into MedImmune, Inc., which subsequently converted into Medi LLC), and (D) Garheng Kong, as the “Representative” of the stockholders of Cellective Therapeutics,
Inc. (the “Cellective Representative”), and (ii) the Consulting Agreement, dated as of November 1, 2005 (the “Tedder Consulting Agreement”), by and between MedImmune, Inc. and Thomas F. Tedder, Ph.D.
(“Tedder”). 
 (b)    Cellective Merger Agreement. 

(i)    Spinco shall assume responsibility for and shall pay to the Cellective Representative (or, if
applicable, to reimburse Medi LLC if Medi LLC has made a payment to the Cellective Representative after the Closing Date that, in accordance herewith, is the responsibility of Spinco), or (if directed in writing by Medi LLC) to Medi LLC for further
payment to the Cellective Representative, in any case within [***] after the successful completion or achievement of any Development Milestone (as defined in Exhibit B of the Cellective Merger Agreement (the “Cellective Milestone
Terms”)) by Spinco, its Affiliates or sublicensees with respect to [***] or any other Cellective CD19 Product, an amount equal to the corresponding one-time,
non-refundable Milestone Payment (as defined in the Cellective Merger Agreement) payable by MedImmune, LLC on such successful completion or achievement in accordance with Article 2 of the Cellective Merger
Agreement (subject to the terms of Sections 2 and 4 of the Cellective Milestone Terms). 

(ii)    Spinco shall assume responsibility for and shall pay to the Cellective Representative (or, if
applicable, to reimburse Medi LLC if Medi LLC has made a payment to the Cellective Representative after the Closing Date that, in accordance herewith, is the responsibility of Spinco), or (if directed in writing by Medi LLC) to Medi LLC for further
payment to the Cellective Representative, in any case within [***] after the first fiscal quarter in which the Net Sales (as defined in Section 1.7 of the Cellective Milestone Terms) of Cellective CD19 Products by Spinco, its Affiliates and
sublicensees achieved the Sales 

  
 19 

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 
Milestone (as defined in Section 3 of the Cellective Milestone Terms) if Cellective CD19 Products are the first Product thereunder to achieve such Sales Milestone, an amount equal to the one-time, non-refundable Milestone Payment of [***] payable by Medi LLC in accordance with Article 2 of the Cellective Merger Agreement (subject to the terms of Sections 3 and
4 of the Cellective Milestone Terms). 
 (iii)    Without prejudice to any other provision hereof, Spinco
shall (A) be responsible for discharging Medi LLC’s diligence obligations set forth in Exhibit C of the Cellective Merger Agreement (the “Cellective Diligence Terms”) with respect to Cellective CD19 Products, and shall use
such efforts to, and shall be required to, Develop and Commercialize (as each such term is defined in the Cellective Diligence Terms) one Cellective CD19 Product, in accordance with the Cellective Diligence Terms; and (B) shall keep records
with respect to the Development and Commercialization of Cellective CD19 Products and provide to Medi LLC (for disclosure to the Cellective Representative), or (if directed in writing by Medi LLC) to the Cellective Representative, within [***] of
the end of each calendar year, an annual report of such activities that satisfies the requirements of Section 5 of the Cellective Milestone Terms. 

(c)    Tedder Consulting Agreement. Spinco shall assume responsibility for and shall pay to the Consultant (as
defined in the Tedder Consulting Agreement) (or, if applicable, to reimburse Medi LLC if Medi LLC has made a payment to the Consultant after the Closing Date that, in accordance herewith, is the responsibility of Spinco), or (if directed in writing
by Medi LLC) to Medi LLC for further payment to Consultant, in any case within [***] after such payment to Consultant is due under Section 2(c) of the Tedder Consulting Agreement, an amount equal to the applicable milestone payment due with
respect to a Cellective CD19 Product under Section 2(c) of the Tedder Consulting Agreement. 
 (d)    Release
Efforts. If requested by Medi LLC following the Closing, Spinco shall cooperate with Medi LLC and shall use commercially reasonable efforts to cause Medi LLC and its Affiliates to be released from, and to have Spinco substituted for Medi LLC and
its Affiliates as an obligor with respect to, the obligations of Medi LLC and its Affiliates to pay to the Cellective Representative and/or the Consultant any amounts due to such Person under the Cellective Merger Agreement or the Tedder Consulting
Agreement with respect to Development Milestones or Sales Milestones under the Cellective Merger Agreement or milestone payments under Section 2(c) of the Tedder Consulting Agreement with respect to Cellective CD19 Products, and the related
diligence and reporting obligations under the Cellective Merger Agreement. Pending such release, Spinco shall notify Medi LLC of the successful completion or achievement of any Development Milestone or Sales Milestone (each as defined in the
Cellective Merger Agreement) or event triggering a payment under the Tedder Consulting Agreement, in each case within [***] of such occurrence. 

7.11    Certain other MEDI-551 Agreements. 

(a)    MEDI-551 License Agreements. Reference is made to (i) the
License Agreement dated September 21, 2004, as amended by a letter dated September 9, 2005 (collectively the “Duke License Agreement”), between Duke University (“Duke”) and Cellective Therapeutics, Inc.
(now 

  
 20 

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 
Medi LLC); and (ii) the Exclusive License Agreement, dated September 21, 2004, as amended by letter dated September 8, 2005 (collectively, the “DFCI License
Agreement”) between Dana-Farber Cancer Institute, Inc. (“DFCI”) and Cellective Therapeutics, Inc. (now Medi LLC). 

(b)    Medi LLC and Spinco acknowledge that assignment of the Duke License Agreement requires the consent of Duke and
assignment of the DFCI License Agreement requires the consent of DFCI, in each case not to be unreasonably withheld. Medi LLC and Spinco shall use all commercially reasonable efforts to obtain such consents promptly, and upon obtaining such consents
the Duke License Agreement or the DFCI License Agreement (as applicable) shall be deemed to be an Assigned Contract and added to Schedule 2.1(b)(iii). Pending assignment to Spinco: 

(i)    Spinco shall not undertake any activity that would require a sublicense under the applicable
agreement and Medi LLC or its applicable Affiliate shall continue to perform such activities in accordance with the Clinical Supply Agreement, the Transition Services Agreement or the Development Services Agreement (as applicable) at Spinco’s
cost as provided for in such agreements; 
 (ii)    Spinco shall take or cause to be taken, at its
expense, such actions as Medi LLC may reasonably require to enable Medi LLC to comply with the Duke License Agreement and the DFCI License Agreement in so far as they relate to CD-19 Products; 

(iii)    Spinco shall assume responsibility for and shall pay to Duke (or, if applicable, to reimburse Medi
LLC if Medi LLC has previously made the applicable payment to Duke), or (if directed in writing by Medi LLC) to Medi LLC for further payment to Duke, all amounts that are paid or payable pursuant to Section 3.01(c)(iii) of the Duke License
Agreement with respect to the exploitation of [***] in any case within [***] after first achievement of each milestone and otherwise in accordance with Article 3 of the Duke License Agreement; and 

(iv)    if and to the extent that the supply of products or services to Spinco under any Transaction
Agreement triggers an obligation to pay any sum to Duke under the Duke License Agreement or to DFCI under the DFCI License Agreement, as between the Parties, Spinco shall be responsible for such cost and an amount equal to the amount paid or payable
to Duke or DFCI (as applicable) shall be added to the fee payable to Medi LLC by Spinco with respect to such supply. 

(c)    If the Duke License Agreement or the DFCI License Agreement (as applicable) has not been assigned to Spinco by
May 31, 2018 or such later date as the Parties may agree, Medi LLC shall grant Spinco a sublicense under the Duke License Agreement or DFCI License Agreement (as applicable) to exploit CD-19 Products. As
between Medi LLC and Spinco, Spinco shall assume all responsibilities under the Duke License Agreement or the DFCI License Agreement (as applicable) with respect to CD-19 Products and such sublicense shall
include such terms as are necessary to ensure that Medi LLC can comply with its obligations under such license. Without limitation of the foregoing, such sublicense shall be subject and subordinate to the terms and conditions of the Duke License
Agreement or the DFCI License Agreement (as applicable) and shall be effective solely to the extent permitted under the terms and conditions of such agreement. Without limitation of the foregoing, as

  
 21 

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 
between Medi LLC and Spinco, Spinco shall be responsible for any and all payments and reports under the Duke License Agreement or the DFCI License Agreement (as applicable) relating to the
exploitation of CD-19 Products and shall pay to Duke or DFCI (or, if applicable, to reimburse Medi LLC if Medi LLC has previously made the applicable payment to Duke or DFCI), or (if directed in writing by
Medi LLC) to Medi LLC for further payment to Duke or DFCI, an amount that is equal to the amount that is paid or payable by Medi LLC under such agreement with respect to exploitation of CD-19 Products by
Spinco, its Affiliates or sublicensees (and provide any associated report) not less than [***] prior to the due date for payment by Medi LLC and otherwise in accordance with the Duke License Agreement or the DFCI License Agreement (as applicable).
The Parties acknowledge that if Medi LLC grants Spinco a sublicense under this Section 7.11(c), Spinco will not have the right to grant any further sublicense without the prior written consent of Duke or DFCI, as applicable and that the
sublicense agreement will provide that, in the event Spinco desires to grant a further sublicense under the Duke License Agreement or the DFCI License Agreement to an Affiliate or a Third Party licensed by Spinco under Patents and Know-How owned by Spinco to exploit CD-19 Products, Spinco shall be able to make a written request to Medi LLC and Medi LLC shall agree, to the extent permissible and subject
to appropriate protections for Medi LLC, to promptly grant a direct sublicense to such Affiliate or Third Party in a separate sublicense agreement, on substantially similar terms and conditions as the sublicense agreement between Spinco and Medi LLC
taking into account the scope of the license granted to such Affiliate or Third Party by Spinco. MedImmune LLC shall not be required to grant any sublicense that would be prohibited under Section 11.10 and no sublicense to an Affiliate or a
Third Party shall relieve Spinco of its obligations hereunder. 
 7.12    MEDI1116 License Agreement. 

(a)    Reference is made to the terms set forth on Schedule 7.12 (the “[***] License Term Sheet”)
for a license agreement (the [***] License Agreement”) to be negotiated between Medi LLC and Spinco following the Closing, pursuant to which, among other things, Spinco will license to Medi LLC the Licensed Technology (as defined in the
[***] License Term Sheet) to exploit Licensed Products (as defined in the [***] License Term Sheet). 
 (b)    Following
the Closing, the Parties shall negotiate in good faith the terms of the definitive [***] License Agreement containing terms that are described in, or are otherwise consistent with, the terms set forth in the [***] License Term Sheet and other
customary terms consistent therewith. The Parties shall enter into the[***] License Agreement as promptly as practicable following the Closing and in any event within [***] of the Closing. Medi LLC and its counsel shall prepare the initial draft of
the [***] License Agreement. 
 (c)    From the Closing Date to the date that the Parties execute and deliver the [***]
License Agreement, Spinco hereby grants to Medi LLC an exclusive license in the Territory, with the right to grant sublicenses through multiple tiers, to and under the Assigned Intellectual Property to research, develop, make, have made, use, sell,
offer to sell, import, and otherwise exploit Licensed Products intended for use in the [***] (as defined in the [***] License Term Sheet); 

  
 22 

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 (d)    Notwithstanding Section 2.1(b), Medi
LLC shall be entitled to retain and use: (i) copies of existing Know-How relating to the Licensed Product, and (ii) [***], in each case, for the purposes described in clause (c) above and when
entered into, the [***] License Agreement.  
 7.13    [***] Consent. Notwithstanding the execution of the
Services Agreement, at any time after the date that is [***] following the Closing Date, but not more frequently than once in any [***] period, upon Spinco’s written request, the AZ Parties shall, for a [***] period following such request,
reengage in discussions and negotiations with [***] and use commercially reasonable efforts to obtain [***] consent to a full assignment and novation to Spinco of the portion of the [***] Collaboration Agreement relating to the [***] [***]
Collaboration Programs (the “[***] Novation Consent”); provided, that, in no event shall such efforts require the AZ Parties to make any payments of cash (except to the extent Spinco consents to reimburse the AZ Parties for
[***] of such amounts), assets or other property to [***], commence any litigation, arbitration or other action, or to waive or modify the terms of any agreements by and among [***] and any of its Affiliates on the one hand, and any of the AZ
Parties or any of their Affiliates on the other hand, except any modification to the [***] Collaboration Agreement that is required solely to address changes needed to effectuate the [***] Novation Consent. Notwithstanding anything to the contrary
set forth above, the AZ Parties’ obligation to seek the [***] Novation Consent pursuant to the foregoing provisions of this Section 7.13 shall expire and be of no further force and effect as of the third anniversary of
the Closing Date. Notwithstanding the foregoing, (a) without the AZ Parties’ prior written consent, Spinco shall not contact, engage in discussions or initiate negotiations with [***] regarding the [***] Novation Consent at any time prior
to the third anniversary of the Closing Date, and (b) following the [***] of the Closing Date and without obtaining the AZ Parties’ prior written consent, Spinco shall have the right to contact, engage in discussions and negotiations with
[***] regarding the [***] Novation Consent at any time; provided, that (i) Spinco shall notify the AZ Parties and keep the AZ Parties informed of the status of any such discussions and negotiations and (ii) any resulting agreement
will be subject to the AZ Parties’ approval, which shall not be unreasonably withheld, conditioned or delayed. 
 ARTICLE VIII

 CONDITIONS TO CLOSING 

8.1    Conditions Precedent to Obligation of the Parties. The respective obligation of each Party to consummate the
Transactions is subject to the satisfaction or waiver, in writing, on or prior to the Closing Date of the following conditions: 

(a)    no Law shall have been enacted, entered, promulgated and remain in effect that prohibits or makes illegal the
consummation of the Transactions; and 
 (b)    there shall not be in effect any Order by a Governmental Authority of
competent jurisdiction restraining, enjoining or otherwise prohibiting the consummation of the Transactions; provided that, prior to asserting the failure of this condition, the Parties shall have used their reasonable best efforts to have
such Order vacated. 

  
 23 

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 8.2    Conditions Precedent to Obligation of Spinco. The
obligation of Spinco to consummate the Transactions is further subject to the satisfaction or waiver, in writing, on or prior to the Closing Date of the following conditions: 

(a)    (i) each of the representations and warranties of the AZ Parties set forth in Article IV which are
qualified by a “Material Adverse Effect” or other “materiality” qualification shall be true and correct in all respects as so qualified at and as of the date of this Agreement and at and as of the Closing Date as though made at
and as of the Closing Date and (ii) each of the representations and warranties of the AZ Parties set forth in Article IV which are not qualified by a “Material Adverse Effect” or other “materiality” qualification
shall be true and correct in all material respects at and as of the date of this Agreement and at and as of the Closing Date as though made at and as of the Closing Date; provided, however, that, with respect to clauses
(i) and (ii) of this Section 8.2(a), representations and warranties that are made as of a particular date or period shall be true and correct (in the manner set forth in clauses (i) or
(ii) of this Section 8.2(a), as applicable), only as of such date or period. Spinco shall have received a certificate signed by an authorized executive officer of each of the AZ Parties, dated the Closing Date, to
the foregoing effect; 
 (b)    The AZ Parties shall have performed and complied in all material respects with all
covenants, obligations and agreements required by this Agreement to be performed or complied with by it on or prior to the Closing Date, and Spinco shall have received a certificate signed by an authorized executive officer of each of the AZ
Parties, dated the Closing Date, to the foregoing effect; 
 (c)    the transactions contemplated by the Securities
Purchase Agreement shall have been consummated in accordance with the terms thereof; and 
 (d)    The AZ Parties shall
have delivered (or caused to be delivered) to Spinco each of the certificates, documents, instruments and other items required to be delivered by it pursuant to Section 3.2. 

8.3    Conditions Precedent to Obligation of the AZ Parties. The obligation of the AZ Parties to consummate
the Transactions is further subject to the satisfaction or waiver, in writing, on or prior to the Closing Date of the following conditions: 

(a)    Spinco shall have performed and complied in all material respects with all agreements, obligations and covenants
required by this Agreement to be performed or complied with by it on or prior to the Closing Date, and the AZ Parties shall have received a certificate signed by an authorized executive officer of Spinco, dated the Closing Date, to the foregoing
effect; 
 (b)    the transactions contemplated by the Securities Purchase Agreement shall have been consummated in
accordance with the terms thereof; and 
 (c)    Spinco shall have delivered (or caused to have been delivered) to AZ
each of the certificates, documents, instruments and other items required to be delivered by it pursuant to Section 3.3. 

  
 24 

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 8.4    Frustration of Closing Conditions. No Party may rely,
either as a basis for not consummating the Transactions or for terminating this Agreement and abandoning the Transactions, on the failure of any condition set forth in Section 8.1, 8.2, or 8.3, as the case may
be, to be satisfied if such failure was caused by such Party’s breach of any provision of this Agreement (including Section 7.1). 

ARTICLE IX 

INDEMNIFICATION 

9.1    Survival. The representations and warranties of the Parties contained in this Agreement shall survive until
the [***] anniversary of the Closing Date, except for Fundamental Representations, which shall survive until the [***] anniversary of the Closing Date and except for the representations and warranties in Article IV as they relate to the
Assigned Intellectual Property and Licensed Intellectual Property, which shall survive until the [***] anniversary of the Closing Date (such applicable time period, the “Survival Period”); provided, further, that any
obligations under Section 9.2 or Section 9.3 shall not terminate with respect to any claims as to which the Person to be indemnified pursuant to this Article IX (the “Indemnified
Party”) shall have (in good faith) given written notice to the indemnifying party pursuant to this Article IX (the “Indemnifying Party”) before termination of the applicable Survival Period. Unless otherwise
expressly provided in this Agreement, all of the covenants and obligations of the Parties contained in this Agreement shall survive the Closing in accordance with their respective terms; provided, however, that, with respect to
covenants and obligations to be performed in whole or in part prior to the Closing, claims in respect of the breach thereof may not be made after the [***] anniversary of the Closing Date. 

9.2    Indemnification by the AZ Parties. From and after the Closing Date and subject to the provisions of
this Article IX, Medi LLC shall reimburse, defend, indemnify and hold Spinco and its directors, officers, employees, Affiliates (other than the AZ Parties and their Affiliates), agents, attorneys, Representatives, successors and permitted
assigns (collectively, the “Spinco Indemnified Parties”) harmless from and against any and all Losses incurred, resulting or arising from or relating to: 

(a)    any inaccuracy or breach of any of the representations or warranties made by any AZ Party in this Agreement or in
any certificate delivered by or on behalf of any AZ Party hereunder; 
 (b)    any breach of or failure to perform any
covenant or agreement made by any AZ Party in this Agreement; and 
 (c)    any other Excluded Asset or Excluded
Liability. 

  
 25 

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 9.3    Indemnification by Spinco. From and after the
Closing Date and subject to the provisions of this Article IX, Spinco shall reimburse, defend, indemnify and hold each of the AZ Parties and their respective directors, officers, employees, Affiliates, agents, attorneys, Representatives,
successors and permitted assigns (the “AZ Indemnified Parties”) harmless from and against any and all Losses incurred, resulting or arising from or relating to: 

(a)    any breach of or failure to perform any covenant or agreement made by Spinco in this Agreement; and 

(b)    the ownership and operation of the Acquired Assets from and after the Closing, and the Assumed Liabilities, except
notwithstanding anything to the contrary herein, (i) to the extent due to the breach by any AZ Party of this Agreement and the other Transaction Agreements, including the representations and warranties set forth herein before or after the
Survival Period and, in any such case, only to the extent expressly set forth therein; (ii) to the extent such AZ Indemnified Party is entitled to indemnification for such Loss under another Transaction Agreement, in which case the
indemnification obligations of such other Transaction Agreement shall control and the AZ Indemnified Party shall not be entitled to indemnification under this Section 9.3 for any such Loss, and (iii) Losses subject to this
Section 9.3(b) shall not include any Loss incurred by an AZ Indemnified Party in their capacity as a counterparty to a contract with Spinco (except this Agreement) or as an owner of capital interests of Spinco. 

9.4    Indemnification Procedures. 

(a)    A claim for indemnification for any matter not involving a Third Party Claim may be asserted by prompt written
notice to the Indemnifying Party, including, to the extent known, the amount of the claim or an estimate thereof, to such Indemnifying Party; provided that the failure to so notify the Indemnifying Party shall not relieve the Indemnifying
Party of any indemnification obligation hereunder unless (and then solely to the extent that) the Indemnifying Party is materially prejudiced as a result of such failure. 

(b)    In the event that any Legal Proceedings shall be instituted, or that any claim or demand shall be asserted or
threatened in writing, by any Person not party to this Agreement in respect of which an Indemnification Claim may be made under this Agreement (a “Third Party Claim”), the Indemnified Party shall promptly cause written notice of the
assertion or written threat of any Third Party Claim of which it has knowledge that is or may be covered by this indemnity to be delivered to the Indemnifying Party; provided that the failure to so notify the Indemnifying Party shall not
relieve the Indemnifying Party of any indemnification obligation hereunder unless (and then solely to the extent that) the Indemnifying Party is materially prejudiced as a result of such failure. The Indemnifying Party shall have the right, at its
sole option and expense, to be represented by counsel of its choice, which must be reasonably satisfactory to the Indemnified Party, and (other than in the case of a claim by a Governmental Authority) to defend against, negotiate, settle or
otherwise address any Third Party Claim. If the Indemnifying Party elects to defend against, negotiate, settle or otherwise address any Third Party Claim, it shall within [***] (or sooner, to the extent that the nature of the Third Party Claim so
requires) (the “Dispute Period”) notify the Indemnified Party of its intent to do so. If the Indemnifying Party does not elect within the Dispute Period to defend against, negotiate, settle or otherwise address any Third Party Claim
or fails to notify the Indemnified Party of its election during the Dispute Period, the Indemnified Party shall have the right, but not the obligation, to defend against such Third Party Claim; provided that the Indemnifying Party may
nonetheless participate in the defense of such Third Party Claim (but not control or make decisions related thereto) with its own counsel and at its own expense. 

  
 26 

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 (c)    If the Indemnifying Party elects to defend against, negotiate,
settle or otherwise address any Third Party Claim, the Indemnifying Party shall (i) conduct the defense of such Third Party Claim with reasonable diligence and keep the Indemnified Party reasonably informed of material developments in the Third
Party Claim at all stages thereof; (ii) promptly submit to the Indemnified Party copies of all pleadings, responsive pleadings, motions and other similar legal documents and papers received or filed in connection therewith; (iii) permit
the Indemnified Party and its counsel to confer on the conduct of the defense thereof; and (iv) permit the Indemnified Party and its counsel an opportunity to review all legal papers to be submitted prior to their submission (to the extent
practical). If the Indemnifying Party has assumed the defense of a Third Party Claim, the Indemnified Party may participate, at its own expense, in the defense of such Third Party Claim; provided, however, that such Indemnified
Party shall be entitled to participate in any such defense with separate counsel at the reasonable expense of the Indemnifying Party if, (x) so requested in writing by the Indemnifying Party to participate or (y) in the reasonable opinion
of counsel to the Indemnified Party, a conflict exists or a potential conflict is likely to exist between the Indemnified Party and the Indemnifying Party that would make such separate representation advisable; and provided, further,
that the Indemnifying Party shall not be required to pay for more than one such counsel for (plus any appropriate local counsel) all indemnified parties in connection with any Third Party Claim. Except as expressly provided in the immediately
preceding sentence, if the Indemnifying Party has assumed the defense of a Third Party Claim, the Indemnifying Party shall not be liable to any Indemnified Party for any legal expenses incurred subsequent to such assumption by the Indemnifying Party
in connection with the defense thereof. 
 (d)    The Parties agree to provide reasonable access to each other Party to
such documents and information as may reasonably be requested in connection with the defense, negotiation or settlement of any such Third Party Claim. The Indemnified Party shall have the right to negotiate, compromise and settle any Third Party
Claim for which the Indemnifying Party may have any Liability under this Agreement but only with the prior written consent of the Indemnifying Party (which consent shall not be unreasonably withheld, conditioned or delayed). The Indemnifying Party
may not enter into any compromise or settlement of, or cease to defend against, a Third Party Claim unless the Indemnifying Party (i) has assumed the defense of such claim pursuant to this Section 9.4 and (ii) has
received the prior written consent of the Indemnified Party (which consent shall not be unreasonably withheld, conditioned or delayed). Notwithstanding the foregoing, the Indemnifying Party may enter into any compromise or settlement of any Third
Party Claim, or cease to defend against any Third Party Claim, if (x) pursuant to or as a result of such compromise or settlement, (A) injunctive or other equitable relief would not be imposed against the Indemnified Party, (B) each
claimant or plaintiff in such Third Party Claim has given to the Indemnified Party an unconditional release from all Liability with respect to such Third Party Claim, (C) a finding or admission of a violation of Law would not be made against
the Indemnified Party, or (D) the Indemnified Party would not have a monetary Liability that will not be paid or reimbursed by the Indemnifying Party; (y) such Third Party Claim would not reasonably be expected to have a material impact on
the ongoing business of the Indemnified Party; or (z) such Third Party Claim is not brought by a Governmental Authority. 

  
 27 

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 (e)    After any final
non-appealable decision, judgment or award shall have been rendered by a Governmental Authority of competent jurisdiction and the expiration of the time in which to appeal therefrom, or a settlement or
arbitration shall have been consummated, or the Indemnified Party and the Indemnifying Party shall have arrived at a mutually binding agreement with respect to an Indemnification Claim hereunder, the Indemnified Party shall forward to the
Indemnifying Party notice of any sums due and owing by the Indemnifying Party pursuant to this Agreement with respect to such matter and the Indemnifying Party shall make prompt payment thereof by wire transfer in immediately available funds within
[***] after the date of such notice or, if applicable, pursuant to the terms of the agreement reached with respect to the Indemnification Claim. 

9.5    Limitations on Indemnified Costs. 

(a)    Notwithstanding anything to the contrary in this Agreement, with the exception of a breach of any Fundamental
Representation, intentional fraud and willful misconduct, no Indemnifying Party shall have any Liability for any Loss under Section 9.2(a) or Section 9.3(a), as applicable, (i) unless such
Loss (or series of related Losses) equals or exceeds[***] (the “De Minimis Amount”), [***] pursuant to the immediately following clause (ii); and (ii) unless the aggregate amount of all Losses incurred by the Spinco Indemnified
Parties under Section 9.2(a) or the AZ Indemnified Parties under Section 9.3(a), as applicable, exceeds [***] (the “Basket”), [***]. 

(b)    Subject to Section 9.5(a), notwithstanding anything to the contrary in this Agreement, Medi LLC’s maximum
aggregate Liability to the Spinco Indemnified Parties for any Loss under Section 9.2(a) (other than in connection with any inaccuracy or breach of any Fundamental Representation) shall not exceed [***]. 

(c)    In no event shall any Indemnifying Party have Liability to any Indemnified Party for any consequential, special,
incidental, indirect, punitive or exemplary damages, except, in each case of the foregoing damages, to the extent any of the foregoing are payable to a Third Party pursuant to a Third Party Claim or arise as a result of fraud or willful misconduct
by the Indemnifying Party. No Indemnified Party shall be entitled to recover from an Indemnifying Party more than once in respect of Losses resulting from a single or series of related claims (whether under this Agreement or any other Transaction
Agreement). Any Liability for indemnification hereunder shall be determined without duplication of recovery by reason of state of facts giving rise to such Liability constituting a breach of more than one representation, warranty, covenant or
agreement. 
 (d)    The amount of any and all Losses under this Article IX shall be determined net of
(i) any Tax benefit actually realized by the applicable Indemnified Parties in the form of Tax refunds received or a reduction of Taxes otherwise owed in the taxable year of such Losses, and (ii) any insurance proceeds actually received by
the applicable Indemnified Parties in connection with the facts giving rise to the right of indemnification (net of any costs of recovery, deductibles or increased premiums as a result of paying such insurance claims), it being agreed that if third

  
 28 

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 
party insurance or indemnification proceeds in respect of such facts are recovered by the Indemnified Party subsequent to the Indemnifying Party’s making of an indemnification payment in
satisfaction of its applicable indemnification obligation, such proceeds shall be promptly remitted to the Indemnifying Party to the extent of the indemnification payment made. The Parties shall make reasonable efforts to mitigate any Losses subject
to an Indemnification Claim. Upon making any payment to an Indemnified Party for any Indemnification Claim pursuant to this Article IX, the Indemnifying Party shall be subrogated, to the extent of such payment, to any and all rights that the
Indemnified Party may have against any Third Parties with respect to the subject matter underlying such Indemnification Claim, and the Indemnified Party shall assign any and all such rights to the Indemnifying Party. 

(e)    Notwithstanding anything to the contrary set forth herein, any amounts paid, or out-of-pocket costs incurred by, Medi LLC pursuant to this Article IX shall be allocated among the AZ Parties in the same proportion as the Purchase Price is being allocated among the AZ Parties
pursuant to Section 1.1 and Medi Ltd and AZCV shall promptly reimburse Medi LLC accordingly. 

9.6    Exclusive Remedy. Following the Closing Date, the sole and exclusive remedy of any Indemnified Parties for
any Losses (including any Losses from claims for breach of contract, warranty, tortious conduct (including negligence) or otherwise and whether predicated on common Law, statute, strict liability or otherwise) that each Party may at any time suffer
or incur, or become subject to, as a result of, or in connection with this Agreement (which, for the avoidance of doubt, does not include the other Transaction Agreements), including any inaccuracy or breach of any representation and warranty
contained in this Agreement by any Party, or any failure by any Party to perform or comply with any covenant or agreement that, by its terms, was to have been performed, or complied with, under this Agreement, shall be indemnification in accordance
with this Article IX, except with respect to any claim based on intentional fraud or willful misconduct or claims for specific performance pursuant to Section 11.8, injunction or other equitable
relief. 
 ARTICLE X 

TAX MATTERS 

10.1    Tax Matters; Cooperation. Each Party shall cooperate fully, as and to the extent reasonably
requested by the other Party, in connection with the filing of Tax Returns and any audit or other Legal Proceeding with respect to Taxes attributable to the Acquired Assets. Such cooperation shall include the retention and (upon any other
Party’s request) the provision of records and information that are reasonably relevant to any such audit or other Legal Proceeding and making employees available on a mutually convenient basis to provide additional information and explanation
of any material provided hereunder. In addition to the provisions in Section 7.3 relating to preservation of records, each Party agrees, upon reasonable request, to use their commercially reasonable efforts to obtain any
certificate or other document from any Governmental Authority or any other Person as may be necessary to mitigate, reduce or eliminate any Tax that could be imposed (including with respect to the Transactions). 

  
 29 

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 10.2    Transfer Taxes. The AZ Parties shall be responsible for
any Transfer Taxes in connection with the sale and purchase of the Acquired Assets, regardless of the Person liable for such Transfer Taxes under applicable Law, and the Parties shall work together to timely file or caused to be filed all
necessary documents (including all Tax Returns) with respect to such Transfer Taxes. 
 10.3    Purchase Price
Allocation. 
 (a)    The Purchase Price (plus the Assumed Liabilities and any liabilities for payments that become
due and payable under any Retained Contracts to the extent properly taken into account pursuant to applicable Tax Law) shall be allocated among the Acquired Assets as set forth on Schedule 10.3 (the “Purchase Price
Allocation”). 
 (b)    The Parties agree to act in accordance with the Purchase Price Allocation, as adjusted,
if applicable, in any tax return, including any forms or reports required to be filed pursuant to applicable Tax Law. The Parties shall cooperate in the preparation of any tax returns and file such forms as required by applicable Law. 

10.4    Withholding Taxes. Spinco shall make any payment pursuant to this Agreement, the MRC Payment
Agreements or any Sublicense Agreement (and, if applicable, any sublicense entered into pursuant to Section 7.11(c)) with respect to any payment obligation under any of the Cellective Merger Agreement, the Tedder Consulting Agreement, and the In-License Agreements (collectively, the “Retained Contracts”) free and clear of any withholding or deduction on account of Taxes, unless otherwise required by applicable Law. To the extent that any
such Tax is deducted or withheld, such amount shall be treated for all purposes of this Agreement as having been paid to the Person in respect of which such deduction or withholding was made; provided, that, to the extent required by applicable Law,
Spinco shall pay an additional amount, if any, as is required under each of the Duke License Agreement and the DFCI License Agreement as each such agreement exists as of the date hereof to be made to ensure that the applicable payee receives the
amount to which it is entitled thereunder in case that withholding Tax applies. Notwithstanding the foregoing, Medi LLC shall cooperate with Spinco and shall use commercially reasonable efforts to cause the applicable payee to cooperate with Spinco
to reduce or eliminate any withholding to the extent that such payee is entitled under an applicable Tax treaty to a reduction or exemption from applicable withholding Tax. Such cooperation shall include causing such payee to deliver any applicable
Tax forms to Spinco or the relevant Governmental Authority (including Internal Revenue Service withholding certificates on forms W-8 or W-9, as applicable), as
applicable, required for a reduction or elimination of withholding Tax. Spinco shall pay over any amounts withheld by Spinco pursuant to this Section 10.4 to the applicable Governmental Authority and furnish proof of such
remittance, to the extent and at the time required under the Retained Contracts as they exist as of the date hereof, to the applicable payee. Spinco shall comply, and Medi LLC shall use reasonable efforts to cause the applicable payee to comply,
with any applicable requirements and obligations under the Retained Contracts. 

  
 30 

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 ARTICLE XI 

MISCELLANEOUS 

11.1    Expenses. Except as specifically provided to the contrary in this Agreement or in the Securities Purchase
Agreement, all costs and expenses incurred in connection with the negotiation and execution of this Agreement, the Securities Purchase Agreement and the other transaction documents referenced herein and therein, and consummation of the Transactions
(including in connection with the formation of Spinco) shall be paid by the Party incurring such costs and expenses, whether or not the Transactions are consummated; provided that, at the Closing, Spinco shall pay or reimburse Medi LLC for, such out
of pocket costs and expenses actually incurred by Medi LLC and its Affiliates, up to a maximum of [***] in the aggregate. 

11.2    Governing Law. This Agreement and all disputes controversies or claims relating to, arising out of or under
or in connection with this Agreement, the other Transaction Agreements and the Transactions, including the negotiation, execution and performance hereunder, shall be governed by, and construed in accordance with, the Laws of the State of New York,
regardless of the Laws that might otherwise govern under applicable principles of choice of Law or conflicts of Law rules or provisions thereof to the extent they would result in the application of the Laws of another jurisdiction. 

11.3    Dispute Resolutions. The Parties agree to unconditionally and irrevocably submit to the exclusive
jurisdiction of the United States District Court for the Southern District of New York sitting in New York County or, if such court does not have subject matter jurisdiction, then the Commercial Division, Civil Branch of the Supreme Court of the
State of New York sitting in New York County and any appellate court from any thereof, for the resolution of any such claim or dispute. The Parties hereby irrevocably waive, to the fullest extent permitted by applicable Law, any objection which they
may now or hereafter have to the laying of venue of any such dispute brought in such court or any defense of inconvenient forum for the maintenance of such dispute. Each of the Parties agrees that a judgment in any such dispute may be enforced in
other jurisdictions by suit on the judgment or in any other manner provided by Law. Each of the Parties hereby consents to process being served by any Party in any suit, action or proceeding by delivery of a copy thereof in accordance with the
provisions of Section 11.6. 
 11.4    Entire Agreement. This Agreement and the
other Transaction Agreements (including all Exhibits and Schedules hereto and thereto) and other documents and instruments delivered pursuant hereto or thereto constitute the entire agreement and supersede all prior representations, agreements,
understandings and undertakings, both written and oral, among the Parties, or any of them, with respect to the subject matter hereof and thereof, and no Party is relying on any prior oral or written representations, agreements, understandings or
undertakings with respect to the subject matter hereof and thereof. 
 11.5    Amendments and Waivers. This
Agreement can be amended, supplemented or changed, and any provision hereof can be waived, only by written instrument making specific reference to this Agreement signed by the Party against whom enforcement of any such amendment, supplement,
modification or waiver is sought. No action taken pursuant to this 

  
 31 

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 
Agreement, including, any investigation by or on behalf of any Party, shall be deemed to constitute a waiver by the Party taking such action of compliance with any representation, warranty,
covenant or agreement contained herein. The waiver by any Party of a breach of any provision of this Agreement shall not operate or be construed as a further or continuing waiver of such breach or as a waiver of any other or subsequent breach. No
failure on the part of any Party to exercise, and no delay in exercising, any right, power or remedy hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of such right, power or remedy by such Party preclude any
other or further exercise thereof or the exercise of any other right, power or remedy. 
 11.6    Notices. All
notices or other communications which are required or permitted hereunder shall be in writing and sufficient if delivered personally or sent by nationally recognized overnight courier or by registered or certified mail, postage prepaid, return
receipt requested, or by facsimile or email, as follows: 
 If to the AZ Parties, to: 

MedImmune, LLC 
 950 Wind River
Lane 
 Gaithersburg, MD 20878 

Attention: General Counsel 

MedImmune Limited 
 1 Francis
Crick Avenue 
 Cambridge Biomedical Campus 

Cambridge 
 CB2 0AA 

Attention: Deputy General Counsel, Corporate 

AstraZeneca Collaboration Ventures, LLC 

c/o AstraZeneca Pharmaceuticals LP 

1800 Concord Pike 
 Wilmington, DE
19850-5437 
 Attention: General Counsel 

With a copy (which shall not constitute notice) to: 

[***] 
 [***] 

[***] 
 [***] 

[***] 

  
 32 

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 If to Spinco, to: 

Viela Bio, Inc. 
 1 Medimmune Way

 Gaithersburg, MD 20878 

Attention: Bing Yao 
 With a copy
(which shall not constitute notice) to: 
 Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. 

701 Pennsylvania Ave., NW, Suite 900 

Washington, DC 20004 
 Attention:
Christopher Jeffers 
 or to such other address as the Party to whom notice is to be given may have furnished to the other Party in writing in accordance
herewith. All such notices and other communications required or permitted by this Agreement shall be deemed to have been duly given (a) if sent to a recipient at the proper address as determined pursuant to this
Section 11.6, by registered or certified mail, return receipt requested, five calendar days after being deposited in the United States mail, postage prepaid; (b) if sent by Express Mail, Federal Express or similar
reputable overnight delivery service that maintains records of receipt for next Business Day delivery, the next Business Day after being entrusted to such service, with delivery charges prepaid or charged to the sender’s account; (c) if
sent by facsimile transmission or email, on the date of transmission with electronic confirmation of transmission; and (d) if delivered by hand, on the date of delivery. 

11.7    Severability. If any term or other provision of this Agreement is invalid, illegal or incapable of being
enforced by any applicable Law or public policy, all other terms or provisions of this Agreement shall nevertheless remain in full force and effect so long as the economic or legal substance of the Transactions is not affected in any manner
materially adverse to any Party. Upon such determination that any term or other provision is invalid, illegal or incapable of being enforced, the Parties shall negotiate in good faith to modify this Agreement so as to effect the original intent of
the Parties as closely as possible in an acceptable manner in order that the Transactions are consummated as originally contemplated to the greatest extent possible. Except as otherwise expressly provided for in this Agreement, nothing contained in
any representation or warranty, or the fact that any representation or warranty may or may not be more specific than any other representation or warranty, shall in any way limit or restrict the scope, applicability or meaning of any other
representation or warranty contained in this Agreement. 
 11.8    Specific Performance. Each of the AZ Parties
on the one hand and Spinco on the other hand acknowledges and agrees that any breach of this Agreement may give rise to irreparable harm for which monetary damages would not be an adequate remedy. Each Party accordingly agrees that, in addition to
any other remedies available under applicable Law or this Agreement, each of Spinco and the AZ Parties shall be entitled to seek enforcement of the terms of this Agreement by decree of specific performance without the necessity of proving the
inadequacy of monetary damages as a remedy and to obtain injunctive relief against any breach or threatened breach of this Agreement. Any Party seeking an injunction or injunctions to prevent breaches of this Agreement and to enforce specifically
the terms and provisions of this Agreement shall not be required to provide any bond or other security in connection with such order or injunction. All rights and remedies existing under this Agreement are cumulative to, and not exclusive of, any
rights or remedies otherwise available. 

  
 33 

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 11.9    No Third-Party Beneficiaries; No Successor Liability.
Nothing in this Agreement shall create or be deemed to create any third party beneficiary rights in any Person that is not a Party (or its permitted successors and assigns) except with respect to indemnification as contemplated by
Section 9.2 and Section 9.3. It is expressly understood that the Parties intend that Spinco shall not be considered a successor to any of the AZ Parties or any of their Affiliates by reason of any
theory of Law or equity. 
 11.10    Assignment. 

(a)    No Party may assign or transfer this Agreement or any rights or obligations hereunder, directly or indirectly (by
operation of Law or otherwise), without the prior written approval of the other Parties and any attempted assignment without such required approval shall be null, void and of no effect; provided, however, that (A) the AZ Parties may assign
their respective rights, interests, and obligations hereunder to an Affiliate of the AZ Parties or to any successor in interest (whether by merger, acquisition, asset purchase or otherwise) to all or substantially all of the business to which this
Agreement relates, in each case without Spinco’s prior written approval, and (B) Spinco may assign its rights, interests, and obligations hereunder (in whole and not in part) to a wholly owned Affiliate of Spinco without the AZ
Parties’ prior written approval. In addition, following the earlier to occur of (X) the consummation in full of the Milestone Closing (as defined in the Securities Purchase Agreement), and (Y) the consummation of a Qualified IPO (as
defined in the Restated Certificate (as defined in the Securities Purchase Agreement)), Spinco may assign its applicable rights, interests, and obligations hereunder related to one or more Programs to a Third Party without the AZ Parties’ prior
written approval, so long as (i) such assignment shall be in connection with the divestment by Spinco of all or substantially all of the assets relating to such Program or Programs (whether by asset purchase or exclusive out-license), (ii) in connection therewith, Spinco also assigns to such Third Party its applicable rights, interests, and obligations under the other Transaction Agreements related to such Program or Programs, and
(iii) proper provision shall be made so that the successors and assigns of Spinco shall succeed to Spinco’s applicable rights and obligations set forth herein and therein. Furthermore, if Spinco or any of its successors or assigns
(I) consolidates with or merges into any other Person and shall not be the continuing or surviving corporation or entity of such consolidation or merger or (II) transfers, licenses or conveys all or substantially all of its rights and
assets to any Person, then, and in each such case, Spinco may assign its rights, interests and obligations hereunder (in whole and not in part) to such Person without the prior written approval of the AZ Parties so long as in connection therewith
Spinco (i) also assigns to such Person all of its applicable rights, interests, and obligations under the other Transaction Agreements, and (ii) ensures that proper provision shall be made so that the successors and assigns of Spinco shall
succeed to Spinco’s rights and obligations set forth in this Agreement. Notwithstanding anything to the contrary set forth herein, no assignment or succession pursuant to this Section 11.10 shall relieve the assigning
Party or predecessor Party of its obligations hereunder. Upon any permitted assignment, the references in this Agreement to a Party shall also apply to any such assignee unless the context otherwise requires. 

  
 34 

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 (b)    Notwithstanding the foregoing, in the event a Party assigns its
rights or obligations under this Agreement or otherwise makes payments from a jurisdiction other than the jurisdiction in which such Party is organized (each, an “Assignment”), and immediately after such Assignment the amount of Tax
required to be withheld on any payment pursuant to this Agreement is greater than the amount of such Tax that would have been required to have been withheld absent such Assignment, then such increased withholding tax shall be borne by the Party
making such Assignment. 
 11.11    Neutral Construction. The Parties have participated jointly in the
negotiation and drafting of this Agreement and, in the event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as jointly drafted by the Parties and no presumption or burden of proof shall arise favoring
or disfavoring any Party by virtue of the authorship of any provision of this Agreement. 

11.12    Counterparts. This Agreement may be executed and delivered in one or more counterparts, and by the
different Parties in separate counterparts, each of which when executed and delivered shall be deemed to be an original but all of which taken together shall constitute one and the same agreement. Any facsimile or electronically transmitted copies
hereof or signatures hereon shall, for all purposes, be deemed originals. 
 [Signature Page Follows] 

  
 35 

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their
respective officers thereunto duly authorized, as of the date first written above. 
  

			
	AZ PARTIES:
	
	MEDIMMUNE, LLC
		
	By:	 	 [***]

	Name:	 	[***]
	Title:	 	[***]
	
	MEDIMMUNE LIMITED
		
	By:	 	 [***]

	Name:	 	[***]
	Title:	 	[***]
	
	ASTRAZENECA COLLABORATION VENTURES, LLC
		
	By:	 	 [***]

	Name:	 	[***]
	Title:	 	[***]
	
	SPINCO:
	
	VIELA BIO, INC.
		
	By:	 	 /s/ Zhengbin (Bing) Yao

	Name:	 	Zhengbin (Bing) Yao
	Title:	 	CEO

  
 [Signature Page to
Asset Purchase Agreement] 

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 Exhibit A 

Certain Definitions; Interpretive Matters 

(a)    For purposes of this Agreement, the following terms shall have the meanings specified in this Exhibit A:

 “Affiliate” means, with respect to a Person, any other Person that controls, is controlled by, or is under common
control with such Person. For purposes of this Agreement, a Person will be deemed to control another Person if it owns or controls, directly or indirectly, more than 50% of the equity securities of such other Person entitled to vote in the election
of directors (or, in the case that such other Person is not a corporation, for the election of the corresponding managing authority), or otherwise has the power to direct the management and policies of such other Person. The Parties acknowledge that
in the case of certain entities organized under the laws of certain countries outside the United States, the maximum percentage ownership permitted by law for a foreign investor may be less than 50%, and that in such case such lower percentage will
be substituted in the preceding sentence, provided that such foreign investor has the power to direct the management and policies of such entity. Notwithstanding the foregoing or anything else to the contrary herein or in the other
Transaction Agreements, for purposes of this Agreement and the other Transaction Agreements, Spinco shall not be considered an Affiliate of the AZ Parties, notwithstanding the fact that Spinco may be considered an affiliate of the AZ Parties. 

“Assigned Contracts” means the Contracts set forth on Schedule 2.1(b)(i). 

“Assigned Intellectual Property” means, collectively, (a) the Patents set forth on Schedule 2.1(b)(i) (the
“Assigned Patents”), (b) the Know-How owned by the AZ Parties and their Affiliates to the extent such Know-How exclusively relates to the Products or
the Programs, and (c) any copyright of the AZ Parties and their Affiliates in any document to the extent recording the Know-How described in (b). 

“AZ Employees” means, collectively, (i) the individuals set forth on Schedule 7.5(a) and (ii) employees who
are hired by the AZ Group as employees in connection with, or otherwise assigned to work on, the Programs after the date hereof through the Closing Date whom the AZ Group designates as AZ Employees, each such designation subject to the prior written
consent of Spinco. 
 “AZ Group” means Medi LLC and its Affiliates. 

“AZ’s Knowledge” means [***]. 

“[***] Collaboration Product” means any composition comprising or containing [***] and/or [***] (or any analog, fragment or
derivative of any of the foregoing compounds or molecules that has the same activity as, respectively, [***] or [***]), and any and all formulations, forms and dosage strengths thereof. An analog, fragment or derivative will be deemed to have the
same activity as the corresponding compound or molecule if it specifically binds to the same target(s) as such compound or molecule as its primary intended target. 

  
 A-1 

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 “Biological Materials” means any biological substances and materials,
including any tissues, cells, cell lines, organisms, blood samples, genetic material, antibodies, or plasmids, in each case relating exclusively to the Products or held for exclusive use in the Programs. For the sake of clarity, human tissue samples
taken from a human patient in the context of a Clinical Study with respect to a Product or a Program do not relate exclusively to such Product or such Program. 

“BioWa License Agreement” means the License Agreement, dated November 16, 2005, between BioWa, Inc. and MedImmune, Inc.

 “BioWa/Lonza License Agreement” means the Non-Exclusive License Agreement, dated
November 4, 2013, between Lonza Sales AG, BioWa, Inc., and MedImmune, LLC. 
 “BLA/NDA” means a Biologics License
Application (as that term is defined in section 351(a) of the Public Health Service Act) or a New Drug Application (as that term is defined in section 505(b) of the FD&C Act), filed with the FDA in the United States with respect to any Product,
or any corresponding foreign application or similar application or submission filed with a Regulatory Authority to obtain marketing approval for a biological or pharmaceutical product in a country or group of countries. 

“Business Day” means any day of the year on which national banking institutions in New York, U.S. are open to the public for
conducting business and are not required or authorized by applicable Law to close. 
 “Cellective CD19 Product” means a
Product containing, as an active ingredient, an antibody or protein that specifically binds to CD19 and is a Product as defined in the Cellective Merger Agreement. 

“Clinical Study” means any investigation in human subjects intended to determine the clinical pharmacological,
pharmacokinetic, and/or other pharmacodynamic effects of an investigational agent, and/or to identify any adverse reactions to an investigational agent to assess the agent’s safety and efficacy. 

“COBRA” means the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended. 

“Code” means the Internal Revenue Code of 1986, as amended. 

“Competing Product” means any [***] Competing Product, [***] Competing Product, [***] Competing Product, [***] Competing
Product, [***] Competing Product, [***] Competing Product, [***] Competing Product, or Mabkine Competing Product. 

  
 A-2 

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 “Contract” means any written or oral agreement, contract, indenture, note,
mortgage, loan, instrument, license, guarantee, bond, lease, commitment, understanding or undertaking. 
 “Covered Autoimmune
Disease” means any disease listed on Schedule 7.9. 
 “Development” means all activities relating to
preparing and conducting preclinical testing, toxicology testing, human clinical studies, regulatory activities (e.g., regulatory applications), formulation, manufacturing process development, scale-up
and associated validation, quality assurance and quality control activities and the terms “Develop”, “Developing” and “Developed” shall be construed accordingly. 

“Development Costs” means, all costs and expenses actually incurred by a Person (or its Affiliates) or for its account and
specifically attributable to its conduct of specific Development activities, which shall include: (a) amounts paid by such Person (or its Affiliates) to Third Parties contracted to conduct clinical trials such as costs for Third Party suppliers
of clinical services, clinical site recruiting, training and participation, monitoring of clinical sites, data analysis and data quality assurance, and/or Third Party costs for preparing, reviewing or developing data and documents for submission to
Regulatory Authorities; (b) amounts paid for the supply of the Products and comparator drugs for use in clinical trials; (c) amounts paid in connection with obtaining, maintaining and renewing all Regulatory Materials and other
Governmental Approvals which are part of the Acquired Assets; and (d) actual direct costs and expenses of such Person’s (or its Affiliates’) internal employees’ actual work in conducting or managing such Development activities
(including allocations of direct overheads, but not including allocations of general, corporate or administrative overheads). 

“Documents” means all files, documents, instruments, papers, books, reports, records, budgets, forecasts, ledgers, journals,
supplier lists, operating data and plans, technical documentation, and other similar materials; provided, that “Documents” does not include Regulatory Materials or Permits. 

“EMA” means the European Medicines Agency or any successor agency thereto. 

“Employee Benefit Plans” mean all “employee benefit plans,” as defined in section 3(3) of ERISA, and other employee
benefit plans or arrangements or payroll practices, including retirement plans, welfare plans, bonus plans, incentive, equity or equity-based compensation, or deferred compensation arrangements, stock purchase, severance pay, sick leave, vacation
pay, salary continuation, disability, hospitalization, medical insurance, life insurance or scholarship programs which the AZ Group sponsors, maintains, has any obligation to contribute to, has Liability under or is otherwise a party. 

“Excluded Manufacturing Know-How” means all
Know-How that is not generally known and that is related to or applicable to the manufacture of Products except to the extent that such Know-How relates exclusively to
the Products. 

  
 A-3 

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 “Expenses” means any and all expenses, costs, claims, demands, assessments,
judgments, penalties and fees (including reasonable attorneys’ and other professionals’ fees and disbursements). 

“FD&C Act” means the United States Federal Food, Drug, and Cosmetic Act, as amended, and the rules and regulations
promulgated thereunder. 
 “FDA” means the United States Food and Drug Administration or any successor agency thereto.

 “Fundamental Representations” means the representations and warranties of AZ contained in
Section 4.1 and Section 4.2. 
 “Governmental Authority” means any
nation or government or governmental or regulatory body thereof, or political subdivision thereof, whether federal, state, local or foreign, or any agency, instrumentality or authority thereof, or any court or arbitrator (public or private) or any
other entity exercising executive, judicial, legislative, regulatory or administrative functions of or pertaining to regulation or to government. 

“In-License Agreement” means (a) the BioWa License Agreement, (b) the Lonza
License Agreement, (c) the Agreement, dated January 7, 1997, between Medical Research Council, Cambridge Antibody Technology Limited, and Cambridge Antibody Technology Group PLC, (d) the BioWa/Lonza License Agreement, (e) the
Duke License Agreement, and (f) the DFCI License Agreement. 
 “IND” means an Investigational New Drug Application
submitted under Section 505(i) of the FD&C Act, or an analogous application or submission with any analogous agency or Regulatory Authority outside of the United States for the purposes of obtaining permission to conduct clinical trials.

 “Indemnification Claim” means any claim in respect of which payment may be sought under Article IX of this
Agreement. 
 “Inventory” means all inventory of the Products owned by the AZ Parties or its Affiliates as of the Closing
Date, wherever located, including all finished goods, work in process, raw materials, cell banks and other reagents, starting materials, and intermediates from the synthesis of Products. 

“Know-How” means any data, results, technology, business or financial information or
information of any type whatsoever, in any tangible or intangible form, including know-how, practices, techniques, methods, assays, techniques, processes, protocols, inventions, discoveries, improvements,
developments, specifications, formulations, formulae, algorithms, marketing reports, business plans, expertise, technology, test data (including pharmacological, biological, chemical, biochemical, medical, toxicological, preclinical, and clinical
test data and any other research or development data), standard operating procedures, manufacturing records, stability data and other study data and procedures. 

  
 A-4 

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 “Law” means any foreign, federal, state and local law (including common
law), statute, code, ordinance, rule, regulation (including zoning and building code), Order or other requirement. 
 “Legal
Proceeding” means any judicial, administrative or arbitral actions, suits, mediations, investigation, inquiry, proceedings (public or private) or claims (including counterclaims) by or before a Governmental Authority or arbiter. 

“Liability” means any debt, liability or obligation (whether direct or indirect, absolute or contingent, accrued or
unaccrued, known or unknown, liquidated or unliquidated, or due or to become due) and including all costs and expenses relating thereto. 

“Licensed Intellectual Property” means the Patents, Know-How and Biological Materials
licensed to Spinco under the License Agreement or the Sublicense Agreements. 
 “Lien” means any lien, encumbrance, pledge,
mortgage, deed of trust, security interest, charge, condition, restriction, covenant, purchase option, lease, sublease or other third party right, right of first refusal, easement, right of way, servitude, transfer restriction, encroachment,
reservation or title defect of any kind or nature. 
 “Lonza License Agreement” means the Letter Agreement, dated
April 16, 2009, between Lonza Sales AG and MedImmune, LLC, incorporating the terms of the License and Services Agreement, dated January 21, 2005, as amended by an amendment agreement, effective as of March 20, 2009, between
AstraZeneca AB and (by novation) Lonza Sales AG. 
 “Losses” means all damages, losses, claims, Liabilities, demands,
charges, suits, penalties, costs and Expenses. 
 “MAA” or “Marketing Authorization Application” means an
application to the appropriate Regulatory Authority for approval to market a Product (but excluding price approval) in any particular jurisdiction (including a BLA in the U.S.) and all amendments and supplements thereto. 

“Mabkine Competing Product” means any medicinal product for the treatment, prevention or diagnosis of any Covered Autoimmune
Disease, including inflammatory bowel disease, that comprises or contains a biologic agent (e.g., a peptide) that specifically binds both to TNF and IL10 Receptor simultaneously as its intended primary targets, thereby inhibiting TNF-mediated receptor activation and activating IL-10 receptor signaling; provided that, for clarity, neither the molecule identified as [***] nor any product comprising or
containing such molecule shall be a Competing Product for the purpose of Section 7.9.  
 “Material
Adverse Effect” means any fact, event, change, development, condition, circumstance or effect that, individually or in the aggregate, (A) has, or would reasonably be expected to have, a material adverse effect on the Programs and
the Acquired Assets taken as a whole, or (B) prevents or materially impairs or delays, would be reasonably expected to prevent or materially impair or delay, the ability of the AZ Parties to perform their obligations hereunder,

  
 A-5 

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 
including the consummation of the Transactions; provided that, in the case of clause (A) above, “Material Adverse Effect” shall not include any such fact, event,
change, development, condition, circumstance or effect to the extent it results from (i) global or national political conditions, including the outbreak or escalation of war or terrorist activities, (ii) global or national economic,
monetary, or financial conditions, including changes in prevailing interest rates, credit markets, or financial market conditions in or affecting the United States, (iii) changes in applicable Law (or the interpretations thereof) or GAAP (or
the interpretations of), (iv) the taking of any action specifically required to be taken by this Agreement or taken by any Party or any of its Affiliates or any of their respective Affiliates with the prior written consent or at the written
request of the other Party, (v) earthquakes, hurricanes, tsunamis, typhoons, lightning, hailstorms, blizzards, tornadoes, droughts, floods, cyclones, arctic frosts, mudslides, wildfires and other natural disasters and weather conditions,
(vi) impacts on relationships with suppliers, employees, labor organizations, or Governmental Authorities, in each case attributable to the execution, announcement or pendency of this Agreement, the Securities Purchase Agreement or the
transactions contemplated hereunder or thereunder, or (vii) changes in the life sciences and health care industries, including the occurrence of any adverse regulatory, clinical, research, development, manufacturing or commercial activity with
respect to a specific product or class of products similar to any of the Products; except to the extent, in the case of clauses (i), (ii), (iii), and (v), such fact, event, change, development, condition, circumstance or
effect disproportionately affects the Programs or the Acquired Assets, relative to other participants in the industry or industries in which the Programs operate. 

“MEDI-551 Competing Product” means any medicinal product for the treatment,
prevention or diagnosis of any Covered Autoimmune Disease, including neuromyelitis optica, multiple sclerosis or scleroderma, that comprises or contains an antibody or antibody fragment that specifically binds to CD19 as its intended primary target
and induces cell death of CD19+ cells. 
 “MEDI0700 Competing Product” means any medicinal product for the treatment,
prevention or diagnosis of any Covered Autoimmune Disease, including systemic lupus erythematosus, that comprises or contains an antibody or antibody fragment that specifically binds to B7RP-1/BAFF as its
intended primary target and simultaneously inhibits both (a) B7RP1-mediated co-stimulation of cells and (b) BAFF-mediated receptor activation. 

“MEDI1116 Competing Product” means any medicinal product for the treatment, prevention or diagnosis of any Covered Autoimmune
Disease, including systemic lupus erythematosus, that comprises or contains an antibody or antibody fragment that specifically binds to [***] as its intended primary target and inhibits[***]-mediated activation of its receptor [***]. 

“MEDI4920 Competing Product” means any medicinal product for the treatment, prevention or diagnosis of any Covered Autoimmune
Disease, including primary Sjögren’s syndrome, systemic lupus erythematosus, Crohn’s, systemic sclerosis, lupus nephritis, Graft vs Host disease, primary biliary cholangitis or myasthenia gravis, that comprises or contains a peptide
that specifically binds to CD40L as its intended primary target and inhibits CD40L-

  
 A-6 

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 
mediated activation of its receptor CD40; provided that, for clarity, neither the molecule identified as [***] nor any product comprising or containing such molecule shall be a Competing Product
for the purpose of Section 7.9. 
 “MEDI5872 Competing Product” means any medicinal product for
the treatment, prevention or diagnosis of any Covered Autoimmune Disease, including primary Sjögren’s syndrome, that comprises or contains an antibody or antibody fragment that specifically binds to [***] as its intended primary target and
inhibits [***]. 
 “MEDI7734 Competing Product” means any medicinal product for the treatment, prevention or diagnosis of
any Covered Autoimmune Disease, including myositis (DM and PM), systemic lupus erythematosus, lupus nephritis, systemic sclerosis or primary Sjögren’s syndrome, that comprises or contains an antibody or antibody fragment that specifically
binds to [***] as its intended primary target and induces cell death of [***] cells. 
 “MEDI9600 Competing Product” means
any medicinal product for the treatment, prevention or diagnosis of any Covered Autoimmune Disease, including ANCA vasculitis, systemic lupus erythematosus or lupus nephritis, that comprises or contains an antibody or antibody fragment that
specifically binds to[***] as its intended primary target and inhibits IgG-mediated activation of [***]. 

“Order” means any order, injunction, judgment, decree, determination, ruling, writ, assessment or arbitration or other award
of a Governmental Authority. 
 “Ordinary Course of Business” means, with respect to any Person or business, the ordinary
course of business of such Person and its Affiliates or such business, in each case, consistent with past practices. 

“Patents” means all patents (which shall include invention patents, utility models, design patents, industrial designs, and
priority rights), applications for patents, invention disclosures, provisional applications, substitutions, supplementary protection certificates, reissues, reexaminations, renewals, revisions, extensions, divisionals, continuations, inventors’
certificates, utility certificates, patents or certificates of addition, inventors’ certificates of addition, and utility certificates of addition and other indices of invention ownership, 

“Permits” means any approvals, authorizations, consents, licenses, permits or certificates (including certificates of
occupancy) of a Governmental Authority. 
 “Permitted Liens” means (i) Liens for Taxes, assessments or other
governmental charges or levies not yet due or payable or that are being contested in good faith by appropriate Legal Proceedings and for which adequate reserves have been set aside in the relevant financial statements in accordance with generally
applicable accounting principles; (ii) statutory Liens of landlords and mechanics’, carriers’, warehousemen’s, workers’, repairers’ and similar Liens imposed by applicable Law or arising or incurred in the Ordinary
Course of Business with respect to amounts not yet due and payable or being contested in good faith by appropriate Legal 

  
 A-7 

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 
Proceedings; (iii) Liens incurred or deposits made in the Ordinary Course of Business in connection with workers’ compensation, unemployment insurance or other types of social security;
and (iv) licenses and other similar rights granted and obligations incurred in the Ordinary Course of Business or pursuant to any of the Transaction Agreements. 

“Person” means any individual, corporation, limited liability company, partnership, firm, joint venture, association,
joint-stock company, trust, unincorporated organization, Governmental Authority or other entity. 
 “Product” means any
composition comprising or containing [***] [***] [***], [***], [***] [***] (or any analog, fragment or derivative of any of the foregoing compounds or molecules that has the same activity as, respectively, [***], [***], [***], [***], [***], and any
and all formulations, forms and dosage strengths thereof. An analog, fragment or derivative will be deemed to have the same activity as the corresponding compound or molecule if it specifically binds to the same target(s) as such compound or
molecule as its primary intended target. 
 “Regulatory Approvals” means all technical, medical and scientific licenses,
registrations, authorizations and approvals (including approvals of MAAs, BLA/NDAs, supplements and amendments, pre- and post- approvals, pricing and third party reimbursement approvals, and labeling
approvals) of any Regulatory Authority, necessary for the use, development, manufacture, and commercialization of a pharmaceutical product in a regulatory jurisdiction. 

“Regulatory Authority” means, with respect to a country, any national (e.g., the FDA), supra-national (e.g., the European
Commission, the Council of the European Union, or the EMA), regional, state or local regulatory agency, department, bureau, commission, council or other Governmental Authority involved in the granting of a Regulatory Approval or, to the extent
required in such country, price approval, for biological or pharmaceutical products in such country. 
 “Regulatory
Materials” means all regulatory applications, submissions, dossiers, notifications, registrations, Regulatory Approvals, material correspondence or other filings made to or with, or other approvals granted by, a Regulatory Authority that
are necessary or reasonably desirable in order to develop, manufacture or commercialize a product in a particular country or regulatory jurisdiction. Regulatory Materials include all INDs and MAAs. 

“Representatives” means a Person’s or business’ directors, officers, employees, attorneys, consultants, advisors,
financing sources, accountants, representatives, agents or Affiliates. 
 “Spinco Material Adverse Effect” means, with
respect to Spinco, any fact, event, change, development, condition, circumstance or effect that, individually or in the aggregate, prevents or materially impairs or delays, or would be reasonably expected to prevent or materially impair or
delay, the ability of Spinco to perform its obligations hereunder, including the consummation of the Transactions. 

  
 A-8 

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 “Tax Return” means any return (including any information return), report,
statement, schedule, notice, form or other document or information filed with or submitted to, or required to be filed with or submitted to, any Taxing Authority in connection with the determination, assessment, collection or payment of any Tax or
in connection with the administration, implementation or enforcement of or compliance with any Law relating to any Tax. 

“Taxes” means (i) any and all federal, state, local or foreign taxes, charges, fees, imposts, levies or other
assessments, including all net income, gross receipts, capital, sales, use, ad valorem, value added, transfer, franchise, profits, inventory, capital stock, license, withholding, payroll, employment, social security, unemployment, excise, severance,
stamp, occupation, property and estimated taxes, customs duties, fees, assessments and charges of any kind whatsoever, together with any such Liabilities for any other Person, whether arising by reason of consolidated, combined, or similar Tax
Returns, as a transferee, by contract, by operation of Law, or otherwise; and (ii) all interest, penalties, fines, additions to tax or additional amounts imposed by any Taxing Authority in connection with any item described in clause
(i) above. 
 “Taxing Authority” means any Governmental Authority responsible for the administration of any Tax.

 “Third Party” means any Person other than AZ, Spinco, an Investor or any of their respective Affiliates. 

“Transaction Agreements” means, collectively, this Agreement, the Transition Services Agreement, the Clinical Supply
Agreement, the Sublicense Agreements, the Development Services Agreement, the Affiliate Lease Agreement, the License Agreement, the MRC Payment Agreements, the Assignment and Assumption and Bill of Sale, and the Services Agreement. 

“Transactions” means the transactions contemplated by this Agreement and the other Transaction Agreements. 

“Transfer Taxes” means any and all sale, use, stamp, documentary, filing, recording, transfer, real estate transfer, stock
transfer, gross receipts, registration, duty, securities transactions or similar fees or Taxes or governmental charges (together with any interest or penalty, addition to tax or additional amount imposed) as levied by any Taxing Authority in
connection with the Transactions. 
 “United States” or “U.S.” means the United States of America and its
territories, possessions and commonwealths. 

  
 A-9 

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 (b)    Additional Defined Terms. For purposes of the Agreement,
the following terms shall have the meanings defined in the Section indicated: 
  

			
	 Table of Defined Terms
	  	 Section

	Acquired Assets	  	2.1(b)
	Acquired Personal Property	  	2.1(b)(vii)
	Affiliate Lease Agreement	  	3.2(f)
	Agreement	  	preamble
	[***] Collaboration Agreement	  	recitals
	Assignment and Assumption and Bill of Sale	  	3.2(i)
	Assumed Liabilities	  	2.3(b)
	AZ Documents	  	4.2
	AZ Indemnified Parties	  	9.3
	AZ Parties	  	preamble
	AZCV	  	preamble
	[***] Collaboration	  	recitals
	[***] Collaboration Programs	  	recitals
	[***] Collaboration Programs Assignment and Novation	  	recitals
	AZUK	  	preamble
	Basket	  	9.5(a)
	Clinical Supply Agreement	  	3.2(c)
	Closing	  	3.1
	Closing Date	  	3.1
	Cellective Diligence Terms	  	7.10(b)(iii)
	Cellective Merger Agreement	  	7.10(a)
	Cellective Milestone Terms	  	7.10(b)(i)
	Cellective Representative	  	7.10(a)
	Common Stock	  	1.1
	Competing Activities	  	7.9(a)
	Confidential Information	  	7.2
	Development Services Agreement	  	3.2(e)
	De Minimis Amount	  	9.5(a)
	DFCI	  	7.11(a)
	DFCI License Agreement	  	7.11(a)
	Dispute Period	  	9.4(b)
	Duke	  	7.11(a)
	Duke License Agreement	  	7.11(a)
	Excluded Assets	  	2.2(b)
	Excluded Liabilities	  	2.4(b)
	[***] License Agreement	  	7.12(a)
	[***] License Term Sheet	  	7.12(a)
	FTC	  	4.4(k)
	Governmental Approval	  	4.3(b)
	Indemnified Party	  	9.1
	Indemnifying Party	  	9.1
	Investors	  	recitals
	License Agreement	  	3.2(g)
	MedImmune, Inc.	  	7.10(a)
	Medi LLC	  	preamble

  
 A-10 

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

			
	 Medi Ltd
	  	 recitals

	MRC Payment Agreements	  	3.2(h)
	Non-assignable Asset	  	2.5
	Parties	  	preamble
	Party	  	preamble
	Payee	  	10.4
	Payment	  	10.4
	Programs	  	recitals
	Purchase Price	  	1.1
	Restricted Period	  	7.9(a)
	Retained Contract	  	10.4
	Securities Purchase Agreement	  	recitals
	Services Agreement	  	3.2(j)
	Spinco	  	preamble
	Spinco Business	  	recitals
	Spinco Indemnified Parties	  	9.2(a)
	Sublicense Agreements	  	3.2(d)
	Survival Period	  	9.1
	Tedder	  	7.10(a)
	Tedder Consulting Agreement	  	7.10(a)
	Third Party Claim	  	9.4(b)
	Transferred Employees	  	7.5(a)
	Transition Services Agreement	  	3.2(b)
	WARN Act	  	2.4(b)(ii)

 (c)    Other Definitional and Interpretive Matters. Unless otherwise expressly
provided, for purposes of this Agreement, the following rules of interpretation shall apply: 

(i)    Calculation of Time Periods. When calculating the period of time before which, within which
or following which any act is to be done or step taken pursuant to this Agreement, the date that is the reference date in calculating such period shall be excluded. If the last day of such period is a
non-Business Day, the period in question shall end on the next succeeding Business Day. 

(ii)    Exhibits/Schedules. The Exhibits and Schedules to this Agreement are an integral part of
this Agreement and are hereby incorporated herein and made a part hereof as if set forth herein. Any capitalized terms used in any Exhibit or Schedule but not otherwise defined therein shall be defined as set forth in this Agreement. The
representations and warranties contained in Article IV are qualified by reference to the Schedules attached hereto and referred to in Article IV (collectively, the “Disclosure Schedule”). The Parties agree that the
Disclosure Schedule is not intended to constitute, and shall not be construed as constituting, representations and warranties of AZ except to the extent expressly provided in this Agreement. Spinco acknowledges and agrees that (i) the
Disclosure Schedule may include items or information that AZ is not required to disclose under this Agreement, (ii) disclosure of such items or information shall not affect, 

  
 A-11 

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 
directly or indirectly, the interpretation of this Agreement or the scope of the disclosure obligation of AZ under this Agreement, and (iii) inclusion of information in the Disclosure
Schedule shall not be construed as an admission that such information is material to any of AZ, Spinco or the Acquired Assets. Similarly, in such matters where a representation or warranty is given or other information is provided, the disclosure of
any matter in the Disclosure Schedule shall not imply that any other undisclosed matter having a greater value or other significance is material. Spinco further acknowledges and agrees that (A) headings have been inserted on sections of the
Disclosure Schedule for the convenience of reference only and shall not affect the construction or interpretation of any of the provisions of this Agreement or the Disclosure Schedule, (B) cross references that may be contained in sections of
the Disclosure Schedule to other sections of the Disclosure Schedule are not all-inclusive of all disclosures contained on such referenced sections of the Disclosure Schedule, and (C) every matter,
document or item referred to, set forth or described in one section of the Disclosure Schedule shall be deemed to be disclosed under each other section of the Disclosure Schedule and shall be deemed to qualify the applicable representations and
warranties of AZ in this Agreement, to the extent such matter, document or item is cross-referenced by such other section of the Disclosure Schedule. 

(iii)    Gender and Number. Any reference in this Agreement to gender shall include all genders, and
words imparting the singular number only shall include the plural and vice versa. 

(iv)    Headings. The provision of the Table of Contents, the division of this Agreement into
Articles, Sections and other subdivisions and the insertion of headings are for convenience of reference only and shall not affect or be utilized in construing or interpreting this Agreement. All references in this Agreement to any
“Article,” “Section” or other subdivision are to the corresponding Article, Section or other subdivision of this Agreement unless otherwise specified. 

(v)    Herein. The words such as “herein,” “hereinafter,”
“hereof,” “hereunder” and “hereto” refer to this Agreement as a whole and not merely to a subdivision in which such words appear unless the context otherwise requires. 

(vi)    Including. The word “including” or any variation thereof means
“including without limitation,” unless otherwise specified and shall not be construed to limit any general statement that it follows to the specific or similar items or matters immediately following it. 

(vii)    Other. The word “or” shall be exclusive; references to “written” or
“in writing” include in electronic form; and any reference to “days” means calendar days unless Business Days are expressly specified. 

**** 

  
 A-12 

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 Exhibit B 

[***] 

  

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 Exhibit C 

[***] 

  

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 Exhibits D-1,
D-2, D-3 
 [***] 

  

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 Exhibit E 

[***] 

  

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 Exhibit F 

[***] 

  

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 Exhibit G 

[***] 

  

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 Exhibit H 

[***] 

  

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 Exhibit I 

[***] 

  

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 Schedule 2.1(b)(i) 

Assigned Intellectual Property 

Patents 
 MEDI-1116 

Registered owner: MedImmune, LLC 
  

									
	 Title: [***]

					
	 AZ Reference
	  	 Country
	  	 Status
	  	 Application No.
	  	 Grant No.

	[***]	  	[***]	  	[***]	  	[***]	  	[***]

 MEDI-7734 
 Registered
owner: MedImmune, LLC 
  

									
	Title: [***]
					
	 AZ Reference
	  	 Country
	  	 Status
	  	 Application No.
	  	 Grant No.

	[***]	  	[***]	  	[***]	  	[***]	  	
	[***]	  	[***]	  	[***]	  	[***]	  	
	[***]	  	[***]	  	[***]	  	[***]	  	
	[***]	  	[***]	  	[***]	  	[***]	  	
	[***]	  	[***]	  	[***]	  	[***]	  	

 MEDI-4920 
 Registered
owner: MedImmune, LLC 
  

									
	Title: [***]
					
	 AZ Reference
	  	 Country
	  	 Status
	  	 Filing Number
	  	 Grant Number

	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	
	[***]	  	[***]	  	[***]	  	[***]	  	
	[***]	  	[***]	  	[***]	  	[***]	  	
	[***]	  	[***]	  	[***]	  	[***]	  	
	[***]	  	[***]	  	[***]	  	[***]	  	
	[***]	  	[***]	  	[***]	  	[***]	  	
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	
	[***]	  	[***]	  	[***]	  	[***]	  	
	[***]	  	[***]	  	[***]	  	[***]	  	
	[***]	  	[***]	  	[***]	  	[***]	  	
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	
	[***]	  	[***]	  	[***]	  	[***]	  	
	[***]	  	[***]	  	[***]	  	[***]	  	

  

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 MEDI-551 

Registered owner: MedImmune, LLC 
  

									
	Title:    HUMANIZED ANTI-CD19 ANTIBODIES AND THEIR USE IN TREATMENT OF ONCOLOGY, TRANSPLANTATION AND AUTOIMMUNE DISEASE
					
	 AZ Reference
	  	 Country
	  	 Status
	  	 Application No.
	  	 Grant No.

	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]

  

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

									
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]

 MEDI-9600 
 Registered
owner: MedImmune Limited 
  

									
	Title: [***]
					
	 AZ Reference
	  	 Country
	  	 Status
	  	 Filing Number
	  	 Grant Number

	[***]	  	[***]	  	[***]	  	[***]	  	
	[***]	  	[***]	  	[***]	  	[***]	  	
	[***]	  	[***]	  	[***]	  	[***]	  	

  

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 Schedule 2.1(b)(iii) 

[***] 
  

	 	•	 	 [***] 

  

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 Schedule 2.1(b)(vii) 

[***] 
  

	 	•	 	 [***] 

  

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 Schedule 4.3(a) 

[***] 
  

	 	•	 	 [***] 

  

	 	•	 	 [***] 

  

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 Schedule 4.4 

[***] 
  

	 	•	 	 [***] 

  

	 	•	 	 [***] 

  

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 Schedule 7.5(a) 

[***] 
  

					
	First	  	Last	  	Title
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]

 Spinco intends to make offers to the following additional individuals who are not employed by the AZ Group: 

 

					
	First	  	Last	  	Title
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]

  

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 Schedule 7.9 

[***] 
  

			
		  	
	 •[***]
	  	 •[***]

	 •[***]
	  	 •[***]

	 •[***]
	  	 •[***]

	 •[***]
	  	 •[***]

	 •[***]
	  	 •[***]

	 •[***]
	  	 •[***]

	 •[***]
	  	 •[***]

	 •[***]
	  	 •[***]

	 •[***]
	  	 •[***]

	 •[***]
	  	 •[***]

	 •[***]
	  	 •[***]

	 •[***]
	  	 •[***]

	 •[***]
	  	 •[***]

	 •[***]
	  	 •[***]

	 •[***]
	  	 •[***]

	 •[***]
	  	 •[***]

	 •[***]
	  	 •[***]

	 •[***]
	  	 •[***]

	 •[***]
	  	 •[***]

	 •[***]
	  	 •[***]

	 •[***]
	  	 •[***]

	 •[***]
	  	 •[***]

	 •[***]
	  	 •[***]

	 •[***]
	  	 •[***]

	 •[***]
	  	 •[***]

	 •[***]
	  	 •[***]

	 •[***]
	  	 •[***]

	 •[***]
	  	 •[***]

	 •[***]
	  	 •[***]

	 •[***]
	  	 •[***]

	 •[***]
	  	 •[***]

	 •[***]
	  	 •[***]

	 •[***]
	  	 •[***]

	 •[***]
	  	 •[***]

	 •[***]
	  	 •[***]

	 •[***]
	  	 •[***]

	 •[***]
	  	 •[***]

	 •[***]
	  	 •[***]

	 •[***]
	  	 •[***]

	 •[***]
	  	 •[***]

	 •[***]
	  	 •[***]

	 •[***]
	  	 •[***]

  

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

			
	 •[***]
	  	 •[***]

	 •[***]
	  	 •[***]

	 •[***]
	  	 •[***]

	 •[***]
	  	 •[***]

	 •[***]
	  	 •[***]

	 •[***]
	  	 •[***]

	 •[***]
	  	 •[***]

	 •[***]
	  	 •[***]

	 •[***]
	  	 •[***]

	 •[***]
	  	 •[***]

	 •[***]
	  	 •[***]

	 •[***]
	  	 •[***]

	 •[***]
	  	 •[***]

	 •[***]
	  	 •[***]

	 •[***]
	  	 •[***]

	 •[***]
	  	 •[***]

	 •[***]
	  	 •[***]

	 •[***]
	  	 •[***]

	 •[***]
	  	 •[***]

	 •[***]
	  	 •[***]

	 •[***]
	  	 •[***]

	 •[***]
	  	 •[***]

	 •[***]
	  	 •[***]

	 •[***]
	  	 •[***]

	 •[***]
	  	 •[***]

	 •[***]
	  	 •[***]

	 •[***]
	  	 •[***]

	 •[***]
	  	 •[***]

	 •[***]
	  	 •[***]

	 •[***]
	  	 •[***]

  

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 Schedule 7.12 

[***] License Term Sheet 
  

			
	Licensed Product	  	[***]
		
	Licensed Technology	  	[***]
		
	Kidney Field	  	[***]
		
	Spinco Field	  	[***]
		
	Territory	  	[***]
		
	License Grant	  	 [***]
  

[***]

		
	Improvements	  	 [***]
  

[***]

		
	Diligence	  	[***]
		
	Patent Prosecution	  	 [***]
  

[***]

		
	Preclinical Development; Spinco buy-in option	  	 [***]
  

[***]

		
	Clinical Development - Information and data sharing	  	 [***]
  

[***]
  

[***]
  

[***]

		
	Option to utilize clinical trial data	  	 [***]
  

[***]

		
	Manufacturing	  	 [***]
  

[***]
  

[***]
  

[***]
  

[***].

  

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

			
	Commercialization	  	[***]
		
	Term	  	[***]
		
	Termination; Effect of termination	  	 [***]:

•  [***]

•  [***]

[***]
  

[***]

•  [***]

•  [***]

•  [***]

•  [***]
  

[***]
 [***].

  

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 Schedule 10.3 

[***] 
  

			
	 Acquired Asset
	 	 Portion of Purchase Price Allocated to Asset

	[***]	 	[***]
	[***]	 	[***]
	[***]	 	[***]
	[***]	 	[***]
	[***]	 	[***]
	[***]	 	[***]
	[***]	 	[***]

  

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00299-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00299-of-00352.parquet"}]]